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Chapter 1 General introduction

General introduction 9
Sudden death is among the most common causes of death in developed countries. 
Sudden death from cardiac causes accounts for approximately 50% of all deaths from 
cardiovascular diseases and 20% of all deaths.[1-3] The majority (80-85%) of sudden 
cardiac deaths are caused by acute ventricular arrhythmia.[4] An important potential 
cause of ventricular arrhythmia is prolongation of ventricular repolarization, for instance, 
as is observed in the rare and genetically-determined ´congenital long QT syndrome´.[5, 
6] Prolongation of ventricular repolarization may result in early after depolarizations 
(EAD), which in turn may induce re-entry and thereby provoke Torsade de Pointes and 
fatal ventricular arrhythmia.[7-10] 
Ventricular repolarization disturbances
The QT interval on the electrocardiogram (ECG), measured from the Q-top, the begin-
ning of the QRS complex, until the end of the T wave, is the traditional measurement for 
assessing the duration of ventricular de- and repolarization. Although there are several 
formulas to adjust for heart rate (e.g. according to Fridericia or RR-adjusted QT interval), 
Bazett’s formula (QTc=QT/√RR) is most often used since decades (figure 1).[11] Accord-
ing to European regulatory guidelines, QTc prolongation can be distinguished into 3 
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Figure 1 Corrected QT interval using Bazett’s formula 
 
 
 
 
 
 
Figure 1 Corrected QT interval using Bazett’s formula. Source: Al-Khatib SM et al. JAMA 2003;289:2120-2127.
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clinically-relevant categories. For men, the cut-off points are less than 430 milliseconds 
(ms) (normal), 430-450 ms (borderline) and more than 450 ms (prolonged), and for 
women less than 450 ms (normal), 450-470 ms (borderline), and more than 470 ms 
(prolonged).[12] 
The electrical activity of the heart is mediated through channels that regulate the 
flow of ions in and out of cardiac cells. The inward depolarizing currents, mainly through 
Na+ and Ca2+ channels, result in normal depolarization, and outward repolarizing cur-
rents, mainly through K+ channels, result in repolarization (figure 2). Malfunction of ion 
channels may lead to an intracellular excess of positively charged ions, i.e. either by an 
inadequate outflow of potassium ions or by an excessive inflow of sodium ions. The 
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Figure 2 The cardiac action potential Figure 2 The cardiac action potential. (a) action potential showing the five phases of cardiac depolarisation and repolarisation with ion current directions during activation of the different ion channels; (b) ECG. 
Phase 0: Rapid depolarisation is caused by a large inward current of sodium ions (INa). Repolarisation consists of three phases (1-3): Phase 1: 
Rapid repolarisation phase is caused by inactivation of INa and the transient efflux of potassium ions (It0); Phase 2: Plateau phase, which is a 
reflection of a balance between the influx of calcium ions through L-type calcium channels (ICa) and outward repolarising potassium currents 
(IK); Phase 3: Late repolarisation phase results from the efflux of potassium (IKr, IKu, IKs). Phase 4: Resting potential is maintained by the 
inward rectifier potassium current (IK1).
ICa = calcium current; IK = potassium current; IK1 = inwardly rectifying potassium current; INa = depolarising sodium current; It0 = transient 
outward potassium current; IKr = rapidly activating delayed rectifier potassium current; IKs = slowly activating delayed rectifier potassium 
current; IKu = ultra rapidly activating delayed rectifier potassium current. Source: Titier K et al. Drug Safety 2005;28:35-51.
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intracellular excess of positively charged ions prolongs ventricular repolarization and 
results in QT interval prolongation on the ECG.[13] 
Risk factors for repolarization disturbances
Although risk factors of QTc prolongation can be divided into two main categories, i.e. 
congenital and acquired abnormalities, repolarization disturbances often occur due to 
gene-environment interactions.[9]
Congenital Long QT syndrome
The congenital long QT syndrome (LQTS) is an inherited disease characterized by prolon-
gation of ventricular repolarization, which is manifested by QT prolongation, syncopal 
episodes, malignant ventricular tachycardia and fibrillation.[6] The prevalence of LQTS 
is estimated to be approximately 1 in 2000 to 2500 live births.[14, 15] The autosomal 
dominant form (Romano-Ward syndrome) is far more common than the recessive 
form, which is associated with deafness (Jervell and Lange-Nielsen syndrome).[16] The 
majority of LQTS patients is asymptomatic and are either discovered incidentally on an 
ECG, by family history or after they survived an episode of syncope or severe ventricular 
arrhythmia. The prognosis of untreated patients is considered to be quite poor. It is 
estimated that approximately 20% of untreated patients presenting with syncope die 
within 1 year and 50% within 10 years.[17]
LQTS is genetically heterogeneous and is caused by several genes (table 1). The most 
prevalent forms are LQT1 (KCNQ1) and LQT2 (KCNH2) due to mutations in potassium 
channels, and LQT3 (SCN5A) due to a sodium channel mutation. Most LQT1 events are 
triggered by exercise or stress, LQT2 events by emotional stress such as auditory stimuli, 
while LQT3 events most often occur during sleep or at rest.[18] Although the risk of 
cardiac events is higher among patients with LQT1 and LQT2, the frequency of lethal 
cardiac events is higher in LQT3 patients.[19]
Also in those without congenital LQTS, the QT interval is a quantitative trait with 
approximately 30% heritability in the general population.[20-22] Several genetic 
Table 1 Common forms of the long QT syndrome (LQTS)
Genetic subtype
LQT1 LQT2 LQT3
Disease-associated gene KCNQ1 KCNH2/ HERG SCN5A
Ion current affected IKs IKr INa
Pathophysiology
Decreased potassium 
outward current
Decreased potassium 
outward current
Excessive sodium 
inward current
Trigger of arrhythmia
Exercise (diving, 
swimming), stress
Emotional stress 
(acoustic)
Rest, sleep
Occurence > 50% 35-40% 10-15%
IKs = rectifier potassium current, slow component; IKr = rectifier potassium current, rapid component; INa = inward sodium current.
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variants that are associated with QT interval duration have been identified: NOS1AP, 
KCNQ1, KCNE1, KCNH2 (hERG), SCN5A, and loci near NDRG4 and GINS3, PLN, RNF207, 
LITAF, LIG3 and RFFL. These genetic variants explain 5.4-6.5% of the variation in the QT 
interval.[23-28]
Acquired QTc interval prolongation 
In clinical medicine, QT interval prolongation is often not the primary scope of interest 
and QTc prolongation usually attracts more attention. The use of this indicator might 
complicate pathogenetic research since the QTc interval can increase due to QT interval 
prolongation, due to RR interval shortening, or both concomitantly. There are many 
factors that predispose to QTc prolongation including e.g. age, female gender, left ven-
tricular hyperthrophy, heart failure, myocardial ischemia, hypertension, diabetes mel-
litus, elevated serum cholesterol, high body mass index, slow heart rate and electrolyte 
abnormalities (including hypokalemia and hypomagnesemia).[9, 29-32] However, one 
of the most frequent causes of acquired QTc prolongation is the use of specific drugs.
[33]
QTc prolonging drugs
In the past decade, one of the most frequent causes of withdrawal or restriction of 
marketed drugs has been prolongation of the QTc interval.[7, 34] An increasing number 
of antipsychotic, antihistaminic, gastrointestinal and anti-infective drugs (e.g. thiorida-
zine, astemizole, cisapride, grepafloxacin) has been withdrawn from the market due to 
delay of cardiac repolarization and reports of Torsade de Pointes. Several other drugs 
(e.g. terfenadine, haloperidol, sertindole) were restricted in use because of this poten-
tial adverse reaction.[8, 35] Some QTc prolonging drugs which were withdrawn, were 
associated with a QTc interval prolongation of only 5 to 10 ms in patient populations.
[8] However, this was an average and the possibility of more extreme values should be 
taken into account. If such drugs are used on a large scale, it becomes evident that 
non-cardiac drugs associated with a pro-arrhythmogenic potential can be identified as 
a considerable public health problem.[10] 
Virtually all QTc prolonging drugs act by blocking the rapid component of the 
delayed rectifier potassium channel (Ikr) encoded by the human ether a go-go related 
gene (hERG) (figure 3).[8] Previously unrecognized LQTS can be identified in 5 to 20% 
of patients with drug-induced Torsade de Pointes.[36-38] The clinical implications of 
drug-induced QTc prolongation are not completely clear. It is known that some drugs 
associated with QTc prolongation are devoid of torsadogenic effects, whereas others 
seem to be associated with cardiac arrhythmia without QTc prolongation.[8, 39, 40] 
Blocking of the Ikr current is not specific, since drugs that also block this current do not 
always cause Torsade de Pointes (e.g. amiodarone). On the other hand some drugs that 
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prolong the QTc interval with only a few milliseconds were nevertheless implicated in 
the occurrence of cardiac arrhythmias and Torsade de Pointes (e.g. terfenadine).[39, 
40] However, terfenadine is a potent IKr blocker but usually does not prolong the QTc 
interval because it is readily transformed into a metabolite with no effect on the QT 
interval. Therefore, it is likely that other additional pharmacological actions are required 
to cause Torsade de Pointes.[8] These actions may be mediated by other ion channels, 
e.g. Ca2+ or Na+ channels.[41]
The internet based registry of R.L.Woosley (http://www.azcert.org/medical-pros/
drug-lists/drug-lists.cfm) contains drugs that are known to prolong the QTc interval.[33] 
The QTc prolonging drugs are classified into 4 categories, varying from drugs that are 
generally accepted to have a risk of causing Torsade de Pointes (list 1) (table 2) to drugs 
that, in some reports, have a weak association with Torsade de Pointes and are unlikely 
to increase the risk when used in therapeutic dosages (list 4). 
Sudden cardiac death
According to the most recent definition, sudden cardiac death is defined as 1) a witnessed 
natural death attributable to cardiac causes, heralded by abrupt loss of consciousness, 
within one hour of onset of acute symptoms, or 2) an unwitnessed, unexpected death 
of someone seen in a stable medical condition <24 hours previously with no evidence 
of a non-cardiac cause.[42, 43]
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Figure 3 Mechanisms of sudden cardiac death with hERG blockade 
Figure 3 Mechanisms of sudden cardiac death with hERG blockade. Drug blockade of the hERG channel (left) can result in QT interval 
prolongation (middle) and torsade de pointes (right; upper p nel), which can degenerate to ventricular fibrillation (VF) (right; lower panel). 
Source: Roden DM et al. Journal of Clinical Investigation 2005;115:2025-32.
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Sudden cardiac death accounts for more deaths each year than the total number of 
deaths from AIDS, breast cancer, lung cancer and stroke together. It is estimated that 
more than 3 million people die yearly from sudden cardiac death worldwide.[4] 
The incidence of sudden cardiac arrest in the general Dutch population was 9.2 per 
10,000 inhabitants.[3] This can be extrapolated to approximately 40 sudden cardiac 
arrests per day in the Netherlands. The incidence of sudden cardiac death in the general 
Table 2 Drugs that may cause Torsade de Pointes. Source: http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm [33]
Anti-arrhythmics
Amiodarone
Disopyramide
Dofetilide
Ibutilide
Procainamide
Quinidine
Sotalol
Anti-histamines
Astemizole
Terfenadine
Anti-infectives
Clarithromycin
Erythromycin
Pentamidine
Sparfloxacin
Anti-malarials
Chloroquine
Halofantrine
Anti-psychotics
Chlorpromazine
Haloperidol
Mesoridazine
Pimozide
Thioridazone
Gastro-intestinal drugs
Cisapride
Domperidone
Opiate agonists
Levomethadyl
Methadone
Other
Arsenic trioxide
Bepridil
Droperidol
Probucol
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Dutch population was almost 1 per 1,000 person-years per year.[44] In Dutch patients 
who had undergone 24-hour ambulatory electrocardiography for various indications, 
3.7% of the patients experienced sudden death within 2 years after electrocardiogra-
phy.[45] 
Most sudden cardiac arrests occur out-of-hospital with a survival rate of less than 
1%.[4] The majority (80%) of cardiac arrests occur at home and approximately 40% of 
sudden cardiac deaths are unwitnessed.[44, 46] Since a large proportion (33-50%) of 
sudden cardiac death victims have no warning symptoms and are not identified as being 
at high risk before the event, it may be important to improve the outcome of resuscita-
tion attempts outside the hospital.[47] The short time frame after cardiac arrest during 
which circulation has to be restored to prevent death or irreversible cerebral damage 
is essential.[48]In recent years, automated external defibrillators (AEDs) are used more 
frequently, allowing non-physicians to defibrillate shortly after the onset of ventricular 
fibrillation.[49]
Etiology
The majority (80-85%) of sudden cardiac deaths are caused by acute ventricular 
arrhythmias. Preceding acute myocardial infarction is present in 20% of the cases. Sud-
den cardiac death associated with bradyarrhythmias (15%) usually represents end-stage 
heart failure.[4] 
Coronary artery disease is the most common underlying disease in all cases of sud-
den cardiac death (75-80%). Dilated and hyperthrophic cardiomyopathy is the second 
most common underlying cause (10-15%). Primary electrical heart disease and genetic 
ion-channel abnormalities (<5%) account for only a small proportion of sudden deaths 
from cardiac causes.[4, 50]
Brugada syndrome is the most common cause of sudden cardiac death in individu-
als without structural heart disease. Brugada syndrome is characterized by a history of 
syncopy and a typical ECG pattern of ST-segment elevation in leads V1 to V3. It is claimed 
to be responsible for up to 12% of all sudden deaths and approximately 20% of 
deaths occurring in patients with structurally normal hearts. In the Western world, the 
prevalence is estimated at 1 in 5000 individuals. This syndrome exhibits an autosomal 
dominant pattern of inheritance. All identified mutations have been in a subunit of the 
sodium cardiac channel (SCN5A).[17] 
Prevention of sudden cardiac death
In all LQTS patients, it is important to avoid drugs known to prolong the QTc interval and 
electrolyte abnormalities. The major therapeutic options for LQTS are beta-blockers and 
implantable cardioverter-defibrillators (ICDs). The aim of beta-blockade is to decrease 
the heart rate at exercise; beta-blockers do not substantially shorten the QT interval.[51] 
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Beta-blocking agents represent the first choice therapy in symptomatic LQTS patients, 
unless specific contraindications are present.[18]
The use of ICDs is indicated as primary prevention in patients at high risk for sud-
den cardiac death, including LQTS patients with symptoms before puberty and those 
with very long QTc intervals (e.g. >500 ms). ICD implantation should be considered as 
secondary prevention in patients who have survived a life-threatening arrhythmic event.
[50-52]
As has been illustrated in this introduction, sudden cardiac death is a major clinical and 
public health problem. Many causes of QTc prolongation and thereby sudden cardiac 
death have been identified, however, not all risk factors are known yet. The occurrence 
of ventricular arrhythmias is a multifactorial process involving several factors.[53] In 
order to take effective preventive measures, persons at risk for sudden cardiac death 
should be identified. It is therefore important to identify risk factors that will predict fatal 
arrhythmic events.[54]
Scope and outline of this thesis
In this thesis, the effect will be studied of certain drugs and endocrine factors on QTc 
prolongation and sudden cardiac death. The studies presented in this thesis used data 
from the Rotterdam Study and the Integrated Primary Care Information (IPCI) project.
[55, 56]
The Rotterdam Study is a large prospective population-based cohort among 7,983 
inhabitants of Ommoord, a suburb of Rotterdam, who were 55 years or older. Since the 
start of the study in 1989, participants have visited the research center up to 4 times. 
In 2000 the first extended cohort was enrolled, which included 3011 inhabitants aged 
55 years or older at that time, who visited the research center up to 2 times. The IPCI 
project is a general practice research database, containing the complete medical records 
on approximately 1 million patients.
In the first studies, the association is investigated between QTc interval prolongation 
and sudden cardiac death and several types of drug classes (psychotropic drugs, calcium 
channel blockers, hERG-encoded potassium channel blocking drugs, domperidone and 
anticonvulsants. In the second part of this thesis, we evaluated the effects of endocrine 
factors (thyroid hormones, testosterone, glucose and insulin) on the QT(c) interval. 
In chapter 2.1, we study the association between use of psychotropic drugs and the 
duration of the QTc interval. In chapter 2.2 we study the effect of the interaction of 
calcium channel blockers with NOS1AP variants on QTc interval duration. In chapter 3.1 
we explore the association between use of hERG-encoded potassium channel blocking 
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drugs and sudden cardiac death. Chapter 3.2 describes the association between use 
of domperidone and ventricular arrhythmias and sudden cardiac death. Chapter 3.3 
focuses on the association between anticonvulsants and sudden cardiac death.
In chapter 4.1 we study the effect of thyroid hormones on QTc duration. In chapter 
4.2 we assess the association between use of antithyroid drugs (as proxy for underlying 
hyperthyroidism) and sudden cardiac death. In chapter 5.1 we explore the effect of 
serum levels of testosterone on QTc and RR length in males. Chapter 5.2 describes the 
association of glucose and insulin with the QTc and RR interval. In chapter 6, we discuss 
the main findings of this thesis and we provide suggestions for future research.
In addition, in chapter 7 we present recently discovered genes involved in atrial fibrilla-
tion and the PR interval during studies which were performed at the last stage of the 
research period for this thesis. Atrial fibrillation is an electrical disorder of the heart’s 
upper chambers characterized by an irregular heart rhythm. The overall lifetime risk 
of AF is almost 25% in the US and Europe.[57, 58] In chapter 7.1 we have replicated 
variants on chromosome 4 associated with atrial fibrillation in 4 independent cohorts. 
The primary aim of genome-wide association (GWA) studies is to identify novel genetic 
loci associated with interindividual variation in the levels of risk factors and the degree 
of clinical disease. In chapter 7.2 we conducted meta-analyses of genome-wide associa-
tion studies for atrial fibrillation in collaboration with the CHARGE (Cohorts for Heart 
and Aging Research in Genomic Epidemiology) Consortium [59] and identified the new 
locus ZFHX3 for atrial fibrillation. The electrocardiographic PR interval reflects atrial and 
atrioventricular nodal conduction, disturbances of which increase risk of atrial fibrilla-
tion. In chapter 7.3 we conducted meta-analyses of GWA studies for the PR interval in 7 
community-based studies and identified 9 loci. Five of these 9 loci were also associated 
with atrial fibrillation.
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Abstract
Background
To study whether listed putative QTc-prolonging psychotropic drugs indeed prolong the 
QTc interval under everyday circumstances, and to evaluate whether this is a class effect 
or an individual drug effect, we conducted a prospective population-based cohort study.
Methods 
This study was conducted as part of the Rotterdam Study, and included 3377 men and 
4845 women (≥55 years), who had triennial ECGs. The primary endpoints of the study 
were the length of the QTc interval at each ECG, the difference in QTc interval between 
consecutive ECGs within one person and the risk of an abnormally prolonged QTc inter-
val. Drug use at the index date was obtained from automated dispensing records. The 
associations were examined by means of a repeated measurement analysis, adjusted for 
age, gender, diabetes mellitus, hypertension, myocardial infarction, heart failure and use 
of class 1 QTc prolonging drugs. 
Results
Of the 8,222 participants, 813 participants developed QTc prolongation during follow-
up (9.9%) and 492 participants (74.4% female) used psychotropic drugs at the time of 
an ECG. Starting tricyclic antidepressants increased the QTc interval significantly with 6.9 
ms (95%CI 3.1;10.7) between consecutive ECGs in comparison with consecutive ECGs 
of participants not using tricyclic antidepressants, in particular starting amitriptyline (8.5 
ms (95%CI 2.8;14.2)), maprotiline (13.9 ms (95%CI 3.6;24.3)) and nortriptyline (35.3 
ms (95%CI 8.0;62.6)). Starting lithium also increased the QTc interval significantly (18.6 
ms (95%CI 4.8;32.4)).
Conclusions
In this population-based prospective cohort study, we confirmed the importance of 
antidepressants and antipsychotics as potential contributors to QTc-prolongation. Espe-
cially starting of tricyclic antidepressant drugs (as a class) is associated with a significant 
intra-individual increase in the QTc interval in comparison to the change in non-users. 
The tricyclic antidepressants appear to prolong the QTc interval as a class effect.
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Introduction
In the past decade, one of the most frequent causes of withdrawal or restriction of mar-
keted drugs has been prolongation of the heart-rate corrected QT (QTc) interval which 
is the traditional measurement for assessing the duration of ventricular repolarization. 
Prolongation of ventricular repolarization may result in early after depolarizations (EAD), 
which in turn may induce re-entry and thereby provoke Torsade de Pointes and fatal 
ventricular arrhythmias.[1-4]
An increasing number of drugs, especially non-cardiac drugs, are known to delay car-
diac repolarization and to induce Torsade de Pointes.[4] The issue of non-cardiac drugs 
associated with a pro-arrhythmogenic potential is identified as a considerable public 
health problem.[4] In recent years, several lists have been published of non-cardiac 
drugs associated with QTc prolongation and cardiac arrhythmias.[5-8] A limitation of 
these lists is that they are mostly based on empirical data and incomplete evidence. In 
addition, it is often unknown whether non-listed drugs of similar therapeutic or chemi-
cal classes do not also provoke QTc prolongation or whether they are not listed due to 
insufficient data. For example, because many, but not all psychotropic drugs are known 
to prolong the QTc interval, the question is whether QTc prolongation is a therapeutic 
and chemical class effect or an individual drug effect.[9-11]
Current guidelines, intended to predict whether a new drug carries an increased risk 
of serious cardiac arrhythmias, place much emphasis on the risk of QTc interval prolon-
gation as a proxy indicator for the risk of ventricular arrhythmias.[12] We conducted a 
population-based prospective cohort study, with serial ECG measurements over time to 
study whether listed as well as non-listed psychotropic drugs are indeed associated with 
QTc prolongation and to evaluate whether this is a class effect or an individual drug 
effect. 
Methods
Setting and study design
The Rotterdam Study is a prospective population-based cohort study, which started with 
a baseline visit between 1990 and 1993. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, the Netherlands, approved the study. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years and over, were invited to participate 
(n=10,275). Of them, 7983 (78%) gave their written informed consent and took part 
in the baseline examination (Rotterdam Study). Objectives and methods of the Rot-
terdam Study have been described in detail elsewhere.[13] At baseline, all participants 
were visited at home for a standardized questionnaire, and 7151 were subsequently 
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examined at the research center. Since the start of the study, follow-up visits took place 
in the period 1993 through 1996 for the second visit, in the period between 1997 
through 1999 for the third visit and in the period between 2002 through 2004 for the 
fourth visit. Furthermore, in 2000 a second cohort (first extended cohort) was enrolled. 
This included all inhabitants of Ommoord, at that time aged 55 years and over and not 
enrolled in the Rotterdam Study, who were invited to participate (n = 4504). Of them, 
3011 (67%) entered the study and took part in the baseline examination. The second 
visit of the first extended cohort took place in the period between 2004 and 2005. 
In addition to follow-up examinations, both cohorts are continuously monitored for 
major morbidity and mortality through linkage of general practitioner and municipality 
records. Furthermore, all drug prescriptions dispensed to participants by automated 
pharmacies are routinely stored in the database since 1 January 1991. 
Study population
All cohort members who had at least one ECG were enrolled in the study. Participants 
could contribute up to four ECGs to the analyses. Overall, 20,596 ECGs were available, 
8586 in men and 12,010 in women. Digitally stored ECGs were available for 5397 
participants at the time of the first visit, of 4798 participants at the time of the second 
visit, of 3818 participants at the time of the third visit and of 3118 participants at the 
time of the fourth visit. There were 2273 ECGs available of the participants of the first 
extended cohort at the time of the first visit and of 1190 at the time of the second visit. 
Missing ECGs were mainly due to temporary technical problems with ECG recording. 
Participants left the cohort mainly due to mortality while a minority was lost to follow-
up (figure 1). For the present study, the visit during which the first ECG was made was 
defined as baseline. Follow-up lasted until reaching one of the censoring dates (death 
or transferring out) or the end of the study period (1 January 2006).
ECG
The primary endpoint of this study was the length of the QTc interval in milliseconds 
(ms). A 12-lead resting ECG was recorded with an ACTA electrocardiograph (ESAOTE, 
Florence, Italy) at a sampling frequency of 500 Hz and stored digitally. All ECGs were 
processed by the Modular ECG Analysis System (MEANS) to obtain ECG measurements, 
in agreement with the FDA guidance for clinical evaluation of QT/ QTc interval prolonga-
tion[14], the MEANS program has been evaluated and validated extensively.[15-18] In 
one of these validation studies, ECGs with selected abnormalities were analyzed by 5 
cardiologists and 11 different computer programs of which MEANS performed as one of 
the best.[18] In another validation study in which QT intervals by manual measurement 
were compared with those generated by ECG machines, manual and automated mea-
surements generated similar numerical results in 3 studies in healthy volunteers, which 
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all included a positive control.[19] MEANS determines common onsets and offsets for all 
12 leads together on one representative averaged beat, with the use of template match-
ing techniques.[16] The MEANS program determines the QT interval from the start of 
the QRS complex until the end of the T wave. To adjust for heart rate, Bazett’s formula 
(QTc=QT/√RR) was used.[20] European regulatory guidelines were used to categorize 
QTc prolongation into 3 categories. For men, the cut-off points were less than 430 ms 
(normal), 430-450 ms (borderline) and more than 450 ms (prolonged), and for women 
less than 450 ms (normal), 450-470 ms (borderline), and more than 470 ms (prolonged).
[21] Furthermore, the MEANS program determines left ventricular hypertrophy and left 
and right bundle branch block.
ECGs of participants who used cardiovascular drugs that are listed as QTc altering 
agents (amiodarone, diltiazem, disopyramide, flecainide, indapamide, isradipine, 
ketanserin, quinidine, losartan, nicardipine, sotalol, triamterene and verapamil) or QTc 
shortening agents (digoxin) at the index date were excluded. In addition, the ECGs of 
persons with a pacemaker were excluded, as well as of persons with evidence of left 
ventricular hypertrophy, left and right bundle branch block, since these conditions are 
associated with a prolonged QTc interval.[22, 23] 
Medication
In this study, the exposure of interest included antidepressant and antipsychotic drugs 
selected from the following sources: drugs specified in lists 1 through 4 from a com-
monly consulted internet based registry of QTc prolonging drugs (http://www.azcert.
org/medical-pros/drug-lists/drug-lists.cfm); drugs in the list with QTc prolonging drugs 
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Figure 1 Diagram of study population of the Rotterdam Study
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from De Ponti et al. [5, 6, 8, 24]; and all other antidepressants and antipsychotics that 
are not listed in one of these two lists. The QTc prolonging drugs from the internet 
based registry are classified into 4 categories, varying from drugs that are generally 
accepted by authorities to have a risk of causing Torsade de Pointes (list 1) to drugs 
that, in some reports, have a weak association with Torsade de Pointes and are unlikely 
to increase the risk when used in therapeutic dosages (list 4). In addition, De Ponti et 
al. have published a list of non-anti-arrhythmic drugs with pro-arrhythmogenic effects, 
based on a structured literature search including published (non-) clinical evidence and 
official warnings in the labelling.[5, 6] 
In our analyses, we included antipsychotics that are listed in the internet based registry 
and the list from De Ponti et al. as QTc prolonging drugs: clozapine, haloperidol, lithium, 
prochlorperazine, quetiapine, thioridazine, and antipsychotics that do not appear as QTc 
prolonging drugs on either list:benperidol, bromperidol, levomepromazine, penfluridol, 
perphenazine, pipamperone, zuclopenthixol. Furthermore, we included all antidepres-
sants that are listed as QTc prolonging drugs: amitriptyline, citalopram, clomipramine, 
doxepin, fluoxetine, imipramine, maprotiline, mianserin, nortriptyline, paroxetine, 
sertraline, trazodone, venlafaxine, and all antidepressants that do not appear as QTc 
prolonging drug on either list: fluvoxamine, moclobemide, tranylcypromine.
The index date was the date of the ECG, psychotropic drugs were considered to be 
current if the duration of the prescription covered the index date. The duration was the 
total number of units issued per prescription divided by the prescribed daily number of 
units. 
Covariates
Diabetes mellitus, hypertension, myocardial infarction and heart failure are considered 
to be risk factors for QTc prolongation and presence of these conditions at each index 
date was included as a covariate.[25-28] Clinical measures were obtained during the 
visits at the Rotterdam Study research center. Diabetes mellitus was defined as the use 
of blood glucose–lowering medication and/or a non-fasting serum glucose level of 11.1 
mmol/l or higher and/or serum glucose levels ≥ 7mmol/l (1997-2000).[29] Hypertension 
was defined according to World Health Organization (WHO) criteria.[30] Myocardial 
infarction at baseline and during follow-up was assessed by hospital discharge diagnosis 
or in case a patient was not hospitalized, when signs and symptoms, analysis of the 
ECG and cardiac enzyme data were diagnostic of a myocardial infarction.[31, 32] Heart 
failure at baseline and during follow-up were assessed by the presence of suggestive 
signs and symptoms and by the use of medication for the indication heart failure.[33, 
34] Class 1 QTc prolonging drugs were defined as drugs of list 1 of the website based 
registry, which contains drugs that are generally accepted to have a risk to cause Torsade 
de Pointes.[8] Potassium at baseline was measured by means of a Microlyte device.
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Statistical analysis
Three types of analyses were conducted to assess the association between exposure 
to psychotropic drug use and QTc prolongation. The first analysis was cross-sectional 
and comprised all ECG measurements (up to four ECGs per individual). Because QTc 
measurements in subsequent ECGs of the same subject are correlated, the associa-
tion between exposure to psychotropic drugs and the length of the QTc-interval was 
examined by means of linear regression repeated measures analyses as implemented 
in PROC MIXED (SAS software). Analyses were adjusted for gender and the following 
time-depending covariates: age, diabetes mellitus, hypertension, myocardial infarction, 
heart failure and use of class 1 QTc prolonging drugs. Several sensitivity analyses were 
performed, first, we adjusted for the dosage of antidepressant drugs. Second, we 
adjusted for potassium levels in participants with an ECG at baseline. Third, we excluded 
all class 1 QTc prolonging drugs. Fourth, since Bazett’s formula tends to under-correct 
for lower heart rates and over-correct for higher heart rates we also included heart rate 
in the model and used Fridericia’s correction (QTc = QT/RR0.33).
 The second analysis was longitudinal and analyzed the within person change in QTc 
between two subsequent ECGs (QTc[tx] – QTc [t x-1]). Four exposure categories were 
distinguished: non-users of a particular drug at tx-1 who were users at tx (I); users at both 
ECGs (II); users at tx-1 who were non-users at tx (III); and non-users at both ECGs (IV). By 
means of linear regression repeated measures analyses, we compared the QTc length 
in category I with category IV as a reference. For the longitudinal analysis, participants 
were censored after first development of QTc prolongation. For the longitudinal study 
design, analyses were adjusted for QTc at the previous measurement in addition to the 
other co-variates. 
The overall effect of each psychotropic class was estimated, both in the cross-sectional 
and longitudinal analysis. The estimates were obtained averaging, within classes, over 
the drug-specific estimates, using random effect models.[35] Likelihood (REML) method, 
implemented in the SAS procedure PROC MIXED.
The third analysis modeled the association between exposure to psychotropics and 
the risk of a prolonged QTc interval by means of logistic regression repeated measures 
analyses (PROC GENMOD). For the third analysis participants were censored after first 
development of QTc prolongation. Analyses were adjusted for the same covariates as in 
the cross-sectional analysis and the QTc interval at baseline. All repeated measurements 
analyses were performed using SAS software, version 9.1. 
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Results 
Study subjects
The baseline characteristics of all participants after exclusion of left ventricular hyper-
trophy (538 ECGs), left and right bundle branch block (387 and 665 ECGs), use of 
cardiovascular QTc prolonging drugs (1334 ECGs), and participants with a pacemaker 
(53 ECGs) are presented in table 1. Overall, 17,516 ECGs in 8,222 participants, remained 
for analysis.
The mean age of the study population at the first ECG in the Rotterdam Study and 
the first extended cohort was 66.7 years (Standard Deviation 8.6 years). Women were 
significantly older than men. 
The mean QTc interval at study entry was significantly lower in males (422.4 ms) than 
in females (432.1 ms). 73.5% had normal QTc durations at baseline and 19.8% had 
borderline QTc prolongation, using the abovementioned gender-specific cut-off points. 
Overall, 813 participants who were free of baseline QTc prolongation developed QTc 
prolongation during follow-up (9.9%), with mean QTc levels of 476.5 ms.
Psychotropic drugs and QTc prolongation, cross-
sectional analysis
Current use of psychotropic drugs at the time of any ECG was relatively low (n=492, 
6.0%). The use of QTc-prolonging psychotropic medications was significantly higher 
in females (4.4%) than in males (1.5%). Of the current antipsychotic drug users 5.1% 
had QTc prolongation, whereas 4.1% of the current antidepressant drug users had QTc 
prolongation.
Table 1 Characteristics of the study population
Rotterdam 
study 
(baseline)
(1990 – 1993)
2nd research 
round 
(1993 – 1996)
3rd research 
round 
(1997 – 1999)
4th research 
round 
(2002 – 2004)
First extended 
cohort 
(baseline)
(2000 – 2002)
2nd research 
round
(2004 – 2005)
Number of 
participants
4562 4140 3193 2531 2035 1055
Gender (female) 60.2 % 59.7 % 58.8 % 60.9 % 55.6 % 57.8 %
Mean age in years 
(SD)
67.8 (8.8) 68.6 (8.2) 71.4 (6.9) 74.6 (6.1) 64.1 (7.7) 65.7 (5.8)
Mean QTc interval 
(SD)  (ms)
427.7 (23.6) 425.6 (23.0) 429.1 (23.1) 432.0 (23.6) 429.7 (21.9) 427.8 (22.8)
ECGs with QTc 
prolongation
6.6 % 5.6 % 7.6 % 9.5 % 6.8 % 6.7 %
SD= standard deviation
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The use of several psychotropic drugs was associated with a significantly increased 
QTc interval in the cross-sectional analyses (table 2). Among the antipsychotics, olan-
zapine and thioridazine were associated with a significantly higher QTc interval. There 
was no evidence that other phenothiazines, that are not listed as QTc prolonging drugs 
increased the QTc interval, but power was limited for several drugs. Among the antide-
pressants only the tricyclic antidepressants were associated with a significant increase in 
QTc interval. Not all of the individual drugs showed a significant higher QTc interval, but 
adjustment for frequency of use showed that the class as a whole was associated with a 
Table 2 Psychotropic medication and QTc interval prolongation (cross-sectional analysis on any ECG) 
Medication De Ponti A Lists
QTc/ 
TdPB
Users QTc (Bazett) increase (ms) in users 
compared to non-users  (95% CI)C
Antipsychotics 84
    Phenothiazines 17 -5.4 (-24.2 ; 13.4)
 Levomepromazine - - 6 -3.1 (-18.0 ; 11.8)
 Periciazine - - 1 NA
 Perphenazine - - 4 -35.7 (-54.9 ; -16.6)
 Prochlorperazine x - 1 NA
 Thioridazine x 1, 3 4 28.3 (5.9 ; 50.8)
 Trifluoperazine x - 1 NA
    Butyrophenones 29 -0.4 (-4.3 ; 3.6)
 Benperidol - - 1 NA
 Bromperidol - - 5 1.8 (-15.6 ; 19.2)
 Haloperidol x 1, 3 8 1.2 (-13.5 ; 15.9)
 Pipamperone - - 15 -0.6 (-10.8 ; 9.6)
    Thioxanthenes 9 -12.2 (-25.5 ; 1.1)
 Zuclopenthixol - - 9 -12.2 (-25.5 ; 1.1)
    Miscellaneous antipsychotics 29 6.5 (-2.2 ; 15.1)
 Clozapine X 2, 3 2 NA
 Lithium - 2, 3 18 10.1 (0.7 ; 19.4)
 Olanzapine X - 3 22.9 (0.1 ; 45.7)
 Penfluridol - - 4 -6.1 (-25.5 ; 13.3)
 Quetiapine X 2, 3 1 NA
 Sulpiride - - 1 NA
Antidepressants 408
    Tricyclic antidepressants 177 6.9 (3.1 ; 10.7)
 Amitriptyline X 3, 4 106 5.1 (1.4 ; 8.9)
 Clomipramine X 3, 4 19 6.6 (-1.6 ; 14.7) 
 Doxepin X 3, 4 4 -7.9 (-27.3 ; 11.5)
 Imipramine X 3, 4 9 12.8 (0.3 ; 25.3)
 Maprotiline X - 33 9.6 (3.1 ; 16.1)
 Nortriptyline X 3, 4 6 23.3 (7.7 ; 38.9)
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higher QTc interval. SSRIs, MAO inhibitors and miscellaneous antidepressants were not 
associated with a QTc increase. 
Additional adjustment for daily dose and potassium did not substantially change the 
estimates. After exclusion of all class 1 QTc prolonging drugs, the results for the classes 
as a whole did not change substantially. In two separate analyses, we adjusted for heart 
rate and used Fridericia’s correction as outcome. There were no considerable changes, 
however, the point estimates for the tricyclic antidepressants decreased slightly.
Psychotropic drugs and QTc prolongation, longitudinal 
analysis
After censoring of ECGs when prolongation occurred during follow-up (361 ECGs) and 
exclusion of participants with QTc elevation at the first ECG (1794 ECGs), 16,389 ECGs 
in 7,667 participants, remained. Starting a psychotropic drug between two consecutive 
ECGs occurred in 193 participants (2.5%). There were too few starters of antipsychotics 
to draw firm conclusions using intra-individual QTc changes from non-user to user, but 
antidepressants could be analysed. The longitudinal analysis showed that starting tricy-
clic antidepressants was associated with an increase in the QTc interval in comparison 
to participants not starting tricyclic antidepressants in two subsequent ECGs (table 3). 
Medication De Ponti A Lists
QTc/ 
TdPB
Users QTc (Bazett) increase (ms) in users 
compared to non-users  (95% CI)C
     Selective serotonin reuptake 
inhibitors
186 0.1 (-1.7 ; 1.8)
 Citalopram X 3, 4 4 6.5 (-13.7 ; 26.7)
 Fluoxetine X 3, 4 25 0.0 (-7.7 ; 7.8)
 Fluvoxamine - - 30 -0.1 (-7.2 ; 7.0)
 Paroxetine X 3, 4 111 0.6 (-3.1 ; 4.2)
 Sertraline - 3, 4 16 -5.2 (-15.1 ; 4.7)
    MAO inhibitors 4 -0.7 (-2.1 ; 0.7)
 Moclobemide - - 3 -0.3 (-19.6 ; 19.0)
 Tranylcypromine - - 1 NA
    Other antidepressants 41 2.21 (-2.7 ; 7.1)
 Mianserin X - 20 -1.7 (-10.3 ; 6.9)
 Mirtazapine - - 12 8.1 (-4.2 ; 20.4)
 Trazodone X - 3 1.1 (-19.6 ; 21.7)
 Venlafaxine X 2, 3 6 6.3 (-9.5 ; 22.2)
A: Present in De Ponti list. TdP= Torsade de Pointes
B: Present in lists from internet based registry. 
CI=Confidence Interval; QTc interval in ms.
C: Adjusted for age and gender, diabetes mellitus, hypertension, myocardial infarction, heart failure and use of class 1 QTc prolonging drugs.
NA: not assessable, measures of association are not calculated for categories with less than 3 users.
Table 2 continued
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Table 3 Difference in QTc interval length between two consecutive ECGs (longitudinal analysis regarding intra-individual change from non-user 
to user)
Medication Number of 
participants 
starting the 
psychotropic drug
QTc change in persons starting 
psychotropic drugs compared to 
non-users
 (95% CI)A
Antipsychotics 34
    Phenothiazines 4 -8.0 (-32.6 ; 16.5)
 Levomepromazine 4 -8.0 (-32.6 ; 16.5)
    Butyrophenones 12 2.0 (-3.2 ; 7.2)
 Benperidol 1 NA
 Bromperidol 2 NA
 Haloperidol 2 NA
 Pipamperone 7 3.7 (-11.8 ; 19.1)
    Thioxanthenes 6 -13.5 (-33.9 ; 6.9)
 Zuclopenthixol 6 -13.5 (-33.9 ; 6.9)
    Miscellaneous antipsychotics 12 12.7 (-5.1 ; 30.4)
 Clozapine 2 NA
 Lithium 8 18.6 (4.8 ; 32.4)
 Penfluridol 1 NA
 Quetiapine 1 NA
Antidepressants 159
    Tricyclic antidepressants 66 10.4 (3.5 ; 17.4)
 Amitriptyline 37 8.5 (2.8 ; 14.2)
 Clomipramine 11 6.0 (-4.9 ; 17.0)
 Doxepin 1 NA
 Imipramine 1 NA
 Maprotiline 12 13.9 (3.6 ; 24.3)
 Nortriptyline 4 35.3 (8.0 ; 62.6)
    Selective serotonin reuptake inhibitors 82 -2.4 (-10.1 ; 5.4)
 Citalopram 1 NA
 Fluoxetine 8 -5.6 (-18.4 ; 7.2)
 Fluvoxamine 12 -19.4 (-31.0 ; -7.8)
 Paroxetine 54 2.6 (-2.1 ; 7.2)
 Sertraline 9 -12.1 (-25.6 ; 1.4)
    MAO inhibitors 1 NA
 Moclobemide 1 NA
    Other antidepressants 10 -0.5 (-2.9 ; 2.0)
 Mianserin 5 0.3 (-16.3 ; 16.9)
 Trazodone 1 NA
 Venlafaxine 3 -2.6 (-44.7 ; 39.4)
CI=Confidence Interval; QTc interval in ms.
A: Difference in QTc prolongation between two consecutive ECGs from patients starting psychotropic drugs compared to patients not using 
psychotropic drugs in two consecutive ECGs. Adjusted for age and gender, diabetes mellitus, hypertension, myocardial infarction, heart failure, 
QTc of previous measurement and use of class 1 QTc prolonging drugs.
NA: not assessable, measures of association are not calculated for categories with less than 3 starters.
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Start of each of the individual drugs was associated with an increase of the QTc interval 
(amitriptyline 8.5 ms (95%CI 2.8;14.2), maprotiline (13.9 ms (95%CI 3.6;24.3)) and 
nortriptyline (35.3 ms (95%CI 8.0;62.6)). 
Risk of an abnormally prolonged QTc interval
Use of some psychotropic drugs was associated with a significantly higher odds of a 
prolonged QTc interval. Of the individual drugs, current use of penfluridol (odds ratio 
1.27 (95%CI 1.08-1.48)), lithium (OR 1.07 (95%CI 1.01-1.15)), amitriptyline (OR 1.05 
(95%CI 1.02-1.08)), and maprotiline (OR 1.13 (95%CI 1.07-1.19)) was associated with 
a significantly higher risk of a prolonged QTc interval.
Discussion
To our knowledge, this is the first large longitudinal prospective cohort study assess-
ing the association between psychotropic drugs and QTc-prolongation in a population 
of older adults. The cross-sectional analyses and within person longitudinal analyses 
showed that use of some antipsychotics (especially lithium, olanzapine and thioridazine) 
and almost all tricyclic antidepressants are associated with a significant increase in QTc 
interval. Most of these drugs were listed by either de Ponti or the internet-based registry. 
Maprotiline, which was clearly associated with an increase in QTc interval, is not listed 
on the internet based registry. For many of the listed drugs we could not confirm a sig-
nificant increase in the QTc interval. However, this may have been due to limited power 
from small sample sizes. In general, the direction of change was as expected. One of 
our original study questions was to see whether QTc prolongation was associated with 
the therapeutic/chemical class rather than with individual drugs. The only class that 
was associated with an overall increase of the QTc interval were tricyclic antidepres-
sant drugs. In this class most of the individual drugs (amitriptyline, imipramine and 
maprotiline) were associated with a significant increase of the QTc interval. Although 
for clomipramine, nortriptyline and doxepin no such association was demonstrated 
(although they are on the list), this might be explained by a lack of power. We cannot 
find a logical explanation for the significant QTc interval shortening of fluvoxamine; 
chance could underlie this observation but a genuine effect cannot be excluded.
Our results are in agreement with previously reported information on these drugs. 
Amitriptyline and maprotiline are the tricyclic antidepressant drugs which have been 
implicated most frequently in case reports of Torsade de Pointes and QTc prolongation 
is considered a risk factor for Torsade de Pointes.[10] Previously, we have demonstrated 
that QTc prolongation is associated with an increased risk of sudden cardiac death.
[36] In elderly patients using antipsychotic drugs, QTc prolongation is common.[37] 
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Lithium has been reported in the literature as a cause of QTc interval prolongation.[6, 
38] Thioridazine, which was associated with a significant increase in QTc interval in our 
cross-sectional analyses has been withdrawn in 2005 due to QTc prolongation, cardiac 
arrhythmias and sudden death.[39] Some QTc prolonging drugs which were withdrawn 
from the market because of Torsade de Pointes, were associated with a QTc interval 
prolongation of only 5 to 10 ms in patient populations.[2]
Although all listed drugs have been reported to be associated with Torsade de Pointes 
or cardiac arrhythmias, in our study no significant associations with QTc prolongation 
were found for a number of these listed drugs, which may be explained by between 
patient variation in susceptibility and the small numbers of users of some specific drugs. 
Our study has several strengths. First, the cross-sectional study design allowed us to 
find associations between psychotropic drugs and QTc prolongation. Because of the 
well-known limitation of cross-sectional designs, i.e. the fact that it is often not pos-
sible to assess whether exposure really preceded the outcome, we also performed a 
longitudinal analysis which gave more insight into the question whether the drugs were 
the cause of the QTc prolongation. Second, class effects were calculated using random 
effect models to adjust for the number of users of a specific drug within a class. To 
minimize bias by simultaneous use of other QTc prolonging drugs, we adjusted for use 
of other listed QTc prolonging drugs. The population-based design of the study probably 
limited the chance of selection bias. If exposure misclassification occurred it is probably 
non-differential. There is no information bias, since we used pharmacy data, which 
are registered prospectively and irrespective of disease status. One major advantage 
in our study was the availability of data on a large group of participants, including up 
to four ECGs per subject at regular intervals during follow-up, which allowed us to 
obtain more precise long-term ECG measures for each individual. Furthermore, the use 
of digital ECG recordings, all measured using the MEANS system, likely reduced intra- 
and interobserver variability in the assessment of the QTc interval. Confounding was 
minimized by adjusting for all known risk factors of QTc prolongation. An advantage of 
the Rotterdam Study is the prospective ascertainment of risk factors over a long period 
of follow-up. However, our study has also some potential limitations. Some participants 
were lost to follow-up, however, since only 196 out of 10,994 participants of the Rot-
terdam Study were lost to follow-up, loss-to-follow-up bias is unlikely. The association 
between psychotropic drugs and sudden cardiac death was not assessed directly, due 
to a low number exposed cases. However, we demonstrated in an earlier study that QTc 
prolongation is an important risk factor for sudden cardiac death.[36] 
In conclusion, in the longitudinal analysis of this large population-based prospective 
cohort, we confirmed that all drugs that demonstrated QTc prolongation are already 
listed. Although not all tricyclic antidepressants are listed, QTc prolongation following 
starting of tricyclic antidepressants seems to be a class effect. 
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Abstract
Background
Common variation in the NOS1AP gene has been associated with QT interval variation 
in several large population samples. NOS1 is presumed to influence intracellular calcium. 
We aimed to study whether NOS1AP single nucleotide polymorphisms rs10494366 T>G 
and rs10918594 C>G modify the QTc prolonging effect of calcium channel blockers.
Methods 
We included 16,603 ECGs from 7565 participants (≥ 55 yr), who were genotyped, 
from the prospective population-based Rotterdam Study after exclusion of patients with 
left ventricular hypertrophy, left and right bundle branch block, as well as carriers of 
pacemakers. The endpoint was the length of the QTc interval in calcium channel blocker 
users and non-users with the minor alleles compared to the major alleles (wild type). We 
used a repeated measurement analysis, adjusted for all known confounders. 
Results
Use of verapamil was associated with a significant QTc interval prolongation (6.0 ms 
(95%CI 1.7;10.2)) compared to non-users. Furthermore, users of verapamil with the 
rs10494366 GG genotype showed significantly more QTc prolongation than users 
with the TT genotype (25.4 ms (95%CI 5.9;44.9) (P-value for multiplicative interaction 
0.0038). Users of isradipine with the GG genotype showed more QTc prolongation than 
users with the TT genotype (19.8 ms (95%CI 1.9;37.7)), however, SNP rs10494366 
did not modify the effect on QTc interval on a multiplicative scale (p=0.3563). SNP 
rs10918594 showed similar results. 
Conclusions
In conclusion, we demonstrated that the minor alleles of both NOS1AP SNPs significantly 
potentiate the QTc prolonging effect of verapamil.
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Introduction
In the past decade, one of the most frequent causes of withdrawal or restriction of 
marketed drugs was prolongation of the heart-rate corrected QT (QTc) interval in com-
bination with case reports of sudden cardiac death.[1-4]
The QTc interval is the traditional measurement for assessing the duration of ventricu-
lar repolarization. QTc prolongation may result in early after depolarizations (EAD) and 
re-entry, and thereby provoke Torsade de Pointes and fatal ventricular arrhythmias.[1-5] 
The QTc interval is influenced by factors such as gender, age and use of certain drugs. 
An increasing number of drugs has been recognized to delay cardiac repolarization and 
to induce Torsade de Pointes.[4] However, it is mostly unknown which underlying risk 
factors may modify the risk of drug-induced QTc-prolongation. As the QT interval is a 
quantitative trait with approximately 30% heritability,[6-8] it is likely that such genetic 
effect modifiers exist.
Recently, one of us with others reported the finding from a genome-wide associa-
tion study showing that a common variant (rs10494366, minor allele frequency 38%) 
in the NOS1AP gene is associated with QT interval variation in several large popula-
tion samples, which was replicated in the Rotterdam Study.[9-12] The NOS1AP gene 
encodes the nitric oxide synthase 1 activating protein.[9] The mechanism by which 
common variation in NOS1AP affects the QTc interval is presently unknown. NOS1AP is 
a regulator of neuronal nitric oxide synthase which forms a ternary complex with PSD95 
(membrane-associated guanylate kinase) [13] and Dexras 1 (member of the Ras family 
of small monomeric G proteins).[14] NOS1 has a role in cardiac contractility [15, 16], and 
it is hypothesized that nitric oxide signalling may be involved in cardiac repolarization. 
Since both NOS1 and calcium channel blockers suppress L-type calcium channels, we 
conducted a population-based prospective cohort study to investigate whether NOS1AP 
single nucleotide polymorphisms rs10494366 T>G and rs10918594 C>G modify the 
QTc prolonging effect of calcium channel blockers.
Methods
Setting and study design
The Rotterdam study is a prospective population-based cohort study, which started with 
a baseline visit between 1990 and 1993. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, the Netherlands, approved the study. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years and over, were invited to participate 
(n=10,275). Of them, 7983 (78%) gave their written informed consent and took part 
in the baseline examination. Objectives and methods of the Rotterdam Study have been 
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described in detail elsewhere.[17, 18] At baseline, all participants were visited at home 
for a standardized questionnaire, and 7151 were subsequently examined at the research 
center. Since the start of the study, follow-up visits took place in the period 1993 through 
1996 for the second visit, in the period between 1997 through 1999 for the third visit 
and in the period between 2002 through 2004 for the fourth visit. Furthermore, in 
2000 a second cohort (first extended cohort) was enrolled. This included all inhabitants 
of Ommoord, at that time aged 55 years and over, who were invited to participate (n = 
4504). Of them, 3011 (67%) entered the study and took part in the baseline examina-
tion. The second visit of the first extended cohort took place in the period between 
2004 and 2005. In addition to follow-up examinations, the total cohort is continuously 
monitored for major morbidity and mortality through linkage of general practitioner 
and municipality records. Furthermore, all drug prescriptions dispensed to participants 
by automated pharmacies are routinely stored in the database since 1 January 1991. 
Study cohort
All cohort members of the Rotterdam Study and the first extended cohort, who had 
at least one ECG and genotyping, were enrolled in the study population. Participants 
could contribute up to four ECGs to the analyses. Overall, 20,596 ECGs were available, 
8586 in men and 12,010 in women. Digitally stored ECGs were available for 5397 
participants at the time of the first visit (75% of 7151 participants visiting the research 
center), of 4798 participants at the time of the second visit (76% of 6315 participants 
visiting the research center), of 3818 participants at the time of the third visit (91% of 
4215 participants visiting the research center), and of 3118 participants at the time 
of the fourth visit (99% of 3145 participants visiting the research center). There were 
2273 ECGs available of the participants of the first extended cohort at the time of the 
first visit (84% of 2722 participants who visited the research center), and of 1190 at 
the time of the second visit (53% of 2249 participants who visited the research center). 
Missing ECGs were mainly due to temporary technical problems with ECG recording. 
For the present study, the visit during which the first ECG was made was defined as 
baseline. ECGs of participants who used digoxin, which is a QTc shortening agent, were 
excluded. In addition, the ECGs were excluded of persons with a pacemaker, as well 
as of persons with evidence of left ventricular hypertrophy, or left and right bundle 
branch block, since these conditions are associated with a prolonged QTc interval.[19, 
20] Consequently, 7565 participants (4404 women and 3161 men) were included. 
QTc interval
The primary endpoint of the study was the length of the QTc interval in ms. A 12-lead 
resting ECG was recorded with an ACTA electrocardiograph (ESAOTE, Florence, Italy) at 
a sampling frequency of 500 Hz and stored digitally. All ECGs were processed by the 
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Modular ECG Analysis System (MEANS) to obtain ECG measurements, in agreement 
with the FDA guidance for clinical evaluation of QT/ QTc interval prolongation.[21] The 
MEANS program has been evaluated and validated extensively.[22-25] In one of the vali-
dation studies, ECGs with selected abnormalities were analyzed by 5 cardiologists and 
11 different computer programs of which MEANS performed as one of the best.[25] In 
a validation study in which QT intervals by manual measurement were compared with 
those generated by ECG machines, manual and automated measurements generated 
similar numerical results in 3 studies in healthy volunteers, which all included a positive 
control.[26] MEANS determines common onsets and offsets for all 12 leads together 
on one representative averaged beat, with the use of template matching techniques.
[23] The MEANS program determines the QT interval from the start of the QRS complex 
until the end of the T wave. To adjust for heart rate, Bazett’s formula (QTc=QT/√RR) 
was used.[27] European regulatory guidelines were used to categorize QTc prolongation 
into 3 categories. For men, the cut-off points were less than 430 ms (normal), 430-450 
ms (borderline) and more than 450 ms (prolonged), and for women less than 450 ms 
(normal), 450-470 ms (borderline), and more than 470 ms (prolonged).[28] Additionally, 
the MEANS program determines left ventricular hypertrophy and left and right bundle 
branch block.
Drug exposure 
In this study, the exposure of interest included calcium channel blockers. In our analyses, 
we included the following drugs that are available in the Netherlands and are used by 
at least 40 participants in the Rotterdam Study: calcium channel blockers with mainly 
vascular effects: amlodipine, isradipine and nifedipine; and calcium channel blockers 
with direct cardiac effects: diltiazem and verapamil. 
Isradipine is included in a commonly consulted internet based registry of QTc pro-
longing drugs[29]; diltiazem, isradapine and verapamil are included in the list with QTc 
prolonging drugs from De Ponti et al.[30] The lists with QTc prolonging drugs are based 
on the medical literature and on the FDA database for reported adverse events. 
Participants were classified as current users of calcium channel blockers if the dura-
tion of the prescription covered the date of the ECG (index date). The duration was the 
total number of units issued per prescription divided by the prescribed daily number of 
units. 
Covariates
Diabetes mellitus, hypertension, myocardial infarction and heart failure are considered to 
be risk factors for QTc prolongation and presence of these conditions at each index date 
was included as a covariate.[31-34] Clinical measures were obtained during the visits 
at the Rotterdam Study research center. In 1990-1993 non-fasting blood samples were 
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obtained, while in 1997-2000 blood samples were obtained after overnight fasting. 
Diabetes mellitus was defined as the use of blood glucose–lowering medication and/or 
a non-fasting serum glucose level of 11.1 mmol/l or higher and/or serum glucose levels 
≥ 7 mmol/l (1997-2000).[35] Hypertension was defined as a systolic blood pressure ≥ 
160 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg and/or use of antihyperten-
sive medication, encompassing grade 2 and grade 3 hypertension according to World 
Health Organization (WHO) criteria.[36] Myocardial infarction at baseline and during 
follow-up was assessed by hospital discharge diagnosis or in case a patient was not 
hospitalized, when signs and symptoms, analysis of the standard 12-lead electrocardio-
gram and cardiac enzyme data were diagnostic of a myocardial infarction.[37, 38] Heart 
failure at baseline and during follow-up were assessed by the presence of suggestive 
signs and symptoms and by the use of medication for the indication heart failure.[39, 
40]. Use of QTc prolonging drugs (list 1) of the website based registry at the index date 
was considered as a covariate.[29]
Genotyping
All participants were genotyped for the NOS1AP SNP rs10494366 T>G which was previ-
ously shown to be associated with the QT interval in 3 independent samples.[9] The 
partially correlated SNP rs10918594 C>G, which was associated with QT interval in 
one of the samples,[9] was also genotyped. Both were genotyped using Taqman assays 
C_1777074_10 and C_1777009_10 (Applied Biosystems, Foster City, Ca., USA) in 1 ng 
of genomic DNA extracted from leukocytes, as previously reported.[41] 
Statistical analysis
The association between exposure to calcium channel blockers and the length of the 
QTc interval was examined by means of linear regression repeated measures analyses 
implemented in PROC MIXED (SAS software, version 9.1), since QTc measurements in 
subsequent ECGs in the same subject are correlated. Analyses were adjusted for gender 
and the following time-depending covariates: age, diabetes mellitus, hypertension, 
myocardial infarction, heart failure and use of list 1 QTc prolonging drugs. 
Genotype frequencies were tested for Hardy-Weinberg equilibrium using a Chi-square 
test. In a second analysis, users with the minor alleles were compared with users with 
the major alleles. For all calcium channel blockers, we tested whether the 2 NOS1AP 
variant alleles modified the QT prolonging effect on a multiplicative scale. Subsequently, 
analyses were performed by adjusting for dosage and duration of use. All analyses were 
performed with SAS, version 9.1.
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Results
Study subjects
The baseline characteristics of all 7565 participants (16,603 ECGs) of the study popula-
tion remaining after exclusion of left ventricular hypertrophy (538 ECGs), left and right 
bundle branch block (387 and 665 ECGs), use of digoxin (557 ECGs), participants with 
a pacemaker (53 ECGs) and missing genotypes (2055 ECGs) are presented in table 1. 
At the time of an ECG, 750 participants used calcium channel blockers with mainly 
vascular effects and 429 participants used other calcium channel blockers with direct 
cardiac effects.
Genotyping
The G-allele (minor) frequency of rs10494366 T>G was 36.5% and of rs10918594 C>G 
was 31.4%. Successful genotype calls were made in 96.3% and 97.3% of subjects, 
respectively. Both SNPs were in Hardy-Weinberg equilibrium (p= 0.53 for rs10494366 
and p= 0.78 for rs10918594). The two SNPs were in linkage disequilibrium with an r2 
of 0.63 and D’ of 0.88 (95%CI 0.87 – 0.90). Upon phasing, we observed two common 
two-SNP haplotypes: TC (61.2%) and GG (29.2%), consisting of the two major and 
two minor alleles, respectively, and two minor haplotypes containing one major and one 
Table 1 Characteristics of the study population
Rotterdam study 
(baseline)
(1990 – 1993)
First extended cohort 
(baseline)
(2000 – 2002)
Number of participants 5233 2332
Gender (female) 3108 (59.4%) 1296 (55.6%)
Mean age in years (SD) 68.5 (8.7) 64.4 (7.6)
Mean QTc interval (SD) (ms) 428.3 (24.1) 429.9 (22.3)
ECGs with QTc prolongation 389 (7.4%) 170 (7.3%)
NOS1AP rs10494366
TT 2136 (40.8%) 930 (39.9%)
TG 2380 (45.5%) 1094 (46.9%)
GG 717 (13.7%) 308 (13.2%)
NOS1AP rs10918594
CC 2442 (46.7%) 1091 (46.8%)
CG 2258 (43.1%) 1006 (43.1%)
GG 533 (10.2%) 235 (10.1%)
Diabetes mellitus 502 (9.6%) 261 (11.2%)
Heart failure 133 (2.5%) 44 (1.9%)
Hypertension 1397 (26.7%) 683 (29.3%)
Myocardial infarction 584 (11.2%) 121 (5.2%)
Use of QTc prolonging drugs 110 (2.1%) 46 (2.0%)
SD= standard deviation
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minor allele each: GC (7.2%) and TG (2.3%). Genotype distributions were similar for 
men and women and there were no age differences among genotypes.
QTc interval
The mean QTc interval at study entry was significantly lower in males (421.8 ms) than 
in females (431.5 ms). 74.3% had normal QTc durations at baseline and 19.3% had a 
borderline QTc interval and 6.4% a prolonged QTc interval, using previously described 
gender specific cut-off points. Overall, 559 participants developed QTc prolongation 
during follow-up, with mean QTc levels of 473.9 milliseconds. 
Current use of verapamil was associated with a significant QTc interval prolonga-
tion (6.0 ms (95%CI 1.7 ; 10.2)), after adjustment for age, gender, diabetes mellitus, 
heart failure, hypertension, myocardial infarction and use of list 1 QTc prolonging drugs 
(table 2).
Calcium channel blockers, NOS1AP variant alleles and 
QTc interval
Minor alleles of both NOS1AP SNPs were associated with a significant QTc interval 
prolongation, after complete adjustment (approximately 3.4 ms per additional G-allele 
(95%CI 2.4 ; 4.4) for rs10494366) (table 3). 
SNP rs10494366 T>G in combination with current use of isradipine was associated 
with a significant QTc prolongation for the GG genotype compared to users with the 
TT genotype (19.8 ms (1.9 ; 37.7)). However, SNP rs10494366 T>G did not modify the 
effect on QTc interval on a multiplicative scale in association with isradipine (p=0.3563). 
Users of verapamil with the GG-genotype had significantly more QTc prolongation than 
Table 2 Calcium channel blockers and QTc prolongation
Non-
users
Prolongation QTc 
interval non-users
Users1 Prolongation QTc 
interval (95% CI)2
Calcium channel blockers with 
mainly vascular effects 
6815 Reference 750 0.0 (-1.6 ; 1.7)
             Amlodipine 7327 Reference 238 0.9 (-1.7 ; 3.6)
             Isradipine 7521 Reference 44 0.8 (-6.0 ; 7.6)
             Nifedipine 7206 Reference 359 -0.5 (-2.9 ; 1.9)
Calcium channel blockers with 
direct cardiac effects
7136 Reference 429 2.0 (-0.1 ; 4.1)
             Diltiazem 7269 Reference 296 1.7 (-0.8 ; 4.3)
             Verapamil 7453 Reference 112 6.0 (1.7 ; 10.2)
CI=Confidence Interval; QTc interval in ms
1: Since some specific drugs were used by <40 participants, numbers do not add up
2:QTc prolongation of calcium channel blocker users compared to non-users, adjusted for age and sex, diabetes mellitus, hypertension, 
myocardial infarction, heart failure and use of list 1 QTc prolonging drugs.
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users with the TT-genotype. Moreover, SNP rs10494366 T>G modified the effect on 
the QTc interval on a multiplicative scale in association with verapamil (p=0.0038). This 
association is still significant after Bonferroni correction (0.05/5=0.01). We observed no 
difference in effect on QTc prolongation of the SNPs between men and women. Similar 
effects were observed for the rs10918594 C>G SNP.
Nine of the 18 verapamil users with the GG genotype were male, the mean age was 
69.4 years (SD 7.8). The mean defined daily dosage (DDD) was 1.0 (SD 0.5) and the 
mean duration of verapamil use was 89 days (SD 70). None of the 18 participants had 
diabetes mellitus or a myocardial infarction, all participants were diagnosed with heart 
failure, 4 with hypertension and none of the participants used QTc prolonging drugs.
Additional adjustment for daily dose and duration of use did not substantially change 
the estimates. 
Discussion
We demonstrated in this large prospective cohort study of an elderly population, that the 
minor alleles of both NOS1AP SNPs significantly potentiated the QTc interval prolonging 
effect of verapamil. Furthermore, regression coefficients indicated that a similar effect 
Table 3 Calcium channel blockers, NOS1AP and QTc prolongation
Users1 rs 10494366 
TT
Users1 rs 10494366 
TG2
Users1 rs 10494366 
GG2
P-value 
multi-
plicative 
test
Non-users 2581 Reference 2953 3.4 (2.4 ; 4.4) 852 7.3 (5.8 ; 8.7)
Calcium channel 
blockers with mainly 
vascular effects 
314 Reference 328 2.8 (-1.5 ; 7.0) 108 5.2 (-0.8 ; 11.2) 0.1849
             Amlodipine 92 Reference 110 3.5 (-3.6 ; 10.7) 36 1.9 (-7.9 ; 11.7) 0.4640
             Isradipine 22 Reference 17 5.3 (-8.6 ; 19.2) 5 19.8 (1.9 ; 37.7) 0.3563
             Nifedipine 151 Reference 156 1.4 (-5.1 ; 7.8) 52 5.6 (-3.5 ; 14.6) 0.5463
Calcium channel 
blockers with direct 
cardiac effects
171 Reference 193 1.8 (-4.2 ; 7.8) 65 10.8 (2.5 ; 19.1) 0.9209
             Diltiazem 120 Reference 129 -0.7 (-7.8 ; 6.4) 47 4.3 (-5.2 ; 13.7) 0.1986
             Verapamil 47 Reference 47 5.0 (-8.4 ; 18.3) 18 25.4 (5.9 ; 44.9) 0.0038
CI=Confidence Interval; QTc interval in ms
1: Since some specific drugs were used by <40 participants, numbers do not add up
2: QTc prolongation of users with TG or GG genotype compared to users with the TT genotype, adjusted for age and sex, diabetes mellitus, 
hypertension, myocardial infarction, heart failure and use of list 1 QTc prolonging drugs.
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might exist for isradipine, although SNP rs10494366 T>G did not modify the effect on 
QTc interval on a multiplicative scale in association with isradipine. 
Current use of verapamil was associated with a significant increase in the QTc interval. 
For amlodipine, isradipine, nifedipine and diltiazem we could not confirm a significant 
increase in the QTc interval. This might be due to the fact that verapamil causes a high-
affinity blockage of the hERG-current (IC50 range 0.14 – 0.83 mM), whereas amlodipine 
(IC50 unknown), diltiazem (IC50 range 10 –17.3 mM), isradipine (after 10 mM 3.1 ± 1.8% 
inhibition), and nifedipine (IC50 275 mM) weakly or do not block the hERG-current.
[42-45] The concentration of verapamil needed to block the hERG-encoded potassium 
channels overlaps with the concentration needed to block the calcium channel (IC50 
range 0.25 – 15.5 mM), whereas the concentrations of the other calcium channel block-
ers needed to block the calcium channels are much lower than the concentration needed 
to block the hERG-encoded potassium channels (amlodipine, isradipine and nifedipine 
(IC50 range 0.1 – 1.0 mM) and diltiazem (IC50 range 0.63 – 5.0 mM)).[45] Although 
a QTc interval prolongation of 6 ms in one individual usually remains without clinical 
consequences, an average shift of 6 ms in a Gaussian distribution on a population level 
will inevitably push more individuals into the upper percentiles of the QTc interval with 
its increased risk of Torsade de Pointes and sudden cardiac death. 
Recently, it was found that SNP rs10494366 T>G was associated with an increase 
in the adjusted QTc interval.[10] In participants with minor alleles of SNP rs10494366 
T>G the effect of verapamil on the QTc interval is potentiated. The effect we found 
was significant on a multiplicative scale which suggests interaction on one common 
pathway. Although the mechanism by which NOS1AP influences the QT interval and 
interacts with verapamil is not known, it may involve calcium and potassium currents 
in the cardiomyocyte. NOS1AP has been found to activate NOS1.[13] NOS1 stimulates 
sarcoplasmatic reticulum (SR) Ca2+ release, which leads to increased intracellular cal-
cium.[46] The elevation of intracellular Ca2+ suppresses the Ca2+ entry pathway, the 
L-type calcium channels.[47] Furthermore, elevations in intracellular calcium selectively 
enhances the delayed rectifier current, which leads to increased outflow of potassium.
[47] Verapamil suppresses L-type calcium channels, which are also suppressed by NOS1.
[45] Moreover, verapamil blocks the hERG-encoded potassium channels.[42-44] Thus, 
the physiological feedback system, i.e. the Ca2+ sensitivity of the potassium current, is 
disturbed due to the high-affinity hERG-current blockage caused by verapamil. This sug-
gests a model in which increased intracellular calcium and slow outflow of potassium 
in participants with minor alleles of NOS1AP using verapamil, leads to additional QTc 
prolongation.
Our study has several strengths. First, the availability of data on a large group of 
participants, including up to four ECGs per subject at regular intervals during follow-up, 
which allowed us to obtain more precise long-term ECG measures for each individual. 
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Furthermore, the use of digital ECG recordings all measured using the MEANS system 
likely reduced intra- and interobserver variability in the assessment of the QTc interval. 
Second, the prospective ascertainment of risk factors over a relatively long period of 
follow-up. Third, the availability of genetic material and complete coverage of drug dis-
pensing records allowed us to study the association between calcium channel blockers, 
NOS1AP variant alleles and QTc prolongation. The population-based design of the study 
probably limited the chance of selection bias. Also information bias is unlikely since 
we used pharmacy data, which are registered prospectively and irrespective of disease 
status, while the QTc-intervals were digitally recorded. Confounding was minimized by 
adjusting for all known risk factors of QTc prolongation. However, our study has also 
some potential limitations. The limited exposure to calcium channel blockers at the time 
of sudden cardiac death events, prohibited us from examining the effect modification 
of NOS1AP variant alleles on sudden cardiac death. However, the NOS1AP variant alleles 
may modify the risk of sudden cardiac death associated with QTc prolonging drugs. 
Furthermore, in this study we used QTc prolongation as a surrogate marker of sudden 
cardiac death. However, we demonstrated in an earlier study that QTc prolongation 
itself was associated with a three-fold increased risk of sudden cardiac death.[48]
In conclusion, we demonstrated that the minor alleles of both NOS1AP SNPs signifi-
cantly potentiate the QTc prolonging effect of verapamil. Because QTc prolongation is 
associated with an increased risk of sudden cardiac death, this gene-drug interaction 
may be of clinical importance.
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Abstract
Background
Virtually all QTc prolonging drugs act by blocking the hERG (human ether a go-go 
related gene) encoded potassium channels, whereas not all QTc prolonging drugs are 
associated with an increased risk of serious cardiac arrhythmias. To investigate whether 
binding capacity to hERG-encoded potassium channels can actually predict hard clinical 
endpoints, we studied whether non-cardiovascular drugs, which are known to block 
the hERG-encoded potassium channels, are associated with an increased risk of sudden 
cardiac death and whether the ratio between therapeutic plasma concentrations and 
the concentration which inhibits 50% of the potassium channels is an indicator of the 
risk of sudden cardiac death.
Methods 
We studied the risk of sudden cardiac death associated with use of non-cardiovascular 
hERG-encoded potassium channels inhibiting drugs in the Integrated Primary Care 
Information (IPCI) database, a longitudinal general practice research database. We 
performed a population-based case-control study, matched for age, gender, GP practice 
and calendar time. We calculated odds ratios with conditional logistic regression analy-
sis, multivariably adjusted. In addition, we compared hERG-encoded potassium channel 
inhibiting capacity of the different drugs, defined as the effective free therapeutic 
plasma concentration (ETCPunbound) divided by the concentration which inhibits 50% of 
the potassium channels (IC50), with the risk of sudden cardiac death. 
Results
We identified 1424 cases of sudden cardiac death and 14,443 controls. Current use of non-
cardiovascular hERG-encoded potassium channels inhibiting drugs was associated with an 
increased risk of sudden cardiac death (ORadj 1.67 (95%CI 1.19-2.33)). The risk of sudden 
cardiac death was significantly increased in users of antipsychotics (ORadj 3.90 (2.06-7.37)). 
Patients using hERG-encoded potassium channels inhibiting drugs with a high ETCPunbound/ 
IC50 ratio (≥0.033) had a higher risk of sudden cardiac death (ORadj 2.03 (1.21-3.40)) than 
patients using drugs with a low ETCPunbound/ IC50 ratio (<0.033) (ORadj 1.47 (0.96-2.27)).
Conclusions
We confirmed that current use of non-cardiovascular hERG-encoded potassium chan-
nels inhibiting drugs was associated with an increased risk of sudden cardiac death in 
the general population. In addition, we demonstrated that drugs with a high hERG-
encoded potassium channels inhibiting capacity had a higher risk of sudden cardiac 
death than patients using drugs with a low potassium channels inhibiting capacity.
53hERG-encoded potassium channels inhbiting drugs and SCD
Introduction
In the past decade, one of the most frequent causes of withdrawal of or restriction in 
use of marketed drugs was prolongation of the heart-rate corrected QT (QTc) interval. 
The QTc interval is the traditional measurement for assessing the duration of ventricular 
repolarization.[1] Prolongation of ventricular repolarization may result in early after 
depolarizations (EAD), which in turn may induce re-entry and thereby provoke Torsade 
de Pointes and fatal ventricular arrhythmias.[1-4] The issue of non-cardiac drugs associ-
ated with a pro-arrhythmogenic potential is identified as a considerable public health 
problem.[1] 
Virtually all drugs that prolong the QTc interval block a specific potassium current, 
the rapid component of the delayed rectifier (IKr).[5] IKr is generated by expression of the 
human Ether-à-go-go Related Gene (hERG), which is also known as KCNH2. IKr is often 
used interchangeably with the term hERG-encoded potassium channel, and conducts 
K+ ions out of cardiomyocytes and is responsible for timely repolarization.[6] 
The exact clinical implications of drug-induced QTc prolongation are not quite clear. 
It is known that some drugs associated with QTc prolongation are devoid of torsa-
dogenic effects, whereas others seem to be associated with cardiac arrhythmia with 
just marginal QTc prolongation.[3, 7, 8] In 2003, collaborating researchers from several 
pharmaceutical industries published an extensive review on the ability of QTc prolonging 
drugs to bind to hERG-encoded potassium ion channels in relation to free plasma con-
centrations.[7] Drugs with a small margin (i.e. drugs that block the potassium channels 
in concentrations close to therapeutic plasma concentration) had a high risk of serious 
cardiac arrhythmias. Drugs with a high margin (i.e. those that block the potassium chan-
nel only at high-therapeutic plasma concentrations) seemed to have a lower risk. In this 
review, e.g. sertindole and thioridazine had a small margin, suggesting a high risk of 
cardiac arrhythmias. Amiodarone had a very high margin, which is in line with its known 
low risk of Torsade de Pointes.[7] However, most of these predictions were based on a 
literature survey of non-clinical and clinical data. This ratio between therapeutic plasma 
concentrations and the concentration which inhibits 50% of the potassium channels 
might be a helpful tool in the prediction of the risk of ventricular arrhythmias. 
To investigate whether binding capacity to hERG-encoded potassium channels can 
actually predict hard clinical endpoints, we studied whether non-cardiovascular drugs, 
which are known to block the hERG-encoded potassium channels, are associated with 
an increased risk of sudden cardiac death and whether the ratio between therapeutic 
plasma concentrations and the concentration which inhibits 50% of the potassium 
channels is an indicator of the risk of sudden cardiac death.
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Methods
Setting and study design
Data were retrieved from the Integrated Primary Care Information (IPCI) project, a 
longitudinal observational database, containing data from computer-based medical 
patient records of a large group of general practitioners (GPs) in the Netherlands, for 
a population based case-control study. In the Dutch health care system, the GP has a 
pivotal role by acting as a gatekeeper for all medical care. Details of the database have 
been described elsewhere.[9, 10] Briefly, the database contains the complete medical 
records on approximately 1 million patients. The electronic records contain coded and 
anonymous data on patient demographics, symptoms (in free text), diagnoses (using 
the International Classification for Primary Care (ICPC) [11] and free text) from GPs 
and specialists, referrals, laboratory findings, hospitalisations, and drug prescriptions, 
including their indications and dosage regimen. To guarantee completeness of the data, 
GPs participating in the IPCI project are not allowed to maintain a system of paper-based 
records besides the electronic medical records. The system complies with European 
Union guidelines on the use of medical data for medical research and was considered as 
valid for pharmaco-epidemiological research in several validation studies that evaluated 
the quality of the available information.[9] The Scientific and Ethical Advisory Board of 
the IPCI project approved this study. 
The source population comprised all patients of 18 years and older in the IPCI data-
base with a valid database history (date of registration with GP) of at least one year. The 
study population comprised all cases with sudden cardiac death occurring in the source 
population during the study period plus their matched controls (see below). The study 
period started on 1 January 1995 and ended on 1 May 2007. All subjects were followed 
until death, transferring out of the GP practice, last data draw down or end of the study 
period, whichever came first. 
Definition of sudden cardiac death
Sudden cardiac death was defined as: 1) a witnessed natural death attributable to 
cardiac causes, heralded by abrupt loss of consciousness, within one hour of onset of 
acute symptoms, or 2) an unwitnessed, unexpected death of someone seen in a stable 
medical condition <24 hours previously with no evidence of a non-cardiac cause.[12, 13]
The computerised medical and demographic data were screened for all deaths, 
which occurred during the study period. The medical records of all identified cases of 
death were reviewed manually to assess whether death could be classified as sudden 
cardiac death. Validation was performed independently by two medically trained per-
sons blinded to exposure and in case of discrepancy, a specialized physician arbitrated. 
To each case of sudden cardiac death, up to twenty controls were randomly drawn from 
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the source population matched on age (year of birth), gender, and practice (GP). The 
index date was defined as the date on which sudden cardiac death occurred in cases. 
This date was also the index date for matched controls. 
Use of non-cardiovascular hERG -encoded potassium 
channels inhibiting drugs
In this study, the exposure of interest included all non-cardiovascular hERG-encoded 
potassium channels inhibiting drugs [7, 14] which are prescription drugs in the study 
population and are not available as over-the-counter drugs. Since IPCI contains GP 
records with prescription information, information about use of over-the-counter drugs 
is not available. The following drugs were included: the antidepressants amitriptyline, 
fluoxetine, and imipramine; the anticonvulsant phenytoin; the antihistamines chlor-
pheniramine, ebastine, mizolastine; the antimicrobials ciprofloxacin, clarithromycin, 
erythromycin, and ketoconazole; the antipsychotics haloperidol, olanzapine, pimozide, 
risperidone, and thioridazine; the gastrointestinal drug cisapride; and the hormone 
antagonist tamoxifen.
The duration of each prescription was calculated by dividing the total number of 
units issued per prescription by the prescribed daily number of units. Use was defined as 
current if the index date fell within a period of use or within a maximum of 7 days after 
the end of the last prescription (to deal with carry-over effects and/or irregular use by 
patients). Past use was defined as discontinuation of the drug, more than 7 days before 
the index date. If patients did not receive a prescription in the study period prior to the 
index date they were considered as non-exposed. 
Covariates
Known risk factors and other covariates for sudden cardiac death were gathered from 
the medical records through computerized searches and manual validation. Myocardial 
infarction, arrhythmias, transient ischemic attack, stroke and heart failure were assessed, 
based on the diagnoses provided by the general practitioner and by specialists in the 
medical records. Hypertension was identified through the diagnoses in the medical 
records, the use of antihypertensive medication and/or blood pressure measurements 
above 140/90 mmHg.[15] Diabetes mellitus and hypercholesterolemia were identified 
through diagnoses in the medical records from GPs and specialists and/ or the use of 
antidiabetic or lipid lowering medication. Use of QTc prolonging drugs, antiarrhythmic 
drugs, digoxin, CYP3A4 affecting drugs, laxatives, diuretics, oral corticosteroids and 
beta agonists at the index-date were considered as a covariate.[16] 
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Statistical analysis
The relative risk of sudden cardiac death associated with use of non-cardiovascular 
hERG-encoded potassium channels inhibiting drugs was estimated by calculation of 
the adjusted odds ratios using conditional logistic regression analyses. Covariates which 
were univariately associated with sudden cardiac death (at a p< 0.1 level) were included 
in the regression analyses if they changed the point estimate of the association between 
use of these drugs and sudden cardiac death by more than 5%.[17] 
First, we assessed the association of use of any non-cardiovascular hERG-encoded 
potassium channels inhibiting drug with sudden cardiac death. Among current users 
we evaluated the effect of duration (< 30 days; ≥ 30 days and < 90 days; ≥ 90 days) 
of continuous use which was defined as the delay between first intake and the index 
date. In addition, we evaluated the effect of anti-hERG -encoded potassium channels 
inhibiting capacity, defined as the effective free therapeutic plasma concentration 
(ETCPunbound) divided by the concentration which inhibits 50% of the potassium chan-
nels (IC50), among current users. Redfern et al. suggested that the “safe” margin of 
the IC50/ETCPunbound ratio is 30, since drugs with a ratio smaller than 30 have a high 
torsadogenic propensity, whereas drugs with a ratio greater than 30 appeared to have a 
low torsadogenic propensity.[7] Therefore, we used an ETCPunbound/ IC50 ratio of 0.033 
corresponding to an IC50/ETCPunbound ratio of 30, as a cut-off point. We investigated 
potential effect modification by age and gender. Second, we assessed separately per 
drug whether current use was associated with an increased risk of sudden cardiac 
death. We assessed the effect of dosage among current users (<1 DDD; ≥ 1DDD). All 
analyses were performed using SPSS for Windows version 15.0 (Chicago, Illinois, USA).
Results
Subject characteristics 
The source population for this study comprised 478,661 subjects with at least one year 
of valid history during the study period. The total number of person-years of follow-
up was 1,905,382 years, 14,259 persons died, 926 persons were classified as definite 
sudden cardiac death, 498 as probable sudden cardiac death. Overall, there were 1424 
cases and 14,443 matched controls. The mean age of the cases was 72.9 years and 58.4 
% were male. 
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Association between non-cardiovascular hERG -encoded 
potassium channels inhibiting drugs and sudden cardiac 
death
Of all cases, 54 patients were current users at the index date and 227 patients were 
past users (table 2). There was a significant association between current use and sud-
den cardiac death (adjusted OR 1.67 (95% CI 1.19-2.33)). Past use was not associated 
with an increased risk of sudden cardiac death (ORadj 1.00 (0.85-1.19)). Patients using 
Table 1 Baseline characteristics, demographics, distribution of covariates
Characteristic
Sudden cardiac 
death cases 
(n = 1424)
Controls
 (n = 14,443)
OR (95% CI)1
Gender
    Male 831 (58.4%) 8739 (60.5%)
    Female 593 (41.6%) 5704 (39.5%)
Age (mean, SD) (years) 72.9 (13.9) 66.7 (13.8)
    ≤ 55 170 (11.9%) 3008 (20.8%)
    55 – 65 193 (13.6%) 2853 (19.8%)
    66 – 75 366 (25.7%) 4274 (29.6%)
    > 75 695 (48.8%) 4308 (29.8%)
Co-morbidities
    Myocardial infarction 77 (5.4%) 271 (1.9%) 2.75 (2.06 – 3.67)*
    Transient ischemic attack 65 (4.6%) 383 (2.7%) 1.18 (0.88 – 1.59)
    Stroke 59 (4.1%) 259 (1.8%) 1.66 (1.21 – 2.28)*
    Arrhythmia 141 (9.9%) 837 (5.8%) 1.45 (1.18 – 1.79)*
    Hypertension 268 (18.8%) 2284 (15.8%) 1.18 (1.04 – 1.34)*
    Diabetes mellitus 284 (19.9%) 1274 (8.8%) 2.43 (2.09 – 2.84)*
    Heart failure 272 (19.1%) 615 (4.3%) 4.09 (3.42 – 4.90)*
    Hypercholesterolemia 204 (14.3%) 1619 (11.2%) 1.60 (1.35 – 1.91)*
    Smoking 283 (19.9%) 2857 (19.8%) 1.28 (1.10 – 1.50)*
    Alcohol abuse 30 (2.1%) 107 (0.1%) 3.59 (2.31 – 5.58)*
Concomitant medication
    QTc prolonging drugs 58 (4.1%) 283 (2.0%) 2.01 (1.48 – 2.75)*
    Antiarrhythmic drugs 19 (1.3%) 104 (0.7%) 1.76 (1.03 – 2.99)*
    Digoxin 118 (8.3%) 317 (2.2%) 3.52 (2.76 – 4.48)*
    CYP3A4 inducing drugs 10 (0.7%) 45 (0.3%) 2.05 (0.97 – 4.30)
    CYP3A4 inhibiting drugs 65 (4.6%) 302 (2.1%) 1.78 (1.32 – 2.38)*
    Laxatives 89 (6.3%) 431 (3.0%) 1.65 (1.27 – 2.14)*
    Diuretics 241 (16.9%) 901 (6.2%) 3.09 (2.58 – 3.69)*
    Oral corticosteroids 44 (3.1%) 137 (0.9%) 2.71 (1.87 – 3.91)*
    Beta agonists 144 (10.1%) 851 (5.9%) 1.83 (1.50 – 2.24)*
1: Odds Ratios matched for age, gender, practice and calendar time
 SD Standard Deviation
 * P<0.05
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hERG-encoded potassium channels inhibiting drugs less than 30 days had a higher risk 
of sudden cardiac death (ORadj 1.86 (1.25-2.777)) than patients using these drugs more 
than 30 days (ORadj 1.30 (0.70-2.40)). Patients using hERG-encoded potassium channels 
inhibiting drugs with a high ETCPunbound/ IC50 ratio (≥0.033) had a higher risk of sudden 
cardiac death (ORadj 2.03 (1.21-3.40)) than patients using drugs with a low ETCPunbound/ 
IC50 ratio (<0.033) (ORadj 1.47 (0.96-2.27)). 
Stratified analyses showed that the risk of sudden cardiac death was higher in 
women (ORadj 2.02 (1.32-3.10)) than in men (ORadj 1.23 (0.71-2.12)) and higher in 
patients younger than 65 years (ORadj 2.68 (1.40-5.13)) than in patients older than 65 
years (ORadj 1.44 (0.98-2.12)), but these differences were not statistically significant. 
Table 2 Use of non-cardiovascular hERG-encoded potassium channels inhibiting drugs and risk of sudden cardiac death
Non-cardiovascular 
hERG-encoded potassium 
channels blocking drugs 
Cases 
(n=1424)
Controls 
(n = 14,443)
OR (95% CI)1 OR (95% CI)2
Never use 1143 (80.3) 12099 (83.8) Reference Reference
Past use 227 (15.9) 2088 (14.5) 1.08 (0.92 – 1.27) 1.00 (0.85 – 1.19)
Current use 54 (3.8) 256 (1.8) 1.81 (1.30 – 2.53) 1.67 (1.19 – 2.33)
    Duration of use
        < 30 days 38 (2.7) 162 (1.1) 2.00 (1.35 – 2.96) 1.86 (1.25 – 2.77)
        ≥ 30 days 16 (1.1) 94 (0.7) 1.47 (0.81 – 2.67) 1.30 (0.70 – 2.40)
        < 90 days 52 (3.7) 254 (1.8) 1.77 (1.27 – 2.49) 1.64 (1.17 – 2.31)
        ≥ 90 days 2 (0.1) 2 (0) NA NA
    ETCPunbound/ IC50 ratio
        < 0.033 28 (2.0) 176 (1.2) 1.61 (1.05 – 2.47) 1.47 (0.96 – 2.27)
        ≥ 0.033 26 (1.8) 80 (0.6) 2.19 (1.31 – 3.64) 2.03 (1.21 – 3.40)
Effect modification
    Gender
        Females 33 (5.6) 143 (2.5) 2.10 (1.37 – 3.22) 2.02 (1.32 – 3.10)
        Males 21 (2.5) 113 (1.3) 1.46 (0.85 – 2.50) 1.23 (0.71 – 2.12)
    Age 
        < 65 years 13 (3.6) 66 (1.1) 3.07 (1.63 – 5.76) 2.68 (1.40 – 5.13)
        ≥ 65 years 41 (3.9) 190 (2.2) 1.55 (1.06 – 2.28) 1.44 (0.98 – 2.12)
1: Odds Ratios matched for age, gender, practice and calendar time
2: Odds Ratios matched for age, gender, practice and calendar time, adjusted for use of diuretics.
ETCPunbound/ IC50 ratio: Measure of anti-hERG-encoded potassium channels inhibiting activity.[14]
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Association between individual drug (groups) and sudden 
cardiac death
The risk of sudden cardiac death was significantly increased in users of antipsychotics 
(ORadj 3.90 (2.06-7.37)), predominantly in users of haloperidol and risperidone (table 
3). The risk was not increased in users of antidepressants, anticonvulsants, antihista-
mines, antimicrobials, gastrointestinal drugs and hormone antagonists, probably due 
to the limited number of exposed cases. The risk of sudden cardiac death tended to be 
higher in users of antimicrobials and the hormone antagonist tamoxifen, although non-
significantly (ORadj 2.22 (0.89 – 5.49) and ORadj 2.78 (0.91-8.50), respectively). Patients 
using higher dosages (≥ 1 DDD) of antidepressants, antimicrobials and antipsychotics 
had a higher risk of sudden cardiac death than patients using lower dosages (< 1 DDD) 
(table 3).
Table 3 Current use of individual non-cardiovascular hERG-encoded potassium channels inhibiting drugs and risk of sudden cardiac death
ETCPunbound/ 
IC50 ratio
Cases 
(n=1424)
Controls 
(n = 14,443)
OR (95% CI)1 OR (95% CI)2
Antidepressants
Current use 12 126 0.98 (0.53 – 1.81) 1.01 (0.54 – 1.90)
    Amitriptyline 0.00880 9 100 0.90 (0.44 – 1.83) 0.91 (0.44 – 1.87)
    Fluoxetine 0.00935 3 24 1.42 (0.40 – 5.05) 1.62 (0.45 – 5.78)
    Imipramine 0.0312 0 2 NA NA
    <1 DDD 10 112 0.88 (0.44 – 1.74) 0.89 (0.44 – 1.79)
    ≥1 DDD 2 14 2.69 (0.58 – 12.47) 2.44 (0.50 – 12.00)
Anticonvulsants
Current use 3 14 1.36 (0.31 – 6.04) 1.15 (0.25 – 5.21)
    Phenytoin 0.0436 3 14 1.36 (0.31 – 6.04) 1.15 (0.25 – 5.21)
Antihistamines
Current use 0 15 NA NA
    Chlorpheniramine 0.00688 0 7 NA NA
    Ebastine 0.0170 0 3 NA NA
    Mizolastine 0.0249 0 5 NA NA
Antimicrobials
Current use 10 18 2.99 (1.24 – 7.24) 2.22 (0.89 – 5.49)
    Ciprofloxacin 0.00547 3 5 2.75 (0.58 – 12.91) 2.35 (0.48 – 11.65)
    Clarithromycin 0.0367 5 12 2.30 (0.67 – 7.87) 1.50 (0.42 – 5.35)
    Erythromycin 0.00235 1 1 NA NA
    Ketoconazole 0.0932 1 0 NA NA
    <1 DDD 5 13 2.22 (0.65 – 7.55) 1.79 (0.50 – 6.35)
    ≥1 DDD 5 5 4.06 (0.80 – 20.51) 3.52 (0.72 – 17.18)
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Discussion
In this study, we demonstrated that current use of non-cardiovascular hERG-encoded 
potassium channels inhibiting drugs in the general population was associated with an 
increased risk of sudden cardiac death. The risk tended to be higher in women than in 
men, which is in line with earlier findings that women seem to be more susceptible to 
drug-induced cardiac arrhythmias than men.[3, 8] 
In line with regulatory recommendations, most new drugs are tested for their ability 
to block hERG-encoded potassium channels.[18] However, some QTc prolonging drugs 
that do not seem to cause Torsade de Pointes, also block this current, whereas on the 
other hand some drugs that prolong the QTc interval with only few milliseconds are 
implicated in the occurrence of cardiac arrhythmias.[7, 8, 19, 20] Since the amount of 
QTc prolongation is not a specific predictor of symptomatic cardiac rhythm disorders, it 
is important to have another measure to predict arrhythmias. 
ETCPunbound/ 
IC50 ratio
Cases 
(n=1424)
Controls 
(n = 14,443)
OR (95% CI)1 OR (95% CI)2
Antipsychotics
Current use 20 35 3.90 (2.06 – 7.37) 3.90 (2.06 – 7.37)
    Haloperidol 0.133 11 16 3.49 (1.43 – 8.53) 3.49 (1.43 – 8.53)
    Olanzapine 0.0225 3 1 NA NA
    Pimozide 0.0287 0 7 NA NA
    Risperidone 0.0121 5 9 3.90 (1.13 – 13.53) 3.90 (1.13 – 13.53)
    Thioridazine 29.7 1 2 NA NA
    <1 DDD 12 19 3.66 (1.59 – 8.45) 3.66 (1.59 – 8.45)
    ≥1 DDD 8 16 5.20 (2.10 – 12.91) 5.20 (2.10 – 12.91)
Gastrointestinal 
drugs
Current use 7 37 1.56 (0.63 – 3.86) 1.27 (0.51 – 3.20)
    Cisapride 2.45 7 37 1.56 (0.63 – 3.86) 1.27 (0.51 – 3.20)
Hormone 
antagonists
Current use 5 15 3.24 (1.11 – 9.52) 2.78 (0.91 – 8.50)
    Tamoxifen 0.0210 5 15 3.24 (1.11 – 9.52) 2.78 (0.91 – 8.50)
ETCPunbound/ IC50 ratio: Measure of anti-hERG-encoded potassium channels inhibiting activity.[14]
Effects of DDDs are presented for classes with at least 10 exposed cases.
1: Odds Ratios matched for age, gender, practice and calendar time
2: Odds Ratios matched for age, gender, practice and calendar time. Antidepressants adjusted for diabetes mellitus and heart failure; 
anticonvulsants adjusted for hypertension, heart failure and use of steroids and antiarrhythmics; antimicrobials adjusted for diabetes mellitus, 
heart failure, QTc prolonging drugs (other than drugs studied), use of antipsychotics, gastrointestinal drugs, CYP3A4 inhibitors, digoxin, 
diuretics, steroids and beta agonists; gastrointestinal drugs adjusted for diabetes mellitus, heart failure and diuretics and hormone antagonists 
adjusted for heart failure, diabetes mellitus and use of digoxin, diuretics  and steroids.
Table 3 continued
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We were able to demonstrate that drugs with a high hERG-encoded potassium chan-
nels inhibiting capacity (drugs that block the potassium channels in concentrations close 
to therapeutic plasma concentrations) had a higher risk of sudden cardiac death than 
patients using drugs with a low potassium channels inhibiting capacity (drugs that block 
the potassium channels only at high-therapeutic plasma concentrations). This suggests 
that the ratio between therapeutic plasma concentrations and the concentration which 
inhibits 50% of the potassium channels might be a helpful tool in the prediction of fatal 
ventricular arrhythmias.
In a previous study, it was demonstrated that hERG-encoded potassium channels 
inhibiting drugs were associated with an increased number of reports of serious ventric-
ular arrhythmias and sudden death in the adverse drug reactions database of the World 
Health Organization.[14] These reports are voluntarily submitted to pharmacovigilance 
centres and often do not contain a full medical history whereas data on other risk fac-
tors may be incomplete or lacking. Moreover, since reporting of adverse drug reactions 
is voluntarily, not all adverse drug reactions are reported and not all adverse reactions 
are recognized by the doctor. Earlier, we demonstrated in IPCI that use of non-cardiac 
QTc prolonging drugs specified in list 1 from a commonly consulted internet based 
registry of QTc prolonging drugs was associated with an increased risk of sudden cardiac 
death.[16, 21] This study, however, was smaller than the current one (700 cases are in 
common), focused on QTc prolonging drugs in general, and did not take hERG-encoded 
potassium channels inhibiting activity into account. The increased risk of sudden cardiac 
death in users of antipsychotics has been described before.[22, 23]
In our population, we were able to take advantage of the fact that in the Dutch health 
care system, all medical information (including specialist and hospital care) is collected at 
practices that cover the general population instead of selected socio-economic groups. 
As a consequence, there was extensive information available on drug use, potential con-
founders, and all circumstances surrounding death. Nevertheless, our study has some 
potential limitations. First, we cannot exclude that some misclassification of outcome 
occurred. We may have missed some deaths although this will be minimal, since death 
is consistently registered by GPs. Second, not all acute deaths may have been of cardiac 
origin. We determined sudden cardiac death, however, on the basis of the full medical 
records and all circumstances surrounding the death were available. Recently, an evalu-
ation comparing different methods to determine the incidence of sudden cardiac death 
suggested that this method provides a very reliable way of determining sudden cardiac 
death cases.[24] Misclassification of exposure may have occurred for various reasons. 
First, we used outpatient prescription data and we had no information as to whether the 
prescription was actually filled and taken. Second, the legend duration for a calculated 
prescription may not reflect actual use. Third, hERG-encoded potassium channels inhibi-
tion might be only one out of several mechanisms of drug-induced QTc prolongation 
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and sudden cardiac death. Recently, several new genetic loci were found.[25] Possibly, 
some of these might also modify the magnitude of QTc prolongation by drugs.
In conclusion, we confirmed that current use of non-cardiovascular hERG-encoded 
potassium channels inhibiting drugs was associated with an increased risk of sudden 
cardiac death in the general population. In addition, we demonstrated that drugs with 
a high hERG-encoded potassium channels inhibiting capacity had a higher risk of sud-
den cardiac death than patients using drugs with a low potassium channels inhibiting 
capacity. This suggests that the ratio between therapeutic plasma concentrations and 
the concentration which inhibits 50% of the potassium channels might be a helpful tool 
in the prediction of fatal ventricular arrhythmias.
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Abstract 
Background
Recently a 4-fold increase in risk of sudden cardiac death (SCD) was reported for dom-
peridone in a study that focused on QTc prolonging drugs as a class and sudden cardiac 
death. We wanted to evaluate the association between use of domperidone and serious 
non-fatal ventricular arrhythmia (VA) and SCD in the general population. 
Methods
Design: Population-based case-control study during 1996-2007.
Setting: Integrated Primary Care Information (IPCI) database, a longitudinal general 
practice research database in the Netherlands.
Population: All patients ≥ 18 years without cancer were included in the source population. 
Exposure: Use of domperidone (current, past and none) and daily dose of use.
Outcome: Serious non-fatal VA or SCD.
Analysis: Controls matched to cases on age, gender, practice and index date. Com-
parison of exposure odds for SCD alone and ventricular arrhythmia plus SCD by means 
of conditional logistic regression, multivariate adjusted. In addition, we stratified by 
insurance since there was differential misclassification due to insurance (since the drug 
is mostly used OTC and reimbursed).
Results
The study population comprised 1366 cases (62 VA and 1304 SCD) and 14,114 matched 
controls. Of all cases, 10 patients were current domperidone users at the index date, 
all with SCD. The matched unadjusted OR of domperidone and SCD was 3.72 (95%CI 
1.72 – 8.08). Daily doses >30 mg were associated with a significant increased risk of 
SCD (ORadj 11.4 (1.99 - 65.2)). Since there was a near interaction with health insurance 
(P=0.050), all analyses were stratified by insurance. In publicly insured patients, 7 cases 
were current users at the index date. Current use was associated with a significant 
increased risk of SCD (ORadj 4.17 (1.33- 13.1)). In privately insured patients there was 1 
exposed case and in non-insured 2.
Conclusions
Current use of domperidone, especially high doses, is associated with an increased risk 
of SCD. We could not demonstrate an effect of domperidone on non-fatal VA due to 
absence of exposed cases. 
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Introduction
Domperidone is a peripheral dopamine D2-receptor antagonist with gastrokinetic and 
anti-emetic properties and has been marketed since March 1978 as a prescription drug 
for the following indications: nausea, vomiting, and dyspepsia associated with motility 
disorders.[1] In many countries, such as the Netherlands, domperidone is also available 
as over the counter product for treatment of nausea and dyspepsia associated with 
motility disorders. In the Netherlands, domperidone was available as over the counter 
drug, but reimbursement was possible when prescribed. As of January 2004, domperi-
done was no longer reimbursed, even when prescribed. As of January 2005, the drug 
was reimbursed in case of chronic use (> 6 months). 
A recent epidemiological study conducted in the Netherlands evaluated the use of 
non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death (SCD). In a 
sub-analysis it was found that domperidone increased the risk of SCD almost 4-fold.[2] 
Since the study was not primarily focused on individual drugs and modeling was not 
specific for the individual drugs, the marketing authorization holder asked for a more 
specific study that would focus on domperidone and would include not only SCD but 
also non-fatal ventricular arrhythmias (VA’s). 
Prolongation of the heart-rate corrected QT (QTc) interval, which is the traditional 
measurement for assessing the duration of ventricular repolarization, life-threatening 
ventricular tachyarrhythmias and even cardiac arrests have been reported after intra-
venous use of domperidone, however often confounded by concomitant medications 
and co-morbidity.[3] Prolongation of ventricular repolarization may result in early after 
depolarizations (EAD), which in turn may induce re-entry and thereby provoke Torsade 
de Pointes and fatal ventricular arrhythmias.[4-8] 
Inhibition of the human ether-a-go-go-related gene (hERG), which encodes a delayed 
rectifier K+ current, leads to prolongation of the QTc interval.[9] Domperidone has been 
shown to inhibit the hERG current and to cause a significant prolongation of cardiac 
repolarization.[3] Domperidone is mainly metabolised via the cytochrome P450 3A4 
(CYP3A4) isoenzyme, in vitro data indicate that the concomitant use of drugs that sig-
nificantly inhibit this enzyme may result in increased plasma concentrations of domperi-
done. Even though no effect on QTc was seen with oral domperidone as monotherapy, 
prolongation of the QTc interval was observed when combined with ketoconazole, a 
CYP3A4 inhibitor.[10] 
The primary purpose of this study was to evaluate the association between use of 
domperidone and serious fatal (SCD) and non-fatal VA, while controlling specifically 
for confounding factors in this association. This was done in the same database as was 
used for the initial study [2], but was extended to include ventricular arrhythmia and 
updated until 2007.
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Methods
Setting
All data were retrieved from the Integrated Primary Care Information (IPCI) database, 
a longitudinal database of electronic medical records from general practitioners (GPs) 
in the Netherlands. In the Dutch health care system, the GP has a pivotal role by acting 
as a gatekeeper for all medical care. Nearly every citizen is enrolled in the practice of 
a GP independent of health status.[11] Details of the database have been described 
elsewhere.[11, 12] Briefly, the database currently contains the complete medical records 
of 1 million citizens. The electronic records contain coded (using the International clas-
sification for Primary Care[13] and free text) and narrative data on demographics, health 
care insurance (public or private as a proxy for income), symptoms, and diagnoses from 
GPs and specialists, referrals, laboratory findings, hospitalizations, and drug prescrip-
tions, including their indications and dosage regimen. To maximize completeness of 
the data, GPs participating in the IPCI project are not allowed to maintain a system of 
paper-based records besides the electronic medical records. The project complies with 
European Union guidelines on the use of medical data for medical research and has 
been proven valid for pharmaco-epidemiological research in several validation studies 
that evaluated the quality of the available information.[12] The Scientific and Ethics 
Advisory Board of the IPCI project approved this study (project number: 07/07).
Source population
The source population comprised all patients of 18 years and older in the IPCI database 
with a valid database history of at least one year. Follow-up started whenever all entrance 
criteria (one year of valid database capture, age of 18 years, and 1 January 1995) were 
reached. All subjects in the source population were followed until the occurrence of 
the outcome of interest (SCD, non-fatal VA or the earliest of both), cancer (exclusion 
criterion), death, transferral out of the practice, date of last data collection from the GP 
or end of the study (1 May 2007), whichever came first. The study population comprised 
all cases with serious VA or SCD occurring in the source population during the study 
period and their matched controls.
Case and control definition
The primary outcome of interest was serious idiopathic VA (ventricular fibrillation (VF) or 
Torsade de Pointes (TdP)) and SCD. Potential cases were identified through a sensitive 
search on codes and narratives. Subsequently, the medical records of all potential cases 
were reviewed manually to assess whether death could be classified as SCD or whether 
non-fatal VA could be classified as VF or TdP. Initial validation was performed indepen-
dently by two medically trained persons who were blinded to exposure and classified 
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cases as potential or none cases. All potential cases were re-assessed by a specialized 
physician and classified as probable or definite. 
Case assessment of SCD was based on the most recent definition of SCD: a natural 
death due to cardiac causes heralded by abrupt loss of consciousness within 1 h after 
the onset of acute symptoms or an unwitnessed, unexpected death of someone seen 
in a stable medical condition < 24 h previously with no evidence of a noncardiac cause.
[14] Cases were classified as SCD if the medical record indicated that death occurred 
within 1 h after the onset of symptoms, and if the following wording was found in the 
free text: ‘sudden cardiac death’, ‘acute cardiac death’, ‘mors subita’, ‘sudden death’, 
‘died suddenly’, ‘died unexpectedly’, or if this was an unwitnessed, unexpected death 
of someone seen in ‘good health’ or in a stable medical condition, 24 h previously 
and without evidence of a non-cardiac cause (e.g. pneumonia, convulsion, choking, 
stroke or suicides). The assessment of SCD was done independently of the previous 
assessment of SCD in the same database (Straus et al.)[2] and more strict with regards 
to any prior symptoms in the unwitnessed cases to avoid protopathic bias (specifically 
for domperidone) due to chest pain. 
Non-fatal VA cases were identified by broad searching on the following codes or 
text words/abbreviations: collapse, VES, VF, ventricular & arrhythmia, PVC, ventricle, 
tachycardia, Torsade, VT, rhythm disturbance, flutter, cardioversion, defibrill*, QRS, QTc, 
ECG abnormalities, death and ICPC diagnosis codes: K79, K80, K84. All potential cases 
either had been referred or seen by a cardiologist or an ECG was performed. All non-
fatal VA cases were divided in TdP (diagnosis made by a specialist with the help of an 
ECG) or VF (diagnosis by an ECG). For all VA’s it was assessed whether they occurred as 
primary or secondary disorder (i.e. as primary disorder or after myocardial infarction). 
The date of onset of VA was assessed based on the information in the electronic medical 
record (including free text). All assessments were done while being blinded to exposure.
To each case, up to 20 (SCD) or 40 (non-fatal VA) controls were randomly drawn from 
the source population matched on age (year of birth), gender and practice. The index 
date was defined as the date on which VA or SCD occurred in the cases. This date was 
also the index date for matched controls. 
Exposure definition
The exposure of interest was use of domperidone. In order to classify use at the index 
date, we calculated the duration of each prescription, by dividing the total number of 
units issued per prescription by the number of units prescribed daily. Exposure at the 
index date was categorized into three groups of current-, past-, and never use. Since 
domperidone is normally prescribed for shorter periods of time, use was defined as 
current if the index date fell within a period of use or within a maximum of 7 days after 
the end of the last prescription to account for carry-over effects. Past use was defined 
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as discontinuation of domperidone for more than 7 days. If patients had no prescription 
prior to the index date they were considered non-exposed. 
To better study the effect of stopping and potential confounding by indication, we 
subcategorized past exposure into recent past exposure (stopping between 8 days and 
3 months), moderate past exposure (3-6 months), distant past exposure (6-12 months 
previous) and very distant past exposure (> 1 year prior). 
If domperidone was prescribed ‘as needed’, the GP estimated duration was taken if 
available, otherwise a default of 30 days was taken. Among current users, we evaluated 
the effect of daily dose (<30, 30 mg (1 DDD) and >30 mg), which allows for dose 
response assessment.
Covariates
Known risk factors for VA/ SCD and other covariates were gathered from the medical 
records. Cerebrovascular ischaemia, cardiovascular ischaemia, heart failure, depression, 
schizophrenia, epilepsy, neuropathy, dyspepsia and COPD were assessed, based on the 
diagnoses provided by the GP and specialists in the medical records. Hypertension was 
identified through the diagnoses in the medical records, use of antihypertensive medica-
tion and/or blood pressure measurements, according to the guidelines of the World 
Health Organization (a blood pressure exceeding 140 mmHg systolic and/or 90 mmHg 
diastolic).[15] Diabetes mellitus and hypercholesterolaemia were identified through 
diagnoses in the medical records from GPs and specialists and/or use of antidiabetic or 
lipid-lowering medication. Diabetic gastropathy (nausea, vomiting, heartburn, abdomi-
nal bloating and early fullness in persons with diabetes mellitus) was assessed through 
manual review of the patient’s files in the year prior to the index date. Information on 
smoking and alcohol abuse was obtained from the codes and narratives in the medical 
records. As concomitant medication, we considered QTc prolonging drugs as specified 
in the most recent version of list 1 (drugs that are generally accepted by authorities 
to have a risk of causing Torsades de Pointes) (http://www.azcert.org/medical-pros/
drug-lists/drug-lists.cfm).[16] Furthermore, we considered drugs that may interact with 
domperidone metabolism (CYP3A4 inhibiting and inducing drugs) and drugs that affect 
hERG, digoxin, diuretics, laxatives, systemic beta-agonists and oral corticosteroids. 
Covariate drug use was classified as current (prescription duration covers the index date 
or stopped less than 8 days ago), past (stopped at index date between 7-365 days) or 
never use. As a measure of health status, the number of GP office visits in the year prior 
to the index date was assessed by the total number of visits during the one year prior.
Statistical analysis
Prescription rates (number of users per year) of domperidone were calculated in the 
source population and stratified by health care insurance to inspect potential differential 
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misclassification due to insurance (since the drug is mostly OTC and reimbursed). The 
association between VA/ SCD and the covariates was assessed through conditional 
logistic regression analysis separately for SCD as well as together. All covariates that 
were univariately associated with the outcome (p<0.10) were considered as potential 
confounders. Subsequently the multivariate models were built to include all covariates 
that changed the association between current use of domperidone and the outcome by 
more than 5% (i.e. 0.95> ORadjusted/OR unadjusted>1.05). Analyses were conducted with 
and without adjustment for the number of visits in the previous year, since GP visits have 
no etiological relationship with the outcome. Interaction of the association between 
domperidone exposure and specific covariates (age, gender, insurance type) was tested 
on the basis of multiplicative interaction using logistic regression (with the matching 
factors as covariates). In addition, we stratified for type of health care insurance. 
Sensitivity analyses were conducted to investigate various sources of bias and residual 
confounding. First, the effect of residual confounding by diabetic gastroparesis was 
addressed by excluding all diabetes patients. In addition we conducted an analysis that 
excluded all patients with prior cardiovascular disease (heart failure and myocardial 
infarction) to avoid residual confounding due to severity of underlying cardiovascular 
disease. Additional misclassification of exposure due to unmeasured OTC use of dom-
peridone was inspected by censoring at 1/1/2004 which was the date that prescribed 
domperidone was no longer reimbursed, thereby taking away any incentive to get the 
drug on prescription. 
Results
The source population for this study comprised 478,661 subjects with at least one year 
of valid history during the study period. Figure 1 shows the prevalence of domperidone 
use in the source population over calendar time by type of health care insurance. Publicly 
insured persons had a higher prevalence of recorded domperidone use than privately 
insured patients, but in 2004 (when reimbursement was lifted for all OTC drugs even 
when prescribed) the prevalence dropped in publicly insured patients and remained stable 
in privately insured patients, pointing to differential misclassification by insurance type. 
Overall, 926 persons were classified as definite SCD and 498 as probable SCD (table 1). 
After exclusion of 120 cases with cancer prior to the index date, the study population 
comprised 1304 cases of SCD and 13,480 matched controls. The mean age of the cases 
was 72.5 years and 58 % were male. 
Of the potential VA cases, 287 were classified as definite VF, and 6 as Torsade de 
Pointes, however only 57 and 6 were not preceded by other disease (such as myocardial 
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Figure 1 Prevalence of domperidone use by calendar year
Table 1 Baseline characteristics, demographics, distribution of covariates
Sudden cardiac death Serious ventricular arrhythmia
Characteristic Cases 
(n = 1304)
Controls
 (n = 13480)
OR (95%CI) Cases 
(n=62)
Controls 
(n=634)
OR (95%CI)
Gender
    Male 755 (57.9) 8211 (60.9) 41 (66.1) 439 (69.2)
Age (mean, SD) (years) 72.5 (14.1) 66.3 (13.9) 64.9 (15.2) 61.6 (14.1)
    ≤ 55 166 (12.7) 2938 (21.8) 13 (21.0) 212 (33.4)
    55 – 65 180 (13.8) 2733 (20.3) 14 (22.6) 146 (23.0)
    66 – 75 330 (25.3) 3948 (29.3) 20 (32.3) 171 (27.0)
    > 75 628 (48.2) 3861 (28.6) 15 (24.2) 105 (16.6)
Co-morbidities
Ischaemic cerebro-/
cardiovascular disease
385 (29.5) 1916 (14.2) 2.01 (1.74 - 2.33) 22 (35.5) 62 (9.8) 5.43 (2.77 - 10.66)
    Angina 294 (22.5) 1408 (10.4) 2.04 (1.74 - 2.39) 19 (30.6) 46 (7.3) 6.44 (3.13 - 13.25)
    Myocardial infarction 64 (4.9) 234 (1.7) 2.64 (1.92 - 3.64) 5 (8.1) 11 (1.7) 5.14 (1.39 - 19.03)
     Transient ischemic attack 59 (4.5) 339 (2.5) 1.22 (0.90 - 1.66) 2 (3.2) 11 (1.7) 1.54 (0.31 - 7.77)
     Cerebrovascular accident 51 (3.9) 215 (1.6) 1.76 (1.25 - 2.48) 1 (1.6) 3 (0.5) 2.75 (0.28 - 27.29)
    Hypertension 487 (37.3) 4103 (30.4) 1.24 (1.09 - 1.42) 20 (32.3) 167 (26.3) 1.01 (0.51 - 1.99)
    Diabetes mellitus 258 (19.8) 1165 (8.6) 2.47 (2.10 - 2.91) 10 (16.1) 51 (8.0) 1.77 (0.73 - 4.27)
    Diabetic gastropathy 30 (2.3) 138 (1.0) 2.06 (1.34 - 3.17) 1 (1.6) 4 (0.6) 2.76 (0.31 - 24.85)
    Heart failure 237 (18.2) 536 (4.0) 4.00 (3.29 - 4.85) 9 (14.5) 9 (1.4) 7.37 (2.35 - 23.06)
    Hypercholesterolemia 178 (13.7) 1459 (10.8) 1.56 (1.30 - 1.88) 16 (25.8) 82 (12.9) 4.41 (2.08 - 9.35)
    Depression 91 (7.0) 699 (5.2) 1.40 (1.10 - 1.79) 5 (8.1) 33 (5.2) 1.40 (0.42 - 4.62)
    Schizophrenia 11 (0.8) 20 (0.1) 6.14 (2.74 - 13.8) 0 (0) 0 (0) NA
     Chronic obstructive lung 
disease
183 (14.0) 1118 (8.3) 1.58 (1.31 - 1.90) 11 (17.7) 63 (9.9) 1.80 (0.77 - 4.24)
    Epilepsy 15 (1.2) 63 (0.5) 2.39 (1.29 - 4.43) 0 (0) 1 (0.2) NA
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infarction). 21 of these 63 persons died within 30 days after the onset of VA. One 
case of the 63 serious VA cases had cancer and was excluded. There were no currently 
exposed cases to domperidone, which hampers the possibility to assess the association 
between VA and prescribed domperidone.
Domperidone and sudden cardiac death
Of all SCD cases, 10 patients were current domperidone users at the index date and 94 
patients were past users (table 2). The matched unadjusted relative risk of domperidone 
and SCD was 3.72 (95%CI 1.72 - 8.08). Current use of domperidone was associated 
with SCD in the entire population although this was not significant anymore when 
adjusting also for GP visits. This effect of GP visits was mostly due to the strong correla-
tion between GP visits and type of health care insurance (P=5.8 *10-32). 
There was a near interaction with health insurance (P=0.050), but not with age 
(P=0.547) and gender (P=0.491). Because of the interaction with insurance, all subse-
quent analyses were stratified by type of health care insurance. Seven of the currently 
exposed domperidone cases were publicly insured, 1 privately and 2 were not insured. 
Sudden cardiac death Serious ventricular arrhythmia
Characteristic Cases 
(n = 1304)
Controls
 (n = 13480)
OR (95%CI) Cases 
(n=62)
Controls 
(n=634)
OR (95%CI)
    Neuropathy 23 (1.8) 260 (1.9) 0.84 (0.53 - 1.32) 2 (3.2) 14 (2.2) 1.45 (0.30 - 7.10)
    Dyspepsia 319 (24.5) 2741 (20.3) 1.18 (1.02 - 1.38) 13 (21.0) 126 (19.9) 1.13 (0.56 - 2.27)
Life style
    Smoking 256 (19.6) 2631 (19.5) 1.33 (1.13 - 1.56) 16 (25.8) 134 (21.1) 1.64 (0.81 - 3.31)
    Alcohol abuse 24 (1.8) 97 (0.7) 3.31 (2.04 - 5.36) 0 (0) 7 (1.1) NA
    Public insurance 831 (63.7) 5932 (44.0) 2.66 (2.30 - 3.08) 28 (45.2) 366 (57.7) 1.97 (0.96 - 4.05)
    Mean GP visits (SD) 6.7 (7.8) 4.3 (5.0) 1.05 (1.04 - 1.07) 5.4 (5.2) 3.6 (4.1) 1.08 (1.01 - 1.16)
Concomitant medication
    QTc prolonging drugs 53 (4.1) 260 (1.9) 2.11 (1.52 - 2.92) 7 (11.3) 13 (2.1) 8.30 (2.43 - 28.31)
    hERG inhibiting drugs 139 (10.7) 813 (6.0) 1.82 (1.48 - 2.24) 10 (16.1) 43 (6.8) 2.92 (1.19 - 7.18)
    CYP 3A4 inducing drugs 10 (0.8) 40 (0.3) 2.33 (1.08 - 5.05) 0 (0) 0 (0) NA
    CYP 3A4 inhibiting drugs 59 (4.5) 277 (2.1) 1.83 (1.34 - 2.50) 1 (1.6) 13 (2.1) NA
     Drugs for dyspepsia and 
GERD (H2RAs and PPIs)
97 (7.4) 840 (6.2) 1.08 (0.85 - 1.37) 2 (3.2) 40 (6.3) 0.28 (0.04 - 2.09)
    Laxatives 81 (6.2) 378 (2.8) 1.77 (1.33 - 2.34) 1 (1.6) 16 (2.5) NA
    Digoxin 112 (8.6) 287 (2.1) 3.74 (2.91 - 4.82) 5 (8.1) 13 (2.1) 3.19 (0.89 - 11.44)
    Diuretics 220 (16.9) 810 (6.0) 3.23 (2.67 - 3.89) 8 (12.9) 33 (5.2) 2.86 (1.12 - 7.26)
    Corticosteroids 36 (2.8) 115 (0.1) 2.49 (1.65 – 3.75) 0 (0) 0 (0) NA
    Beta agonists 134 (10.3) 775 (5.7) 1.94 (1.26 – 2.21) 0 (0) 0 (0) NA
CI=Confidence Interval 
OR=Odds Ratio matched for age, gender, index date and practice
SD=Standard Deviation
Table 1 continued
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In publicly insured persons, domperidone was associated with a significantly increased 
risk of SCD after adjustment for heart failure, hERG inhibiting drugs, laxatives, diuretics, 
steroids and digoxin (OR 4.98 (1.59-15.6)). The association between current use of 
domperidone and SCD decreased slightly after further adjustment for GP visit frequency 
(4.17 (1.33-13.1)). Past use of domperidone was not associated with SCD. In privately 
and non-insured patients we could not estimate the adjusted effect of current use of 
domperidone due to small numbers of exposed persons. The matched unadjusted odds 
Table 2 Risk of sudden cardiac death 
Use of domperidone Cases Controls OR (95% CI)1 OR (95% CI)2 OR (95% CI)3
Overall population 1304 13480
Never use 1200 12781 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 94 671 1.56 (1.23 - 1.98) 1.36 (1.05 - 1.75) 1.28 (0.99 - 1.65)
    recent past 10 54 1.91 (0.95 - 3.86) 1.56 (0.73 - 3.33) 1.39 (0.65 - 2.99)
    moderate past 7 34 2.30 (0.98 - 5.38) 2.24 (0.93 - 5.41) 2.00 (0.83 - 4.86)
    distant past 13 83 1.59 (0.86 - 2.96) 1.26 (0.67 - 2.39) 1.03 (0.53 - 2.00)
    very distant past 64 500 1.46 (1.09 - 1.94) 1.29 (0.95 - 1.75) 1.26 (0.93 - 1.70)
Current use 10 28 3.72 (1.72 - 8.08) 2.44 (1.01 - 5.89) 1.99 (0.80 - 4.96)
           <30 mg 2 10 NA NA NA
           30 mg 4 15 2.57 (0.79 - 8.36) 1.41 (0.38 - 5.32) 1.02 (0.23 - 4.42)
           >30 mg 4 3 16.0 (3.49 - 73.6) 11.2 (2.02 - 62.45) 11.4 (1.99 - 65.2)
Stratified by insurance
Publicly insured 831 5932
Never use 759 5615 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 65 305 1.77 (1.28 – 2.44) 1.47 (1.05 – 2.08) 1.34 (0.94 – 1.90)
Current use 7 12 4.46 (1.46 – 13.7) 4.98 (1.59 – 15.6) 4.17 (1.33  - 13.1)
           <30 mg 1 5 NA NA NA
           30 mg 3 7 3.02 (0.67 – 13.7) 3.27 (0.70 – 15.3) 2.57 (0.54 – 12.2)
           >30 mg 3 0 NA NA NA
Privately insured 412 7289
Never use 387 6918 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 24 358 1.47 (0.87 – 2.48) 1.26 (0.72 – 2.20) 1.22 (0.70 – 2.12)
Current use 1 13 NA NA NA
Not insured 61 259
Never use 54 248 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 5 8 2.05 (0.40 – 10.4) 1.53 (0.25 – 9.40) 1.11 (0.15 – 8.47)
Current use 2 3 NA NA NA
1 Odds ratios matched for age, gender, practice and index date.
2 Overall population:  Odds ratios adjusted for heart failure, insurance type, CYP3A4 inhibitors, HERG inhibiting drugs, laxatives, digoxin, 
diuretics, steroids, beta agonists; Publicly insured: Odds ratios adjusted for heart failure, hERG inhibiting drugs, laxatives, diuretics, steroids and 
digoxin; Privately insured: Odds ratios adjusted for heart failure, diuretics, steroids, beta agonists and digoxin; Not insured: Odds ratios adjusted 
for heart failure, diuretics, steroids, CYP3A4 inhibitors, hERG inhibiting drugs, digoxin and beta agonists 
3 Additionaly adjusted for GP visits
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ratio’s were 0.78 (0.09 – 6.81) for privately insured patients and 1.73 (0.10 – 30.8) for 
none-insured patients.
Dose-response analyses showed that a high daily prescribed dose (>30 mg for total 
population) was associated with a significant increased risk of SCD after complete 
adjustment (11.4 (1.99-65.2)), whereas normal (30 mg) or low dose (< 30 mg) were 
not associated (1.02 (0.23-4.42) and 1.24 (0.19-8.12) respectively). After stratification 
for insurance, dose response could not be assessed in the separate categories because 
of small numbers. Since there were null exposed controls in the high dose category we 
aggregated high and normal dose for publicly insured patients (ORadj 7.21 (2.03 – 25.6)).
Domperidone and ventricular arrhythmia/ sudden 
cardiac death
In order to assess the association between VA/SCD and domperidone, we combined the 
SCD and VA datasets, censoring 17 SCD cases at the moment of VA, as they were also 
included in the VA set (as they had confirmed VA). High dose of domperidone (>30 mg) 
was associated with a significantly increased risk of SCD/VA (11.4 (1.99 – 64.9)) in the total 
population after complete adjustment (table 3), however this was in fact the SCD effect. 
Sensitivity analyses
In view of the possibility of residual confounding by diabetic gastroparesis, we excluded 
diabetes patients (table 4).This increased the association between current use of dom-
peridone and SCD up to 5.12 (2.01 - 13.0) and also the dose response relationship (high 
daily prescribed dose (>30 mg) 54.2 (4.95 - 592.6)). 
Exclusion of cardiovascular diseases increased the association between current use of 
domperidone and SCD after complete adjustment (4.05 (1.60 – 10.2)) and increased the 
dose response relationship (high daily prescribed dose (>30 mg) 35.8 (3.68 – 347.5)). 
Exclusion of all case and matched controls sets (matched on index date) with index 
dates after the first of January 2004 (when domperidone was not reimbursed anymore 
if prescribed) did not change the association of current use of domperidone and SCD 
(2.03 (0.77 – 5.36)) and the dose response relationship (high daily prescribed dose (>30 
mg) 11.6 (2.08 – 64.6)).
Discussion
This study was conducted to investigate the association between use of domperidone 
and the occurrence of serious ventricular arrhythmias. We demonstrated that current 
use of domperidone, and in particular high dose, was associated with a substantial 
increased risk of SCD. We could not assess the risk of ventricular arrhythmia since 
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there were no exposed VA cases. Past use of domperidone was not associated with an 
increased risk of SCD.
Inhibition of the hERG-encoded potassium channels leads to prolongation of the 
QTc interval, which can degenerate into ventricular arrhythmias and eventually lead to 
SCD.[9] Domperidone has been shown to inhibit the hERG-encoded potassium chan-
nels and thereby cause a significant prolongation of cardiac repolarization.[3] The main 
metabolic pathway of domperidone is via the cytochrome P450 3A4 (CYP3A4) isoen-
zyme. Concomitant use of drugs that inhibit this enzyme may result in increased plasma 
concentrations of domperidone. Studies in healthy volunteers have demonstrated 
prolongation of the QTc interval when domperidone was combined with ketoconazole, 
a CYP3A4 inhibitor. When oral domperidone was used as monotherapy, no effect on 
QTc was seen.[10] 
Table 3 Risk of sudden cardiac death and non-fatal ventricular arrhythmia 
Use of domperidone Cases Controls OR (95% CI)1 OR (95% CI)2 OR (95% CI)3
Overall population 1366 14114
Never use 1258 13384 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 98 700 1.57 (1.24 – 1.99) 1.35 (1.05 – 1.73) 1.26 (0.98 – 1.62)
Current use 10 30 3.54 (1.64 – 7.64) 2.35 (0.99 – 5.62) 1.92 (0.78 – 4.73)
    <30 mg 2 11 NA NA NA
    30 mg 4 16 2.45 (0.76 – 7.86) 1.36 (0.37 – 5.04) 0.99 (0.23 – 4.23)
    > 30 mg 4 3 16.0 (3.48 – 73.4) 11.2 (2.02 – 62.3) 11.4 (1.99 – 64.9)
Publicly insured 865 6194
Never use 790 5858 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 68 323 1.76 (1.28 – 2.41) 1.46 (1.04 – 2.04) 1.32 (0.94 – 1.86)
Current use 7 13 4.45 (1.45 – 13.6) 4.13 (1.32 – 13.0) 4.92 (1.58 – 15.4)
    <30 mg 1 5 NA NA NA
    30 mg 3 8 3.03 (0.67 – 13.7) 3.24 (0.69 – 15.1) 2.56 (0.54 – 12.1)
    > 30 mg 3 0 NA NA NA
Privately insured 440 7655
Never use 414 7274 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 25 367 1.45 (0.87 – 2.42) 1.24 (0.72 – 2.14) 1.20 (0.70 – 2.05)
Current use 1 14 NA NA NA
Not insured 61 265
Never use 54 252 1.0 (reference) 1.0 (reference) 1.0 (reference)
Past use 5 10 2.05 (0.10 – 30.8) 1.53 (0.25 – 9.40) 1.11 (0.15 – 8.47)
Current use 2 3 NA NA NA
1 Odds ratios matched for age, gender, practice and index date.
2 Overall population:  Odds ratios adjusted for heart failure, insurance type, CYP3A4 inhibitors, hERG inhibiting drugs, laxatives, digoxin, 
diuretics, steroids, beta agonists; Publicly insured: Odds ratios adjusted for heart failure, hERG inhibiting drugs, laxatives, diuretics, steroids 
and digoxin; Privately insured: Odds ratios adjusted for heart failure, diuretics, steroids, beta agonists and digoxin; Not insured: Odds ratios 
adjusted for heart failure, diuretics, steroids, CYP3A4 inhibitors, hERG inhibiting drugs, digoxin and beta agonists.
3 Additionaly adjusted for GP visits
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The current study is different from the study reported by Straus et al. for various 
reasons.[2] First, the model was specifically built around domperidone alone and not 
around use of non-cardiac QTc prolonging agents in general. Second, because of the 
potential of protopathic bias due to chest pain and stomach ache, cases of SCD were 
validated more strictly, excluding all those who might have vague chest symptoms. 
Third, the number of cases was larger since the study by Straus et al. ended in 2003. 
Fourth, the analysis now also looked at dose response. Despite the fact that the model-
ling was specific for domperidone, conclusions were the same although more refined, 
namely that domperidone in high dosages is associated with sudden cardiac death in 
the general population.
In our population, we were able to take advantage of the fact that in the Dutch 
health care system, all medical information (including specialist and hospital care) is 
collected at GP practices that cover the general population instead of selected socio-
economic groups. As a consequence, there was extensive information available on drug 
use, potential confounders, and all the circumstances surrounding death. 
Nevertheless, our study has some potential limitations. First, we cannot exclude that 
some misclassification of outcome occurred. We may have missed some deaths although 
this will be minimal, since death is consistently registered by GPs. Second, not all acute 
deaths may have been of cardiac origin. We determined SCD, however, on the basis 
of the full medical records and all circumstances surrounding the death were available. 
Recently, an evaluation comparing different methods to determine the incidence of SCD 
suggested that this method provides a very reliable way of determining SCD cases.[17] 
Third, we may have missed some ventricular arrhythmias, although this will be minimal 
due to the broad search criteria we used. All VA cases were determined based on the 
full medical records and needed to have an ECG confirmation. We may have missed all 
cases who died without ECG evidence but these will be included as SCD. Finally, since 
we only included definite VA cases not preceded by other disease, such as myocardial 
infarction, misclassification will be minimal.
Misclassification of exposure may have occurred for various reasons. First, we used 
outpatient prescription data and we had no information as to whether the prescription 
was actually filled and taken. Second, the legend duration for a calculated prescription 
(indicating the theoretical duration) may not reflect actual use. However, as in most 
cases (7) use was not on an as needed basis, the legend duration probably well matches 
the actual duration of use. Third, since 1/1/2004 domperidone is no longer reimbursed 
even when prescribed (from 1/1/2005 reimbursed again in case of chronic use). Publicly 
insured persons had a higher prevalence of recorded domperidone use than privately 
insured patients, but in 2004 the prevalence dropped in publicly insured patients and 
remained stable in privately insured patients, pointing to differential misclassification 
by insurance type, which can be seen in figure 1. Since we observed near interaction 
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with insurance we stratified by this variable. Fourth, potential non-continuous use may 
explain why the risk for SCD was elevated in some past use categories.
Although we adjusted for all known confounders, residual confounding may exist, 
but is unlikely that this would explain the strong association for high doses of domperi-
done. Adjustment for GP visits showed an effect as confounder which may be explained 
by the fact that prodromal symptoms of SCD, such as nausea and vomiting, can be 
mistakenly diagnosed as symptoms due to gastric pathology. Diabetic gastropathy was 
considered to be a potential confounder. However, in patients without diabetes mellitus, 
the association between current use and SCD increased, which excludes the possibility 
of residual confounding by diabetic gastropathy. In patients without cardiovascular dis-
ease, current use of domperidone was associated with an increased risk, which avoids 
residual confounding due to severity of underlying cardiovascular disease. 
In conclusion, this study underscores our prior conclusion that domperidone use is 
associated with an increased risk of SCD[2], however it refines it to the extent that 
mainly high dosages are associated with an increased risk, and it excludes the possibility 
of diabetic gastropathy and protopathic bias. This study was specifically designed to 
investigate the association between domperidone and VA and this association could not 
be demonstrated due to the lack of exposed and few confirmed VA cases. 
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Abstract
Background
Although sudden cardiac death has been frequently reported as the most common 
direct epilepsy-related cause of death in epilepsy and the indications of anticonvulsants 
(ACs) prescriptions have widened to include chronic pain syndromes, the association of 
ACs with sudden cardiac death is not systematically studied in a population-based study. 
Therefore, we studied whether use of ACs is associated with an increased risk of sudden 
cardiac death in a population-based database.
Methods
We used the Integrated Primary Care Information (IPCI) database, which is a longi-
tudinal general practice research database. Drug use at the index date was assessed 
with drug prescriptions from general practices. We used a conditional logistic regression 
analysis in a case-control analysis, matched for age, gender, practice and calendar time, 
multivariate adjusted.
Results
We identified 926 cases of sudden cardiac death and 9832 matched controls. Cur-
rent use of ACs was associated with a 2.5-fold increased risk of sudden cardiac death 
(adjusted OR 2.5 (95%CI 1.5-4.2)), in particular among carbamazepine users (ORadj 
3.4 (95%CI 1.5-7.7)). Past use was not associated with sudden cardiac death (ORadj 
1.4 (95%CI 0.9-2.3)). The highest risk was observed among users of sodium channel 
blocking ACs (ORadj 2.9 (95%CI 1.5-5.5)). The risk among users of non-sodium channel 
blocking ACs was lower and not significant (ORadj 1.6 (95%CI 0.8-3.5)). 
Conclusions
We demonstrated that current use of ACs is associated with an increased risk of sudden 
cardiac death in the general population, even in persons who use ACs for other indica-
tions than epilepsy. The risk of sudden cardiac death seems to be higher among users of 
carbamazepine and other ACs with sodium channel blocking properties.
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Introduction
Epilepsy is a common chronic neurologic disease affecting over 50 million people world-
wide.[1] The disease is associated with recurrent seizures and an increased mortality rate 
compared to the general population.[2] Although prevalent, death in epilepsy remains 
difficult to predict, because a substantial proportion of deaths is sudden and unexpected.
[3] Various descriptive conditions have been related to sudden cardiac death in epilepsy, 
including age, type and frequency of seizures and severity of epilepsy.[4-7] However, a 
clear pathophysiologic mechanism for sudden cardiac death in epilepsy is lacking. The 
main proposed mechanisms for sudden cardiac death in epilepsy are cardiac arrhythmias 
[8] and central apnoea.[9] There is an emerging interest in cardiac arrhythmias in epi-
lepsy [10-14] and the pro-arrhythmic potential of anticonvulsants (ACs).[15-18]
So far, there has been only sparse evidence for the role of ACs in sudden cardiac 
death in epilepsy, and no individual AC has been associated with sudden cardiac death. 
Yet, ACs could potentially contribute to sudden cardiac death in epilepsy as they may 
disturb heart rhythm in two ways: 1) ACs may influence cardiac conduction directly by 
blocking cardiac sodium current, while blockade of cardiac sodium channels may evoke 
lethal arrhythmias, as large-scale randomized placebo-controlled studies have indicated 
[19, 20]; 2) ACs act centrally in the brain and thereby influence the autonomic control of 
the heart, while autonomic dysfunction is associated with lethal cardiac arrhythmias.[21] 
Although sudden cardiac death has been frequently reported as the most common 
direct epilepsy-related cause of death in epilepsy and the indications of AC prescriptions 
have widened to include chronic pain syndromes, the association of ACs with sudden 
cardiac death is not systematically studied in a population-based study. Therefore, we 
studied whether use of ACs is associated with an increased risk of sudden cardiac death 
in a population-based database.
Methods
Setting and study design
Data were retrieved from the Integrated Primary Care Information (IPCI) project, a 
longitudinal observational database, containing data from computer-based medical 
patient records of a large group of general practitioners (GPs) in the Netherlands, for 
a population based case-control study. In the Dutch health care system, the GP has a 
pivotal role by acting as a gatekeeper for all medical care. Details of the database have 
been described elsewhere.[22, 23] Briefly, the database contains the complete medical 
records on approximately 1 million patients. The electronic records contain coded and 
anonymous data on patient demographics, symptoms (in free text), diagnoses (using 
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the International Classification for Primary Care (ICPC) [24] and free text) from GPs 
and specialists, referrals, laboratory findings, hospitalisations, and drug prescriptions, 
including their indications and dosage regimen. To guarantee completeness of the data, 
GPs participating in the IPCI project are not allowed to maintain a system of paper-based 
records besides the electronic medical records. The system complies with European 
Union guidelines on the use of medical data for medical research and was considered as 
valid for pharmaco-epidemiological research in several validation studies that evaluated 
the quality of the available information.[22] The Scientific and Ethical Advisory Board of 
the IPCI project approved this study. 
The source population comprised all patients of 18 years and older in the IPCI data-
base with a valid database history (date of registration with GP) of at least one year. The 
study population comprised all cases with sudden cardiac death occurring in the source 
population during the study period plus their matched controls (see below). The study 
period started on 1 January 1995 and ended on 1 May 2007. All subjects were followed 
until death, transferring out of the GP practice, last data draw down or end of the study 
period, whichever came first. 
Definition of sudden cardiac death
Sudden cardiac death was defined as: 1) a witnessed natural death attributable to 
cardiac causes, heralded by abrupt loss of consciousness, within one hour of onset of 
acute symptoms, or 2) an unwitnessed, unexpected death of someone seen in a stable 
medical condition <24 hours previously with no evidence of a non-cardiac cause.[25, 26]
The computerised medical and demographic data were screened for all deaths, 
which occurred during the study period. The medical records of all identified cases of 
death were reviewed manually to assess whether death could be classified as sudden 
cardiac death. Validation was performed independently by two medically trained per-
sons blinded to exposure and in case of discrepancy, a specialized physician arbitrated. 
To each case of sudden cardiac death, up to twenty controls were randomly drawn from 
the source population matched on age (year of birth), gender, and practice (GP). The 
index date was defined as the date on which sudden cardiac death occurred in cases. 
This date was also the index date for matched controls. 
Use of anticonvulsants
In this study, the exposure of interest included all available ACs. The following drugs 
were included: phenytoin, carbamazepine, levetiracetam, vigabatrin, ethosuximide, 
clonazepam, phenobarbital, primidone, lamotrigine, oxcarbazepine, gabapentin, and 
valproic acid. The ACs were divided into two groups based on their documented 
ability to block the sodium channel (neural and/or cardiac). Sodium channel blocking 
drugs: phenytoin, carbamazepine, oxcarbazepine, lamotrigine and gabapentin.[27-29] 
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Non-sodium channel blocking drugs included: valproic acid, levetiracetam, primidone, 
phenobarbital, clonazepam, ethosuximide and vigabatrin.[27-32] 
The duration of each prescription was calculated by dividing the total number of 
units issued per prescription by the prescribed daily number of units. Use of ACs was 
defined as current if the index date fell within a period of use or within a maximum of 
28 days after the end of the last prescription (to deal with carry-over effects). Past use 
was defined as discontinuation of an AC >28 days before the index date. If patients had 
no prescription for an AC prior to the index date, they were considered as non-exposed. 
Among current users, we evaluated the effect of duration (≤ 30 and >30 days continu-
ous use).
Covariates
Known risk factors and other covariates for sudden cardiac death were gathered from 
the medical records through computerized searches and manual validation. Myocardial 
infarction, transient ischemic attack, stroke, arrhythmia and heart failure were assessed, 
based on the diagnoses provided by the general practitioner and by specialists in the 
medical records. Hypertension was identified through the diagnoses in the medical 
records, the use of antihypertensive medication and/or blood pressure measurements 
above 140/90 mmHg.[33] Diabetes mellitus, and hypercholesterolemia were identified 
through diagnoses in the medical records from GPs and specialists and/ or the use of 
antidiabetic, or lipid lowering medication. Use of QTc prolonging drugs, antiarrhythmic 
drugs, digoxin, diuretics, calcium channel blockers and beta blockers at the index-date 
were considered as a covariate.[34] 
Statistical analysis
The relative risk of sudden cardiac death associated with use of ACs was estimated by 
calculation of the adjusted odds ratios using conditional logistic regression analysis. 
Covariates which were univariately associated with sudden cardiac death (at a p<0.1 
level) were included in the regression analyses if they changed the point estimate of the 
association between use of ACs and sudden cardiac death by >10%.[35] 
First, we studied whether use of ACs was associated with an increased risk of sudden 
cardiac death. Among current users we evaluated the effect of duration of continu-
ous use which was defined as the delay between first intake and the index date. We 
investigated potential effect modification by age and gender with interaction terms and 
subsequent stratifications. 
Second, we examined whether use of sodium channel blocking and non-sodium 
channel blocking ACs was associated with an increased risk of sudden cardiac death. 
We conducted separate analyses for the individual ACs with at least 3 current users. All 
analyses were performed using SPSS for Windows version 15.0 (Chicago, Illinois, USA).
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Results
Subject characteristics 
The source population for this study comprised 478,661 subjects with at least one year 
of valid history during the study period. During a follow-up of 1,905,382 person-years, 
14,259 persons died, including 926 definite sudden cardiac death cases. We identified 
9,832 matched controls. The mean age of cases was 71.7 years and 62.0% were male 
(table 1). 
Table 1 Baseline characteristics, demographics, distribution of covariates
Characteristic Sudden cardiac 
death cases 
(n = 926)
Controls
(n = 9832)
OR (95% CI)1
Gender
    Male 574 (62.0) 6319 (64.3)
    Female 352 (38.0) 3513 (35.7)
Age (mean, SD) (years) 71.7 (13.7) 66.1 (13.6)
    ≤ 55 121 (13.1) 2145 (21.8)
    55 – 65 145 (15.7) 2147 (21.8)
    66 – 75 248 (26.8) 2818 (28.7)
    > 75 412 (44.5) 2722 (27.7)
Co-morbidities
Ischemic cerebro- or  cardiovascular 
disease
273 (29.5) 1448 (14.7) 2.0 (1.7 – 2.3)
    Arrhythmia 83 (9.0) 553 (5.6) 1.3 (1.0 – 1.7)
    Hypertension 364 (39.3) 3005 (30.6) 1.3 (1.1 – 1.5)
    Diabetes mellitus 169 (18.3) 833 (8.5) 2.3 (1.9 – 2.8)
    Heart failure 162 (17.5) 397 (4.0) 4.0 (3.2 – 5.0)
    Hypercholesterolemia 137 (14.8) 1085 (11.0) 1.7 (1.3 – 2.0)
    Smoking 197 (21.3) 2024 (20.6) 1.3 (1.1 – 1.5)
    Alcohol abuse 22 (2.4) 84 (0.9) 3.5 (2.1 – 5.9)
Concomitant medication
    QTc prolonging drugs 41 (4.4) 186 (1.9) 2.3 (1.6 – 3.3)
    Antiarrhythmic drugs 15 (1.6) 76 (0.8) 1.9 (1.0 – 3.5)
    Digoxin 76 (8.2) 221 (2.2) 3.2 (2.4 – 4.4)
    Diuretics 168 (18.1) 597 (6.1) 3.3 (2.7 – 4.1)
    Calcium channel blockers 87 (9.4) 604 (6.1) 1.4 (1.1 – 1.7)
    Beta blockers 141 (15.2) 1082 (11.0) 1.4 (1.1 – 1.7)
1: Odds Ratios matched for age, gender, practice and calendar time
 SD Standard Deviation
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Association anticonvulsants and sudden cardiac death
Of all cases, 23 were current users at the index date and 24 patients were past users 
(table 2). Current use of ACs was associated with a 2.5-fold increased risk of sudden 
cardiac death (adjusted OR 2.5 (95%CI 1.5-4.2)). Past use was not associated with 
sudden cardiac death (ORadj 1.4 (95%CI 0.9-2.3)). Patients using ACs more than 30 
days had a higher risk of sudden cardiac death (ORadj 3.2 (95%CI 1.5-6.8)) than patients 
using ACs less than 30 days (ORadj 1.8 (95%CI 0.9-3.6)). 
Stratified analyses among current users showed a comparable risk in males and 
females (ORadj males: 2.2 (95%CI 1.1-4.4); ORadj females: 2.4 (95%CI 1.1-5.5)). The 
risk of sudden cardiac death was higher in patients younger than 65 years (ORadj 2.9 
(95%CI 1.1-7.3)) than in patients older than 65 years (ORadj 1.9 (95%CI 1.0-3.7)), but 
these differences were not statistically significant. 
Association of individual ACs and sudden cardiac death
The highest risk of sudden cardiac death was observed among users of sodium channel 
blocking ACs (ORadj 2.9 (95%CI 1.5-5.5)) (table 3). The risk among users of non-sodium 
channel blocking ACs was lower and not significant (ORadj 1.6 (95%CI 0.8-3.5)). 
Table 2 Use of anticonvulsants and risk of sudden cardiac death
Cases 
(n=926)
Controls 
(n = 9832)
OR (95% CI)1 OR (95% CI)2
Never use 879 9583 1.0 (reference) 1.0 (reference)
Past use 24 (2.6) 166 (1.7) 1.5 (1.0 – 2.4) 1.4 (0.9 – 2.3)
Current use 23 (2.5) 83 (0.8) 2.8 (1.7 – 4.6) 2.5 (1.5 – 4.2)
    Duration of use
        ≤ 30 days 11 (1.2) 52 (0.5) 2.3 (1.1 – 4.6) 1.8 (0.9 – 3.6)
        > 30 days 12 (1.3) 31 (0.3) 3.5 (1.7 – 7.2) 3.2 (1.5 – 6.8)
Effect modification
    Gender
        Females 9 (2.6) 34 (1.0) 2.7 (1.2 – 6.1) 2.4 (1.1 – 5.5)
        Males 14 (2.4) 49 (0.8) 2.8 (1.5 – 5.3) 2.2 (1.1 – 4.4)
    Age 
        < 65 years 7 (2.6) 27 (0.6) 4.4 (1.9 – 10.4) 2.9 (1.1 – 7.3)
        ≥ 65 years 16 (2.4) 56 (1.0) 2.2 (1.2 – 4.1) 1.9 (1.0 – 3.7)
1: Odds Ratios matched for age, gender, practice and calendar time
2: Odds Ratios matched for age, gender, practice and calendar time, adjusted for diabetes mellitus, heart failure, hypertension, 
hypercholesterolemia, alcohol abuse, cerebro- and cardiovascular ischemia and use of diuretics, calcium channel blockers, beta blockers and 
antiarrhythmic drugs.
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Although the numbers of the individual ACs were relatively small, separate analyses 
of individual ACs showed an increased and significant risk of sudden cardiac death 
in carbamazepine users (ORadj 3.4 (95%CI 1.5-7.7)). In addition, use of gabapentin 
tended to be associated with an increased risk of sudden cardiac death, however, non-
significant (ORadj 3.0 (95%CI 0.6-14.6)).
Discussion
We found that current use of ACs is associated with a 2.5-fold increased risk of sud-
den cardiac death. Current use of sodium-channel blocking ACs was associated with 
an almost 3-fold increased risk of sudden cardiac death. Notably, carbamazepine was 
associated with an almost 3.5-fold increased risk of sudden cardiac death.
The relation between sudden cardiac death and the use of ACs has so far been 
reported in small cohorts of patients that are treated at specialized epilepsy institutions. 
The small size of these cohorts, their severity of epilepsy, and the fact that they often use 
multiple ACs has made it difficult so far to determine the role of ACs in sudden cardiac 
death.[5, 15, 36-38] In this large-scale population-based study, we studied the role 
of ACs in sudden cardiac death in the general population. Besides patients who used 
Table 3 Current use of individual anticonvulsants and risk of sudden cardiac death
Cases 
(n=926)
Controls 
(n = 9832)
OR (95% CI)1 OR (95% CI)2
Sodium channel blocking ACs* 15 (1.6) 43 (0.4) 3.5 (1.9 – 6.6) 2.9 (1.5 – 5.5)
    Carbamazepine 10 (1.1) 26 (0.3) 4.0 (1.8 – 8.9) 3.4 (1.5 – 7.7)
    Gabapentin 3 (0.3) 6 (0.1) 5.0 (1.1 – 22.3) 3.0 (0.6 – 14.6)
    Lamotrigine 0 3 (0.0) NA NA
    Oxcarbazepine 0 1 (0.0) NA NA
    Phenytoin 3 (0.3) 10 (0.1) 2.0 (0.4 – 9.1) 2.9 (0.5 – 15.3)
Non-sodium channel blocking ACs* 10 (1.1) 51 (0.5) 2.0 (1.0 – 4.1) 1.6 (0.8 – 3.5)
    Clonazepam 4 (0.4) 14 (0.1) 2.9 (0.9 – 9.1) 2.4 (0.7 – 8.2)
    Levetiracetam 0 1 (0.0) NA NA
    Phenobarbital 2 (0.2) 14 (0.1) NA NA
    Primidone 0 4 (0.0) NA NA
    Valproic acid 4 (0.4) 20 (0.2) 2.1 (0.7 – 6.7) 1.8 (0.6 – 5.8)
1: Odds Ratios matched for age, gender, practice and calendar time.
2: Odds Ratios matched for age, gender, practice and calendar time, adjusted for diabetes mellitus, heart failure, hypertension, 
hypercholesterolemia, alcohol abuse, cerebro- and cardiovascular ischemia and use of diuretics, calcium channel blockers, beta blockers and 
antiarrhythmic drugs.
ACs anticonvulsants
* Since few patients used 2 AEDs concomitantly, numbers do not add up.
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ACs for epilepsy, we also included patients who used ACs for other indications, e.g., 
neuropathic pain. As our cases and controls were derived from the general population, 
most of the included epilepsy patient had stable epilepsy and used a single AC, thereby 
reducing confounding by severity of epilepsy and polytherapy of ACs. Our epilepsy cases 
may thus represent a yet unrecognized category of sudden cardiac death in epilepsy. 
Sudden death in epilepsy is frequently described in the literature under the acronym 
SUDEP (Sudden Unexplained Death in EPilepsy). Although the design and confounding 
factors in these studies did not allow for conclusions on a possible association between 
sudden death risk and the use of ACs, these studies have provided important informa-
tion about sudden cardiac death in young epilepsy patients. From these studies, we 
learned that SUDEP is common in young patients with severe therapy-resistant epilepsy, 
and that SUDEP is probably a seizure-related event.[39] However, the literature tends to 
ignore the much larger group of epilepsy patients with more stable epilepsy, suggesting 
that the risk for sudden death does not exist in this group.
In this study, we show that epilepsy is also strongly related with sudden cardiac death 
in elderly patients. In contrast to the young SUDEP cases described in the literature, 
most (78%) of our epilepsy cases used a single AC, implicating stable and non-severe 
epilepsy. None of the 6 witnessed epilepsy cases had a seizure-related death. These 
observations suggest that the disease epilepsy plays not such a prominent role in sudden 
cardiac death in elderly subjects in the general population as it does in young SUDEP 
cases. Sudden cardiac death in elderly patient with non-severe epilepsy might be more 
related to the use of ACs. This hypothesis is further supported by the fact that use of 
ACs is also associated in our population with sudden cardiac death in patients who used 
these drugs for other indications than epilepsy.
To further investigate the role of ACs in sudden cardiac death, the effects of ACs 
with sodium channel blocking properties were tested. Previous studies have associated 
cardiac drugs with sodium-channel blocking properties with sudden cardiac death.
[19, 20] Moreover, patients with congenitally reduced cardiac sodium current (e.g., 
Brugada syndrome) also have an increased risk for ventricular arrhythmias and sudden 
cardiac death. Reduced cardiac sodium current is believed to increase the risk for cardiac 
arrhythmias by causing conduction delay in the heart.[40] Although this same mecha-
nism is proposed in the literature as a possible mechanism by which ACs may increase 
the risk of sudden cardiac death, it has not been studied before.[21] Here, we show 
that use of ACs with sodium channel blocking properties is associated with an almost 
3-fold increased risk of sudden cardiac death, even after correction for all confounding 
factors. Conversely, ACs without sodium channel blocking properties exhibited a lower 
and non-significant association with sudden cardiac death. To our knowledge, this is 
the first study to show that sodium channel blocking ACs are associated with sudden 
cardiac death.
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A sensible dose-response analysis could not be performed since ACs were prescribed 
for different indications (epilepsy and non-epileptic diseases). The prescribed doses for 
epilepsy were higher than for the non-epileptic indications. As the disease epilepsy 
probably also affects the risk of sudden cardiac death and interacts with AC use (gene 
variants of sodium channels co-expressed in the brain predisposing for epilepsy and 
cardiac arrhythmias). In patients with such a genetic susceptibility low doses are suf-
ficient to block the genetically impaired channels. Therefore, a dose-response analysis is 
only possible in stratified groups of epileptic patients (preferably subdivided in mutation 
carriers and non-mutation carriers) and non-epileptic patients. The available numbers of 
cases were not sufficient to perform such an analysis.[41, 42] 
Experimental studies show that phenytoin, phenobarbital and lamotrigine have the 
ability to block cardiac hERG-encoded potassium channels.[43, 44] Sufficient blockade 
of cardiac hERG-encoded potassium channels leads to QT prolongation on the ECG and 
is associated with ventricular arrhythmias and sudden cardiac death.[45] However, these 
ACs are not known to prolong the QT interval on the ECG, suggesting that they block 
cardiac hERG-encoded potassium channels only minimally and clinically non-significantly. 
To further rule out the possibility that hERG-encoded potassium channels inhibition may 
contribute to the inceased risk for sudden cardiac death which is associated with the use 
of sodium channel blocking ACs, we conducted a sub-analysis, in which we excluded 
phenytoin and lamotrigine. Even with the exclusion of these drugs, the use of sodium 
channel blocking ACs was still strongly associated with sudden cardiac death.
Although group sizes were small when we studied each AC individually, we still 
found that carbamazepine was associated with an increased risk of sudden cardiac 
death. To our knowledge, this is the first study which associates carbamazepine with 
sudden cardiac death in stable epilepsy and non-epilepsy patients. Timmings described 
a larger proportion of carbamazepine users among 14 patients who died suddenly 
compared to patients who attended the general epilepsy clinic. However, this was not 
a case-control study and no attempts were made to correct for confounding risk fac-
tors of sudden cardiac death.[36] The Norwegian and The Swedish study showed no 
correlation between specific AC use and sudden cardiac death.[6, 38] An association 
between high serum levels of carbamazepine (>40μmol/L) at the last visit and sudden 
death was suggested in a sub-analysis of the Swedish study.[18] However, this risk 
occurred especially among patients who used polytherapy of ACs. The authors were 
therefore cautious in concluding that high levels of carbamazepine are associated with 
an increased risk of sudden cardiac death, as polytherapy of ACs and high serum levels 
of carbamazepine are both markers of severe and unstable epilepsy. A case-control 
study of 154 SUDEP cases showed an odds ratio of 2 for carbamazepine. These authors, 
too, warn against concluding that carbamazepine is causally related with SUDEP, as 
carbamazepine use may reflect epilepsy severity in this cohort of patients with severe 
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epilepsy, as also suggested by the use of multiple ACs: among cases, 50% had at one 
point used 3 or more ACs compared to 29% of controls.[17] In comparison, among 
cases in our cohort, none had used ≥ 3 ACs.
The association of carbamazepine with sudden cardiac death may be mediated by 
the sodium channel blocking properties of this drug. Cardiac sodium channel blockade 
may increase the risk for ventricular arrhythmias, but also the risk for atrial arrhytmias.
[19, 20, 40] Recently, we showed that sodium channels are also expressed in the 
sinus node of the heart.[46] The sinus node initiates each cardiac contraction and is 
responsible for the heart rate. Blockade of sodium channels in the sinus node may 
slow impulse generation and heart rate. Potentially serious slow heart rates are often 
described in carbamazepine users in the literature.[47-51] As further evidence for a role 
of sodium channel blockade, two other ACs with sodium channel blocking properties 
(phenytoin and gabapentin) showed a trend of increased sudden cardiac death risk, 
similar to carbamazepine.
The major strength of our study lies in its population-based character, minimizing 
selection bias. This enabled us to study patients who used ACs for different indications. 
Furthermore, our access to the databases of the general practitioners allowed us to 
collect extensive information on drug use, concomitant diseases, potential confounders, 
and circumstances surrounding death. 
However, our study has also some limitations, comparable to other studies that 
address sudden cardiac death in the general population. First, although general 
practitioners register death consistently, we may have missed some deaths. Second, 
as the definition of sudden cardiac death depends largely on the available information 
regarding the circumstances surrounding death, misclassifications may have occurred. 
To reduce misclassification, we only included cases with sufficient and clear information 
on the circumstances surrounding death. Third, misclassification of drug exposure may 
have occurred, as we used prescription data by the general practitioner. No information 
was available on the compliance of medication intake. However, it is likely that the 
misclassification will be randomly distributed among cases and controls.
In conclusion, we found that use of ACs is associated with an increased risk of sud-
den cardiac death in the general population, even in persons who use ACs for other 
indications than epilepsy. The risk of sudden cardiac death seems to be higher among 
users of carbamazepine and other ACs with sodium channel blocking properties.
Chapter 3.392
References 
 [1] Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: where do we 
go from here? Bulletin of the World Health Organization. 2001;79(4):344-51.
 [2] Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006 Apr 1;367(9516):1087-100.
 [3] Nashef L. Sudden unexpected death in epilepsy: terminology and definitions. Epilepsia. 1997;38 
(suppl 11):S6-8.
 [4] Leestma JE, Annegers JF, Brodie MJ, Brown S, Schraeder P, Siscovick D, et al. Sudden unexplained 
death in epilepsy: observations from a large clinical development program. Epilepsia. 1997 
Jan;38(1):47-55.
 [5] Walczak TS, Leppik IE, D’Amelio M, Rarick J, So E, Ahman P, et al. Incidence and risk factors in sudden 
unexpected death in epilepsy: a prospective cohort study. Neurology. 2001 Feb 27;56(4):519-25.
 [6] Nilsson L, Farahmand BY, Persson PG, Thiblin I, Tomson T. Risk factors for sudden unexpected death 
in epilepsy: a case-control study. Lancet. 1999 Mar 13;353(9156):888-93.
 [7] Klenerman P, Sander JW, Shorvon SD. Mortality in patients with epilepsy: a study of patients in long 
term residential care. J Neurol Neurosurg Psychiatry. 1993 Feb;56(2):149-52.
 [8] Oppenheimer SM, Gelb A, Girvin JP, Hachinski VC. Cardiovascular effects of human insular cortex 
stimulation. Neurology. 1992 Sep;42(9):1727-32.
 [9] Terrence CF, Rao GR, Perper JA. Neurogenic pulmonary edema in unexpected, unexplained death 
of epileptic patients. Annals of neurology. 1981 May;9(5):458-64.
 [10] Scott CA, Fish DR. Cardiac asystole in partial seizures. Epileptic Disord. 2000 Jun;2(2):89-92.
 [11] Rocamora R, Kurthen M, Lickfett L, Von Oertzen J, Elger CE. Cardiac asystole in epilepsy: clinical 
and neurophysiologic features. Epilepsia. 2003 Feb;44(2):179-85.
 [12] Schuele SU, Bermeo AC, Alexopoulos AV, Locatelli ER, Burgess RC, Dinner DS, et al. Video-electro-
graphic and clinical features in patients with ictal asystole. Neurology. 2007 Jul 31;69(5):434-41.
 [13] Rugg-Gunn FJ, Simister RJ, Squirrell M, Holdright DR, Duncan JS. Cardiac arrhythmias in focal 
epilepsy: a prospective long-term study. Lancet. 2004 Dec 18-31;364(9452):2212-9.
 [14] Hindocha N, Nashef L, Elmslie F, Birch R, Zuberi S, Al-Chalabi A, et al. Two cases of sudden 
unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. Epilepsia. 2008 
Feb;49(2):360-5.
 [15] Timmings PL. Sudden unexpected death in epilepsy: a local audit. Seizure. 1993 Dec;2(4):287-90.
 [16] Aurlien D, Tauboll E, Gjerstad L. Lamotrigine in idiopathic epilepsy - increased risk of cardiac death? 
Acta neurologica Scandinavica. 2007 Mar;115(3):199-203.
 [17] Langan Y, Nashef L, Sander JW. Case-control study of SUDEP. Neurology. 2005 Apr 12;64(7):1131-3.
 [18] Nilsson L, Bergman U, Diwan V, Farahmand BY, Persson PG, Tomson T. Antiepileptic drug therapy 
and its management in sudden unexpected death in epilepsy: a case-control study. Epilepsia. 2001 
May;42(5):667-73.
 [19] Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhyth-
mia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) 
Investigators. N Engl J Med. 1989 Aug 10;321(6):406-12.
 [20] Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac 
Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992 Jul 23;327(4):227-33.
 [21] Tomson T, Kenneback G. Arrhythmia, heart rate variability and antiepileptic drugs. Epilepsia. 
1997;38:S48-51.
 [22] Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. 
Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 
1999 Dec;38(4-5):339-44.
 [23] van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PV, Boon WM, et al. The 
introduction of computer-based patient records in The Netherlands. Ann Intern Med. 1993 Nov 
15;119(10):1036-41.
Anticonvulsants and risk of sudden cardiac death 93
 [24] Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of 
fifteen years of evolution. Fam Pract. 1992 Sep;9(3):330-9.
 [25] Myerburg RJ, Castellanos A. Language and interpretation of clinical trial outcomes: alternates, 
surrogates, and composites. Heart Rhythm. 2004 Nov;1(5):538-9.
 [26] Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Task Force on Sud-
den Cardiac Death of the European Society of Cardiology. Eur Heart J. 2001 Aug;22(16):1374-450.
 [27] Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain. 2006 
Jan;129(Pt 1):18-35.
 [28] Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain research. 
1998 Mar;26(1):16-28.
 [29] Liu Y, Qin N, Reitz T, Wang Y, Flores CM. Inhibition of the rat brain sodium channel Nav1.2 after 
prolonged exposure to gabapentin. Epilepsy Res. 2006 Aug;70(2-3):263-8.
 [30] Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS drug reviews. 2003 
Summer;9(2):199-216.
 [31] Costa C, Martella G, Picconi B, Prosperetti C, Pisani A, Di Filippo M, et al. Multiple mechanisms 
underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke. 2006 
May;37(5):1319-26.
 [32] Johannessen CU, Petersen D, Fonnum F, Hassel B. The acute effect of valproate on cerebral energy 
metabolism in mice. Epilepsy Res. 2001 Dec;47(3):247-56.
 [33] WHO. World Health Organization-International Society of Hypertension Guidelines for the Man-
agement of Hypertension. Guidelines Subcommittee. J Hypertens. 1999 Feb;17(2):151-83.
 [34] Woosley RL. Drugs that prolong the QTc interval and/ or induce Torsade de Pointes. [cited; Available 
from: http:www.azcert.org/medical-pros/drug-lists/drug-lists.cfm
 [35] Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989 
Mar;79(3):340-9.
 [36] Timmings PL. Sudden unexpected death in epilepsy: is carbamazepine implicated? Seizure. 1998 
Aug;7(4):289-91.
 [37] Jick SS, Cole TB, Mesher MD, Tennis PS, Jick H. Sudden unexplained death in young persons with 
primary epilepsy. Pharmacoepidemiol Drug Saf. 1992;1:59-64.
 [38] Kloster R, Engelskjon T. Sudden unexpected death in epilepsy (SUDEP): a clinical perspective and a 
search for risk factors. J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):439-44.
 [39] Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future 
directions. Lancet neurology. 2008 Nov;7(11):1021-31.
 [40] Smits JP, Blom MT, Wilde AA, Tan HL. Cardiac sodium channels and inherited electrophysiologic 
disorders: a pharmacogenetic overview. Expert opinion on pharmacotherapy. 2008 Mar;9(4):537-49.
 [41] Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, et al. Sodium channel 
beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in 
humans. J Clin Invest. 2008 Jun;118(6):2260-8.
 [42] Yamakawa K. Na channel gene mutations in epilepsy--the functional consequences. Epilepsy Res. 
2006 Aug;70 Suppl 1:S218-22.
 [43] Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, 
topiramate and gabapentin on hERG potassium currents. Epilepsy Res. 2005 Jan;63(1):17-25.
 [44] Danielsson BR, Lansdell K, Patmore L, Tomson T. Phenytoin and phenobarbital inhibit human HERG 
potassium channels. Epilepsy Res. 2003 Jun-Jul;55(1-2):147-57.
 [45] Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004 Mar 4;350(10):1013-
22.
 [46] Verkerk AO, Wilders R, van Borren MM, Peters RJ, Broekhuis E, Lam K, et al. Pacemaker current 
(I(f)) in the human sinoatrial node. Eur Heart J. 2007 Oct;28(20):2472-8.
Chapter 3.394
 [47] Takayanagi K, Hisauchi I, Watanabe J, Maekawa Y, Fujito T, Sakai Y, et al. Carbamazepine-induced 
sinus node dysfunction and atrioventricular block in elderly women. Japanese heart journal. 1998 
Jul;39(4):469-79.
 [48] Steckler TL. Lithium- and carbamazepine-associated sinus node dysfunction: nine-year experience 
in a psychiatric hospital. J Clin Psychopharmacol. 1994 Oct;14(5):336-9.
 [49] Hewetson KA, Ritch AE, Watson RD. Sick sinus syndrome aggravated by carbamazepine therapy 
for epilepsy. Postgraduate medical journal. 1986 Jun;62(728):497-8.
 [50] Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepine-induced cardiac dysfunction. Charac-
terization of two distinct clinical syndromes. Arch Intern Med. 1992 Jan;152(1):186-91.
 [51] Johnson CD, Rivera H, Jimenez JE. Carbamazepine-induced sinus node dysfunction. Puerto Rico 
health sciences journal. 1997 Mar;16(1):45-9.
Chapter 4.1 High free thyroxine 
levels are associated 
with QTc prolongation 
in males
van Noord C 
van der Deure WM  
Sturkenboom MCJM  
Straus SMJM  
Hofman A  
Visser TJ  
Kors JA  
Witteman JCM 
Stricker BHC
Chapter 4.196
Abstract
Background
The literature on the effect of excess thyroid hormone on ventricular repolarization is 
controversial. Our aim was to examine whether free T4 and TSH are associated with QTc 
prolongation.
Methods
Setting: A population-based cohort study. 
Participants: 365 men and 574 women aged 55 years and older from the Rotterdam 
Study cohort with an electrocardiogram (ECG) who were randomly sampled for assess-
ment of thyroid status (free T4/TSH) at baseline, after exclusion of participants with 
hypothyroidism, use of antithyroid drugs, thyroid hormones or digoxin, left ventricular 
hypertrophy and left and right bundle branch block.
Endpoints: Length of the QTc interval and risk of borderline QTc prolongation.
Analysis: Linear and logistic regression analysis, adjusted for age and gender, diabetes 
mellitus, myocardial infarction, hypertension and heart failure.
Results
Overall, there was no significant association between TSH and QTc interval (0.8 ms 
(95%CI -3.5;5.2) in the first quintile compared to the fifth quintile). Subjects in the fifth 
quintile of free T4 did not have an increased QTc interval (3.2 ms (95%CI -1.1;7.6)); 
stratification on gender showed an increment of 10.9 ms (95%CI 3.4;18.3) in the fifth 
quintile in men and 1.1 ms (95%CI -4.2;6.3) in the fifth quintile of free T4 in women. 
Compared to subjects in the first quintile, male subjects in the fifth quintile of free T4 
had a significantly increased risk of a borderline QTc interval and QTc prolongation (Odds 
Ratio 2.40 (95%CI 1.20-4.80)). 
Conclusions
High levels of free T4 are associated with substantial QTc prolongation in men of up 
to 10 ms. The fact that free T4 is also associated with a significantly increased risk of 
borderline and prolonged QTc values with its risk of sudden cardiac death, endorses the 
clinical importance of our findings.
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Introduction
An excess of thyroid hormone exerts a major effect on the cardiovascular system, and the 
influence of thyroid disorders on heart rhythm, output and contractility has been widely 
studied.[1] Relatively little, however, is known about the effect of thyroid hormone on 
ventricular repolarization. It has been reported that hypothyroidism is associated with 
prolongation of the heart-rate corrected QT (QTc) interval [2, 3], a measure of duration 
of ventricular repolarization. In hyperthyroidism, the situation is more controversial, 
since prolonged and shortened QTc interval both have been reported.[4-12] Decreased 
repolarization times have been reported in several animal studies [4-7] and in one human 
study [8] and at the same time QTc prolongation has been reported in patients with 
hyperthyroidism. [9-12] A potential explanation for an association with prolongation 
of the QTc interval is an increased activity of cardiac Na+/ K+ ATPase in thyroid hormone 
excess, leading to increased intracellular K+ with subsequent membrane hyperpolariza-
tion and an increase in QTc duration.[1, 11] A prolonged QTc interval may be clinically 
relevant, since an increase of ventricular repolarization time may result in early after 
depolarizations (EAD), which in turn may induce re-entry and thereby provoke Torsade 
de Pointes and fatal ventricular arrhythmias.[13-17]
Because of these contradictory results and limited data concerning hyperthyroidism 
and the duration of the QTc interval, we studied the association of TSH and free T4 with 
the QTc interval in a prospective, population-based study of elderly. 
Methods
Setting and study design
The Rotterdam study is a population-based cohort study, which started with a baseline 
visit between 1990 and 1993. The Medical Ethics Committee of the Erasmus Medical 
Center, Rotterdam, the Netherlands, approved the study. All inhabitants of Ommoord, 
a suburb of Rotterdam, aged 55 years and over, were invited to participate (n=10,275). 
Of them, 7983 (78%) gave their written informed consent and took part in the baseline 
examination. Objectives and methods of the Rotterdam Study have been described in 
detail elsewhere.[18, 19] At baseline, all participants were visited at home for a stan-
dardized questionnaire, and 7151 were subsequently examined at the research center. 
The cohort is continuously being monitored for major morbidity and mortality through 
linkage of the Rotterdam Study database with general practitioner and municipality 
records. 
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Study population
Thyroid status was assessed in a random selection of 2000 participants from the Rotter-
dam Study at baseline, as has been described previously.[20] After exclusion of subjects 
for whom no blood was available or who used amiodarone at baseline (due to the 
effects of this drug on thyroid function)[21], TSH was assessed in 1843 participants. 
Due to technical and logistical reasons, free T4 could only be assessed in 1544 of these 
participants. Electrocardiograms (ECGs) were available for 1126 of these participants at 
the time of the first visit.
We excluded participants with clinical hypothyroidism (TSH > 4.3 mU/l and free T4 
< 11 pmol/l) or subclinical hypothyroidism (TSH > 4.3 mU/l and free T4 ≥ 11 pmol/l) 
(n=72), since hypothyroidism is associated with QTc prolongation.[2, 3] Furthermore, we 
excluded participants with ECG evidence of left ventricular hypertrophy (n=44), left and 
right bundle branch block (n=17 and 30, respectively) and/or participants using digoxin 
(n=21), antithyroid drugs (n=6) and thyroid hormones (n=11), since these conditions 
can alter the QTc interval.[22, 23] Consequently, the study population consisted of 939 
participants (figure 1).
Assessment of thyroid status
At baseline, non-fasting serum samples were obtained, which were put on ice directly 
and processed within 30 minutes after which they were kept frozen at −20°C. TSH 
levels were measured with TSH Lumitest (Henning, Berlin, Germany).[24] The reference 
range of serum TSH levels was 0.4 - 4.3 mU/l. Serum free T4 was measured by a chemo-
luminescence assay (Vitros, ECI Immunodiagnostic System, Ortho-Clinical Diagnostics, 
Amersham, UK), the reference range of serum free T4 levels was 11–25 pmol/l. Partici-
pants with TSH levels lower than 0.4 mU/l and free T4 levels higher than 25 pmol/l were 
considered to have clinical hyperthyroidism, participants with TSH levels lower than 0.4 
mU/l and free T4 levels between 11 and 25 pmol/l were considered to have subclinical 
hyperthyroidism. 
ECG
A 12-lead resting ECG was recorded with an ACTA electrocardiograph (ESAOTE, Flor-
ence, Italy) at a sampling frequency of 500 Hz and stored digitally. The ECGs and serum 
samples were obtained on the same day. All ECGs were processed by the Modular ECG 
Analysis System (MEANS) to obtain ECG measurements. The MEANS program has been 
evaluated extensively and has been validated.[25-28] In one of these validation studies, 
ECGs with selected abnormalities were analyzed by 5 cardiologists and 11 different 
computer programs of which MEANS performed as one of the best [28] In another 
validation study in which QT intervals by manual measurement were compared with 
those generated by ECG machines, manual and automated measurements generated 
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similar numerical results in 3 studies in healthy volunteers, which all included a positive 
control.[29] MEANS determines common onsets and offsets for all 12 leads together 
on one representative averaged beat, with the use of template matching techniques.
[26] The MEANS program determines the QT interval from the start of the QRS complex 
until the end of the T wave. To adjust for heart rate, Bazett’s formula (QTc=QT/√RR) was 
used.[30] European regulatory guidelines were used to categorize the QTc interval into 
3 categories: normal, borderline and prolonged. For men, the cut-off points were < 430 
ms (normal), 430-450 ms (borderline) and > 450 ms (prolonged), and for women < 450 
ms (normal), 450-470 ms (borderline), and > 470 ms (prolonged).[31] Missing ECGs 
3
2000 subjects (random selection of the Rotterdam Study)
1843 subjects: TSH assessment 
1544 subjects: free T4 assessment 
1126 subjects: ECGs available  
157 participants were excluded:
       blood was not available
       use of amiodarone
299 participants were excluded: 
       free T4 could not be assessed due to logistic reasons
418 participants were excluded: 
       ECGs were not available due to temporary technical   
       problems
Figure 1 Diagram of study population 
170 partcipants were excluded:
       clinical or subclinical hypothyroidism (n=72)
       use of antithyroid drugs or thyroid hormones (n=17)
       left ventricular hyperthrophy (n=44)
       left (n=17) and right bundle branch block (n=33)
       use of digoxin (n=21)
939 subjects were included
Figure 1 Diagram of study population 
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were mainly due to temporary technical problems with ECG recording. The index date 
was the date of the ECG at baseline, at the same date blood samples were collected.
Covariates
Diabetes mellitus, hypertension, myocardial infarction and heart failure are considered 
to be risk factors for QTc prolongation and presence of these conditions at each index 
date was included as a covariate.[32-35] Clinical measures were obtained during the 
visits at the Rotterdam Study research center. Diabetes mellitus and hypertension were 
defined according to the World Health Organization criteria.[36, 37] Prevalence of 
myocardial infarction was assessed by hospital discharge diagnosis or in case a patient 
was not hospitalized, when signs and symptoms, analysis of the standard 12-lead ECG 
and cardiac enzyme data were diagnostic of a myocardial infarction.[38, 39] Prevalence 
of heart failure was assessed by the presence of suggestive signs and symptoms as 
previously described.[40, 41] 
Statistical analysis
Two analyses were conducted. First, a linear regression analysis was conducted with 
QTc as outcome and thyroid status (TSH and free T4 levels divided in quintiles) as 
determinants. Second, logistic regression analysis was conducted to assess the risk of 
a borderline QTc interval or QTc prolongation. All analyses were adjusted for age and 
gender and additionally for diabetes mellitus, myocardial infarction, hypertension and 
heart failure. In a separate analysis, we have examined the association between TSH and 
QTc prolongation using log TSH, since TSH is logarithmically distributed.
Because women in general have a longer QTc interval than men, a separate analysis 
was conducted with stratification for gender. In a separate analysis, we also adjusted 
for potassium, calcium and use of class 1 QTc prolonging drugs of list 1 of the website 
based registry at the index-date, since these drugs are generally accepted to have a risk 
of causing Torsade de Pointes.[42] Furthermore, we have performed a sensitivity analysis 
by excluding participants with clinical or subclinical hyperthyroidism. All analyses were 
performed using SPSS for Windows version 11.0 (Chicago, Illinois, USA).
Results
Subject characteristics
The baseline characteristics of the participants are presented in table 1. Overall, 939 par-
ticipants were included, of whom 574 were female and 365 male. The mean age of the 
study population at baseline was 68.0 years (standard deviation (SD) 7.6 years). Women 
were significantly older than men. Mean TSH at baseline was 1.60 mU/l (SD=0.90), 
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mean free T4 was 16.5 pmol/l (SD=3.0). Ten participants had clinical hyperthyroidism 
and 49 participants had subclinical hyperthyroidism. 
QTc prolongation
The mean duration of the QTc interval at baseline was significantly shorter in males 
(424.0 ms) than in females (432.9 ms) (p<0.0001). Overall, 73.6% of the participants 
had normal QTc duration and 20.4% had a borderline QTc interval, using the above-
mentioned gender specific cut-off points. Furthermore, 56 participants had QTc prolon-
gation, with mean QTc levels of 473.7 milliseconds. 
Overall, there was no significant association between TSH and QTc interval with a 
decrease of 0.6 ms (95%CI -2.1 ; 0.9) per mU/l. The first quintile of TSH was not associ-
ated with an increase of the QTc interval (0.8 ms (95%CI-3.5 ; 5.2)) compared to the 
fifth quintile. This effect fluctuated among the other quintiles. TSH was not associated 
with the risk of borderline QTc interval or QTc prolongation (table 2). Additional analyses 
using log TSH did not change the results.
In contrast, there was a significant age- and gender-adjusted association between 
free T4 levels and QTc interval with an increase of 0.6 ms (95%CI 0.1;1.0) per pmol/l. 
The highest quintile of free T4 was not associated with an increase of the QTc interval 
(3.2 ms (95%CI -1.1 ; 7.6)) in comparison to the first quintile. The P-value for linear 
Table 1 Baseline characteristics
Total (Sub) clinical 
hyperthyroidism
No hyperthyroidism
Number of participants 939 59 880
Age (years, mean, SD) 68.0 (7.6) 67.9 (7.4) 68.0 (7.6)
Gender (male) 365 (38.9%) 19 (32.2%) 346 (39.3%)
Mean QTc interval (ms) (SD) 429.4 (21.7) 429.3 (23.4) 429.4 (21.6)
Borderline QTc prolongation 192 (20.4%) 14 (23.7%) 178 (20.2%)
Abnormal QTc prolongation 56 (6.0%) 1 (1.7%) 55 (6.3%)
Body Mass Index (mean, SD) 26.3 (3.7) 26.3 (4.1) 26.3 (3.7)
Diabetes mellitus (n, %) 93 (9.9%) 7 (11.9%) 86 (9.8%)
Myocardial infarction (n, %) 101 (10.8%) 1 (1.7%)* 100 (11.4%)*
Hypertension (n, %) 282 (30.0%) 17 (28.8%) 265 (30.1%)
Heart failure (n, %) 9 (1.0%) 1 (1.7%) 8 (0.1%)
Use of b-blocking drugs (n, %) 12 (1.3%) 0 12 (1.4%)
Use of QTc prolonging drugs (n, %) 13 (1.4%) 1 (1.7%) 12 (1.4%)
Mean TSH (mU/l) (SD) 1.60 (0.90) 0.29 (0.36)* 1.69 (0.86)*
Mean Free T4 (pmol/l) (SD) 16.5 (3.0) 19.8 (5.0)* 16.3 (2.6)*
SD = Standard Deviation
*: P < 0.05
Use of b-blocking drugs and QTc prolonging drugs was defined as use at the index date.
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trend was 0.031 with a gradual increase of the QTc interval among the quintiles. The 
fifth quintile of free T4 was associated with a significantly higher risk of a borderline 
QTc interval or QTc prolongation (Odds Ratio 1.72 (95%CI 1.07-2.77)) compared to 
the lowest quintile (figure 2). The P-value for linear trend was 0.003. After adjustment 
for diabetes mellitus, hypertension, myocardial infarction and heart failure, the results 
changed minimally. 
Stratified analysis for gender
After stratification for gender, the effects were significant in men but not in women 
(table 3). The fifth quintile of free T4 was associated with a significant age-adjusted 
increase of the QTc interval of 10.9 ms (95%CI 3.4 ; 18.3) in men, with a significant lin-
ear trend (P-value 0.004). The fifth quintile of free T4 was associated with a significantly 
increased risk of a borderline QTc interval in men (OR 2.40 (95%CI 1.20 -4.80) with a 
gradual increase (P-value for linear trend 0.003). In women, there was a non-significant 
trend towards a longer QTc-interval in the highest quintiles of free T4. 
Additional adjustment for calcium, potassium and use of class 1 QTc prolonging 
drugs resulted in higher point estimates. The highest quintile of free T4 in males was 
Table 2 Association of thyroid status with QTc interval 
QTc prolongation in 
ms (95% CI)1
QTc prolongation in 
ms (95% CI)2
Risk of borderline 
or abnormal QTc 
prolongation 
(95%CI)1
Risk of borderline 
or abnormal QTc 
prolongation 
(95%CI)2
TSH quintiles
≤  0.86 0.8 (-3.5 ; 5.2) 0.8 (-3.5 ; 5.1) 1.13 (0.70 ; 1.81) 1.13 (0.70 ; 1.83)
0.87 – 1.25 2.1 (-2.2 ; 6.4) 1.9 (-2.3 ; 6.2) 1.17 (0.74 ; 1.88) 1.16 (0.72 ; 1.88)
1.26 – 1.66 1.0 (-3.3 ; 5.3) 1.1 (-3.2 ; 5.4) 1.03 (0.64 ; 1.66) 1.04 (0.64 ; 1.70)
1.67 – 2.31 0.5 (-3.8 ; 4.9) 0.6 (-3.7 ; 4.9) 0.97 (0.60 ; 1.57) 0.98 (0.60 ; 1.60)
≥ 2.32 Reference Reference Reference Reference
P value for 
linear trend 
0.514 0.857 0.424 0.448
Free T4 
quintiles
≤ 13.9 Reference Reference Reference Reference
14.0 – 15.3 -1.2 (-5.6 ; 3.1) -1.2 (-5.6 ; 3.1) 0.93 (0.56 ; 1.54) 0.93 (0.56 ; 1.55)
15.4 – 16.7 0.9 (-3.5 ; 5.3) 1.0 (-3.4 ; 5.3) 1.30 (0.79 ; 2.13) 1.33 (0.81 ; 2.19)
16.8 – 18.6 2.7 (-1.6 ; 7.1) 2.1 (-2.2 ; 6.4) 1.56 (0.97 ; 2.52) 1.43 (0.88 ; 2.34)
≥ 18.7 3.2 (-1.1 ; 7.6) 2.6 (-1.7 ; 6.9) 1.72 (1.07 ; 2.77) 1.59 (0.98 ; 2.58)
P value for 
linear trend
0.031 0.081 0.003 0.014
CI = Confidence Interval
1 : adjusted for age and gender
2 : adjusted for age, gender, diabetes, hypertension, myocardial infarction and heart failure
TSH in mU/l and free T4 in pmol/l
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associated with a significant adjusted increase of the QTc interval of 12.7 ms (95%CI 
5.6 ; 19.9) with a gradual increase (P-value for linear trend <0.0001). The fifth quintile 
of free T4 in males was associated with a significantly higher risk of a borderline QTc 
interval or QTc prolongation (OR 3.29 (95%CI 1.50-7.22)) compared to the first quintile. 
The P-value for linear trend was 0.001.
Exclusion of the 59 participants with clinical or subclinical hyperthyroidism did not 
change the results substantially. The highest quintile of free T4 in males was associated 
with a significant adjusted increase of the QTc interval of 9.7 ms (95%CI 2.1 ; 17.2) 
with a gradual increase (P-value for linear trend 0.008). The fifth quintile of free T4 in 
males was associated with a significantly higher risk of a borderline QTc interval or QTc 
prolongation (OR 2.12 (95%CI 1.02-4.40)) compared to the first quintile. The P-value 
for linear trend was 0.009.
Discussion
In this population-based study, we found an association between free T4 levels and 
prolongation of the QTc interval. As far as we know, this is the first time that this was 
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demonstrated in a large cohort study of an elderly population. The QTc interval increases 
gradually among the quintiles and the prolongation appears to be strongest in men with 
a prolongation of approximately 10 ms in the highest quintile. Even after exclusion of 
participants with hyperthyroidism, free T4 levels are still associated with prolongation 
of the QTc interval. We did not find an association between TSH and the QTc interval. A 
potential explanation for this finding is that an association between TSH and QTc would 
be indirect, while free T4 is more directly related to thyroid hormone action on the 
heart. TSH binds to the TSH-receptor on thyroid cells, resulting in stimulation of thyroid 
hormone production but has probably not an effect on QTc of its own. [43] 
Thyroid hormone may affect ventricular repolarization but the literature differs with 
respect to the direction of this alteration. Hypothyroidism has been associated with 
prolongation of the QTc interval.[2, 3] The mechanism behind this association might 
be an enhanced sympathetic activity.[11] Hyperthyroidism has been found to be associ-
ated with decreased as well as increased repolarization times. In animal studies [4-7] 
and in one human study [8] decreased repolarization times have been found, however, 
Table 3 Association of free T4 with QTc interval stratified for men and women
QTc prolongation in 
ms (95% CI)1
QTc prolongation in 
ms (95% CI)2
Risk of borderline 
or abnormal QTc 
prolongation 
(95%CI)1
Risk of borderline 
or abnormal QTc 
prolongation 
(95%CI)2
Free T4 
quintiles
Male
≤ 13.8 Reference Reference Reference Reference
13.9 – 15.1 1.5 (-5.9 ; 8.9) 0.6 (-6.8 ; 7.9) 0.93 (0.45 ; 1.94) 0.77 (0.36 ; 1.65)
15.2 – 16.6 6.2 (-1.3 ; 13.7) 6.3 (-1.2 ; 13.7) 1.56 (0.77 ; 3.17) 1.63 (0.79 ; 3.37)
16.7 – 18.3 4.2 (-3.1 ; 11.5) 2.8 (-4.5 ; 10.1) 1.66 (0.83 ; 3.31) 1.40 (0.68 ; 2.88)
≥ 18.4 10.9 (3.4 ; 18.3) 10.0 (2.6 ; 17.5) 2.40 (1.20 ; 4.80) 2.16 (1.06 ; 2.88)
P value for 
linear trend 
0.004 0.008 0.003 0.009
Free T4 
quintiles
Female
≤ 14.1 Reference Reference Reference Reference
14.2 – 15.5 -1.9 (-7.3 ; 3.5) -2.0 (-7.31 ; 3.4) 1.13 (0.56 ; 2.30) 1.11 (0.55 ; 2.27)
15.6 – 16.8 -0.8 (-6.0 ; 4.4) -1.0 (-6.2 ; 4.2) 1.28 (0.65 ; 2.52) 1.29 (0.65 ; 2.55)
16.9 – 18.9 -0.6 (-5.9 ; 4.7) -0.9 (-6.2 ; 4.4) 1.38 (0.70 ; 2.73) 1.34 (0.68 ; 2.66)
≥ 19.0 1.1 (-4.2 ; 6.3) 0.3 (-5.0 ; 5.5) 1.55 (0.80 ; 3.01) 1.42 (0.73 ; 2.78)
P value for 
linear trend
0.564 0.799 0.154 0.252
CI = Confidence Interval
1 : adjusted for age
2 : adjusted for age, diabetes, hypertension, myocardial infarction and heart failure
free T4 in pmol/l
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in several small human studies [9-12] and in an animal study [44] QTc prolongation 
has been reported. In a prospective study comparing 16 patients with Graves’ disease 
with a matched reference group, the 24-hour average QTc in the Graves’ patients was 
significantly prolonged and returned to normal after treatment of thyrotoxicosis. QTc 
has also been shown to be positively correlated with free T3 and free T4.[11] 
A prospective study comparing patients with subclinical hyperthyroidism with healthy 
individuals, demonstrated that QTc intervals were significantly longer in patients with 
subclinical hyperthyroidism.[12] This prolongation might have clinical consequences 
since we demonstrated in earlier studies that QTc prolongation was associated with a 
three-fold increased risk of sudden cardiac death.[17] It is assumed, that even a minor 
average increase of the QTc interval in a population may enhance the risk of Torsade 
de Pointes in a small group of susceptible patients, if large numbers of patients are 
exposed. Some QTc prolonging drugs which were withdrawn from the market because 
of Torsade de Pointes, were associated with a QTc interval prolongation of only 5 to 10 
ms in patient populations.[14] 
A possible explanation for the association of hyperthyroidism and QTc prolongation 
can be provided by an increase in the activity of cardiac Na+/ K+ ATPase due to thyroid 
hormone excess, leading to increased intracellular K+ with subsequent membrane 
hyperpolarization.[1, 11] The effect appeared to be strongest in men. Women are 
known to have on average a longer QTc interval than men.[31] The shorter QTc interval 
in men is attributed to the role of testosterone on the duration of the action potential. 
In hyperthyroid men, impaired sexual function, gynaecomastia, asthenospermia and low 
testicular volume are attributed to lowered bio-available testosterone and a decreased 
Free Androgen Index despite an increase in total and SHBG-bound testosterone.[45, 
46] The decreased bio-available testosterone level in hyperthyroid men results in less 
shortening of the QTc interval. Bio-available testosterone decreases with age, and this 
could explain the relative QTc prolongation in men with high free T4 levels in this study 
of an elderly population.[47, 48] Therefore, the difference in the QTc interval between 
male and female disappears in males with high free T4 levels. 
Our study has several strengths. An advantage of the Rotterdam Study is its popu-
lation-based character which decreases the risk of selection bias. The baseline charac-
teristics of our subcohort were comparable to the baseline characteristics of the whole 
population of the Rotterdam Study. Furthermore, the use of digital ECG recordings, all 
measured using the MEANS system, likely reduced intra- and interobserver variability 
in the assessment of the QTc interval. Confounding was minimized by adjusting for all 
known risk factors for QTc prolongation, although we cannot exclude the possibility of 
unknown confounders. However, our study has also some limitations. Because of the 
cross-sectional design we cannot exclude that QTc prolongation was already present 
in some patients before the increase of free T4. Therefore, the results from this study 
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should be confirmed with longitudinal data from other large cohorts. Thyroid status 
was only assessed in a subgroup of the entire cohort of the Rotterdam Study. Validity is 
nevertheless unaffected since the selection was at random. Free T3 measurements are 
not available in the Rotterdam Study, however, since T4 is a pro-hormone of T3 and T3 
exhibits greater activity, we expect that the results might have been more pronounced, 
if we would have used free T3 as exposure. Finally, our study population consisted of 
participants aged 55 years and older. Whether our findings can be generalized to other 
age groups requires further study. 
In conclusion, we demonstrated in this cohort of an elderly population, that high 
levels of free T4 are associated with QTc prolongation in men. Although a QTc interval 
prolongation of 10 ms in one individual usually remains without clinical consequences, 
an average shift of 10 ms in a Gaussian distribution on a population level will inevitably 
push more individuals into the upper percentiles of the QTc interval with its increased 
risk of Torsade de Pointes and sudden cardiac death. 
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Abstract
Background
Thyroid free T4 is associated with QTc-interval prolongation which is a risk factor for 
sudden cardiac death (SCD). Hyperthyroidism has been associated with SCD in case 
reports but there are no population-based studies confirming this. Therefore we inves-
tigated whether use of antithyroid drugs (as a direct cause or as an indicator of poorly 
controlled hyperthyroidism) is associated with an increased risk of SCD.
Methods 
We studied the occurrence of SCD in a two-step procedure in two different Dutch 
populations. First, the prospective population-based Rotterdam Study including 7898 
participants (≥ 55 yr). Second, we used the Integrated Primary Care Information (IPCI) 
database which is a longitudinal general practice research database to see whether we 
could replicate results from the first study. Drug use at the index date was assessed 
with prescription information from automated pharmacies (Rotterdam Study) or drug 
prescriptions from general practices (IPCI). We used a Cox proportional hazards model in 
a cohort analysis, adjusted for age, gender and use of QTc prolonging drugs (Rotterdam 
Study) and conditional logistic regression analysis in a case-control analysis, matched for 
age, gender, practice and calendar time and adjusted for arrhythmia and cerebrovascu-
lar ischaemia (IPCI).
Results
In the Rotterdam Study, 375 participants developed SCD during follow-up. Current use 
of antithyroid drugs was associated with SCD (HRadj 3.9; 95%CI 1.7-8.7). IPCI included 
1424 cases with SCD and 14,443 controls. Also in IPCI, current use of antithyroid drugs 
was associated with SCD (ORadj 2.9; 95%CI 1.1-7.4). 
Conclusion
Use of antithyroid drugs was associated with a threefold increased risk of SCD. Although 
this might be directly caused by antithyroid drug use, it might be more readily explained 
by underlying poorly controlled hyperthyroidism, since treated patients who developed 
SCD still had low TSH levels shortly before death. 
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Introduction
Hyperthyroidism is a common disease in the elderly with an estimated prevalence 
between 0.5% and 6%.[1-3] Thyroid hormone excess in the elderly affects the cardio-
vascular system.[4] A strong positive correlation between free T3 and the QTc interval 
has been reported.[5, 6] Recently, we demonstrated that free T4 is associated with QTc 
prolongation in males.[7] Prolongation of ventricular repolarization may result in early 
after depolarizations (EAD), which in turn may induce re-entry and thereby provoke 
Torsade de Pointes and fatal ventricular arrhythmias.[8-12] 
Cardiovascular disease is the leading cause of death in the western world and sudden 
cardiac death accounts for almost half of these cardiovascular deaths.[13] Clinical or 
subclinical hyperthyroidism is associated with increased overall mortality, in particular 
mortality due to circulatory and cardiovascular diseases. Even subclinical hypo- and 
hyperthyroidism have been associated with an increased risk of mortality in patients 
with cardiac disease.[14-16] In a previous study, no difference was demonstrated in 
mortality or serious vascular events in users of antithyroid drugs.[17] No effects of sub-
clinical hyperthyroidism on cardiovascular events were demonstrated in two prospective 
studies.[18, 19] Two meta-analyses resulted in different conclusions.[20, 21]
There have been several case reports describing an association between undiagnosed 
hyperthyroidism and ventricular arrhythmias.[22, 23] Sudden cardiac death in patients 
with undiagnosed hyperthyroidism has been described in a few case reports, often asso-
ciated with a thyrotoxic crisis.[24, 25] The association of hyperthyroidism with sudden 
cardiac death has not been described in large epidemiologic studies.
Since the association between hyperthyroidism and ventricular arrhythmias or sudden 
cardiac death has been reported in several case reports, but not in large epidemiologic 
studies, we investigated in a prospective population-based cohort study whether use 
of antithyroid drugs (as a direct cause or as an indicator of poorly controlled hyperthy-
roidism) is associated with an increased risk of sudden cardiac death. Subsequently, 
we performed a case-control study in a separate population to see whether we could 
replicate findings from the first study.
Methods
Setting and study design
Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study, which started with 
a baseline visit between 1990 and 1993. The Medical Ethics Committee of the Erasmus 
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Medical Center, Rotterdam, the Netherlands, approved the study. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years and over, were invited to participate 
(n=10,275). Of them, 7983 (78%) gave their written informed consent and took part 
in the baseline examination. Objectives and methods of the Rotterdam Study have been 
described in detail elsewhere.[26, 27] At baseline, all participants were visited at home 
for a standardized questionnaire, and 7151 were subsequently examined at the research 
center. Since the start of the study, three follow-up visits took place approximately every 
3 years. In addition to follow-up examinations, the cohort is continuously monitored for 
major morbidity and mortality through linkage with general practitioner and municipal-
ity records. Drug prescriptions dispensed to participants by automated pharmacies with 
computerized records and a history of several years, are routinely stored in the database 
since 1 January 1991. To have at least four months of medication history, the study 
period started on 1 May 1991. The study ended on one of the censoring dates (death 
or transferring out) or the end of the study period (1 January 2006). Overall, 7898 
participants were included.
Integrated Primary Care Information (IPCI)
Data were retrieved from the Integrated Primary Care Information (IPCI) project, a 
longitudinal observational database, containing data from computer-based medical 
patient records of a large group of general practitioners (GPs) in the Netherlands, for 
a population based case-control study. In the Dutch health care system, the GP has a 
pivotal role by acting as a gatekeeper for all medical care. Details of the database have 
been described elsewhere.[28, 29] Briefly, the database contains the complete medical 
records on approximately 1 million patients. The electronic records contain coded and 
anonymous data on patient demographics, symptoms (in free text), diagnoses (using 
the International Classification for Primary Care (ICPC) [30] and free text) from GPs 
and specialists, referrals, laboratory findings, hospitalisations, and drug prescriptions, 
including their indications and dosage regimen. To maximise completeness of the data, 
GPs participating in the IPCI project are not allowed to maintain a system of paper-based 
records besides the electronic medical records. The system complies with European 
Union guidelines on the use of medical data for medical research and has been proven 
valid for pharmaco-epidemiological research in several validation studies that evaluated 
the quality of the available information.[28] The Scientific and Ethical Advisory Board of 
the IPCI project approved this study. 
The source population comprised all patients of 18 years and older in the IPCI data-
base with a valid database history (date of registration with GP) of at least one year. The 
study population comprised all cases with sudden cardiac death occurring in the source 
population during the study period plus their matched controls (see below). The study 
period started on 1 January 1995 and ended on 1 May 2007. All subjects were followed 
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until death, transferral out of the GP practice, last data draw down or end of the study 
period, whichever came first. 
Sudden cardiac death definition
In both the Rotterdam Study and in IPCI, sudden cardiac death was defined as: 1) 
a witnessed natural death attributable to cardiac causes, heralded by abrupt loss of 
consciousness, within one hour of onset of acute symptoms, or 2) an unwitnessed, 
unexpected death of someone seen in a stable medical condition <24 hours previously 
with no evidence of a non-cardiac cause.[31, 32] 
Rotterdam Study
The ascertainment of sudden cardiac death cases in the Rotterdam Study has been 
described previously.[12] In short, information on vital status is obtained from municipal 
health authorities in Rotterdam and GPs. Two research physicians independently coded 
all reported events, blinded to exposure, and judged the likelihood of sudden cardiac 
death according to the definition above. In cases of disagreement, consensus was 
sought and finally, a cardiologist reviewed all events. The index date was the date of 
death.
IPCI: Case and control definition
The computerised medical and demographic data were screened for all deaths, which 
occurred during the study period. The medical records of all identified cases of death 
were reviewed manually to assess whether death could be classified as sudden cardiac 
death. Validation was performed independently by two medically trained persons 
blinded to exposure and in case of discrepancy, a specialized physician arbitrated. To 
each case of sudden cardiac death, up to twenty controls were randomly drawn from 
the source population matched on age (year of birth), gender, and practice (GP). The 
index date was defined as the date on which sudden cardiac death occurred in cases. 
This date was also the index date for matched controls. 
Use of antithyroid drugs
In this study, the exposure of interest included the available antithyroid drugs carbima-
zole, thiamazole, and propylthiouracil. The duration of each prescription was calculated 
by dividing the total number of units issued per prescription by the prescribed daily 
number of units. Use of antithyroid drugs was defined as current if the index date 
fell within a period of use or within a maximum of 40 days after the end of the last 
prescription (to deal with carry-over effects and/or irregular use by patients). Past use 
was defined as discontinuation of an antithyroid drug, more than 40 days before the 
index date. If patients had no prescription for an antithyroid drug prior to the index date 
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they were considered as non-exposed. Among current users we evaluated the effect of 
duration (≤ 365 days; > 365 days) of use which was defined as the delay between first 
intake and the index date, and the effect of dosage (< 1 defined daily dosage (DDD); ≥ 
1 DDD). The DDD is the recommended average maintenance dose per day for a drug 
used for its main indication in adults.[33]
Covariates
Rotterdam Study
Clinical measures were obtained during the visits at the Rotterdam Study research 
center. Diabetes mellitus was defined as the use of blood glucose–lowering medication 
and/or a non-fasting serum glucose level of 11.1 mmol/l or higher and/or serum glucose 
levels ≥ 7mmol/l (1997-2000).[34] Hypertension was identified through the use of anti-
hypertensive medication and/or the assessment of blood pressure measurements.[35] 
Prevalence and incidence of myocardial infarction, heart failure, stroke and transient 
ischemic attacks were assessed as previously described.[36-40] Hypercholesterolemia 
was defined as a total serum cholesterol level above 6.2 mmol/l or the use of cholesterol-
lowering drugs.[41] Use of QTc prolonging drugs (list 1) of the website based registry, 
use of b-blocking drugs and use of non-dihydropyridine calcium channel blockers at the 
index-date were considered as a covariate.[42] 
IPCI
Known risk factors and other covariates for sudden cardiac death were gathered from the 
medical records through computerised searches and manual assessment. Cerebro- and 
cardiovascular ischemia and heart failure were assessed, based on the diagnoses pro-
vided by the general practitioner and by specialists in the medical records. Hypertension 
was identified through the diagnoses in the medical records, the use of antihypertensive 
medication and/or the assessment of blood pressure measurements.[35] Diabetes mel-
litus, arrhythmias and hypercholesterolemia were identified through diagnoses in the 
medical records from GPs and specialists and/ or the use of antidiabetic, anti-arrhythmic 
or lipid lowering medication. Use of QTc prolonging drugs, use of b-blocking drugs and 
use of non-dihydropyridine calcium channel blockers at the index-date were considered 
as a covariate.[42] 
Statistical analysis
The relative risk of sudden cardiac death associated with use of antithyroid drugs was 
estimated by calculation of the hazard ratios using Cox proportional hazards models 
in the Rotterdam Study, and by calculation of the odds ratios using conditional logistic 
regression analyses in IPCI.
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Covariates which were univariately associated with sudden cardiac death (at a p< 0.1 
level) were included in the regression analyses if they changed the point estimate of the 
association between use of antithyroid drugs and sudden cardiac death by more than 
10%.[43] We assessed the effect of duration of use and dosage and we investigated 
potential effect modification by age and gender, with interaction terms and subsequent 
stratifications. We performed several sensitivity analyses: by excluding users of amio-
darone, participants with atrial fibrillation and adjusted for heart rate at baseline. The 
analyses were performed using SPSS for Windows version 15.0 (Chicago, Illinois, USA).
Results
Subject characteristics 
Rotterdam Study
The baseline characteristics of all participants are presented in table 1. The mean age of 
the study population (7,898 participants) at baseline was 70.5 years (Standard Deviation 
9.7 years), 38.9% was male. 
The mean follow-up period for men was 9.6 years, the mean follow-up period for 
women was 10.0 years. During the follow-up period, 3,589 participants died of all 
causes. Overall, 297 persons were classified as definite sudden cardiac death and 78 as 
probable sudden cardiac death. Of the 375 sudden cardiac death events, 173 were in 
males. The mean age at baseline of the cases was 74.2 years (SD 8.5).
IPCI
The source population for this study comprised 478,661 subjects with at least one year 
of valid history during the study period. The total number of person-years of follow-
up was 1,905,382 years, 14,259 persons died, 926 persons were classified as definite 
sudden cardiac death, 498 as probable sudden cardiac death. Overall, there were 1424 
cases and 14,443 matched controls. The mean age of the cases was 72.9 years and 
58.4 % were male.
Association between antithyroid drugs and sudden 
cardiac death
Rotterdam Study
Of all sudden cardiac death cases, 6 participants were current users of antithyroid drugs 
at the index date and 5 participants had used antithyroid drugs in the past but were 
no longer using them (table 2). Two of these currently exposed cases were classified 
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as definite sudden cardiac death and four as probable. The age ranged from 66 until 
87 years. One of the patients was diagnosed with multinodular goitre, from the other 
patients the underlying cause of the hyperthyroidism was unknown. One of the patients 
had episodes of ventricular tachycardia and ventricular fibrillation in the recent history, 
possibly due to underlying hyperthyroidism. One patient used amiodarone at the time 
of sudden cardiac death. One patient had a TSH of 0.13 (6 days before sudden cardiac 
death), one a TSH<0.01 (15 days before sudden cardiac death). In the third case, the 
treating physician required blood test (including TSH) 11 days before sudden cardiac 
Table 1 Baseline characteristics, demographics, distribution of covariates
Rotterdam Study (cohort study) IPCI (case-control study)
Characteristic Current use 
of antithyroid 
drugs at 
baseline
(n = 61)
No use  
of antithyroid 
drugs at 
baseline
(n = 7837)
Sudden cardiac 
death cases 
(n = 1424)
Controls
(n = 14443)
Gender
    Male 11 (18.0%)* 3064 (39.1%)* 831 (58.4%) 8739 (60.5%)
    Female 50 (82.0%)* 4773 (60.9%)* 593 (41.6%) 5704 (39.5%)
Age (mean, SD) (years) 76.7 (9.0)* 70.6 (9.7)* 72.9 (13.9)* 66.7 (13.8)*
    ≤ 55 - - 170 (11.9%) 3008 (20.8%)
    55 – 65 10 (16.4%) 3001 (38.3%) 193 (13.6%) 2853 (19.8%)
    66 – 75 17 (27.9%) 2614 (33.3%) 366 (25.7%) 4274 (29.6%)
    > 75 34 (55.7%) 2222 (28.4%) 695 (48.8%) 4308 (29.8%)
Co-morbidities
    Myocardial infarction 5 (8.2%) 868 (11.1%) 77 (5.4%)* 271 (1.9%)*
    Transient ischemic attack 1 (1.6%)* 416 (5.3%)* 65 (4.6%)* 383 (2.7%)*
    Cerebrovascular accident 10 (16.4%) 941 (12.0%) 59 (4.1%)* 259 (1.8%)*
    Arrhythmia - - 141 (9.9%)* 837 (5.8%)*
    Hypertension 27 (44.3%) 2549 (32.5%) 268 (18.8%)* 2284 (15.8%)*
    Body Mass Index (mean, SD) 26.1 (3.7) 26.3 (3.7) - -
    Diabetes mellitus 15 (24.6%)* 839 (10.7%)* 284 (19.9%)* 1274 (8.8%)*
    Smoking - - 283 (19.9%) 2857 (19.8%)
    Current smoking 7 (11.5%) 1385 (17.7%) - -
    Past smoking 11 (18.0%)* 2579 (32.9%)* - -
    Alcohol abuse (0%)* 176 (2.2%)* 30 (2.1%)* 107 (0.1%)*
    Heart failure 3 (4.9%) 271 (3.5%) 272 (19.1%)* 615 (4.3%)*
    Hypercholesterolemia 18 (29.5%)* 2995 (38.2%)* 204 (14.3%)* 1619 (11.2%)*
    Use of list1 QTc 
    prolonging drugs
17 (27.9%)* 491 (6.3%)* 58 (4.1%)* 283 (2.0%)*
    Use of b-blocking drugs 18 (29.5%)* 1467 (18.7%)* 209 (14.7%)* 1608 (11.1%)*
    Use of non-dihydropyridine 
    calcium channel blockers
4 (6.6)* 259 (3.3%)* 58 (4.1%)* 279 (1.9%)*
* P<0.05
SD Standard Deviation
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death. The conclusions some days later was: “hyperthyroidism” but no values were 
given in the medical records. Thyroid function was not known for the other three cases.
Current use of antithyroid drugs was associated with a significantly increased risk 
of sudden cardiac death, adjusted for gender and age and use of list 1 QTc prolonging 
drugs (HR 3.9 (95% CI 1.7-8.8)). Past use was not associated with an increased risk of 
sudden cardiac death (HR 2.0 (0.8-4.8)). 
After exclusion of users of amiodarone, the point estimates did not change substan-
tially (risk of sudden cardiac death (HR 3.7 (1.5-8.9))). There was effect modification by 
gender (p=0.005), men had a higher risk of sudden cardiac death (HR 10.4 (2.6-42.5)) 
than women (HR 2.9 (1.1-7.7)). There was no effect modification by age (p=0.74). The 
risk of sudden cardiac death in current users of antithyroid drugs remained unchanged, 
after adjusting for age, gender, list 1 QTc prolonging drugs and heart rate at baseline 
(HR 3.1 (1.0-9.7)). After exclusion of participants with prevalent atrial fibrillation, the HR 
for current use slightly increased (4.3 (1.9-9.6)). Participants using ≥ 1 DDD had a higher 
risk of sudden cardiac death (HR 4.1 (1.3-12.7)) than participants using < 1 DDD (HR 
1.5 (0.2-10.8)). Participants using antithyroid drugs less than 1 year had a higher risk of 
sudden cardiac death (HR 4.5 (1.1-18.3)) than participants using antithyroid drugs more 
than 1 year (HR 2.3 (1.2-4.6)).
IPCI
Of all cases, 7 patients were current users of antithyroid drugs at the index date and 2 
patients were past users. Three of these cases were classified as definite sudden cardiac 
death and four as probable. The age ranged from 60 until 90 years. Two patients were 
diagnosed with toxic multinodular goitre, one with diffuse toxic goitre and one with 
multinodular goitre with degenerate changes, from the other 3 patients the cause of 
hyperthyroidism was unknown. None of the patients used amiodarone at the time of 
Table 2 Risk of SCD 
Rotterdam Study IPCI
Use of 
antithyroid 
drugs
SCD No SCD HR (95% CI)1 HR (95% CI)2 Cases Controls OR (95% CI)3 OR (95% CI)4
Number 375 7523 1424 14443
Never use 364 7383 Reference Reference 1415 14386 Reference Reference
Past use 5 81 2.0 (0.8 - 4.8) 2.0 (0.8 - 4.8) 2 40 0.5 (0.1 - 1.9) 0.5 (0.1 - 1.9)
Current use 6 59 4.3 (1.9 - 9.6) 3.9 (1.7 - 8.8) 7 17 3.3 (1.3 - 8.5) 2.9 (1.1 - 7.4)
SCD = sudden cardiac death
1 Hazard ratios adjusted for gender and time-depending age.
2 Hazard ratios adjusted for gender and time-depending age and use of list1 QTc prolonging drugs.
3 Odds ratios matched for age, gender, practice and calendar time.
4 Odds ratios matched for age, gender, practice and calendar time and adjusted for arrhythmia and cerebrovascular ischemia.
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sudden cardiac death. Six patients died within a few weeks after start of antithyroid 
drugs, when they probably still had low TSH levels and increased free T4 levels.
There was a significant association between sudden cardiac death and use of anti-
thyroid drugs, adjusted for arrhythmia and cerebrovascular ischaemia (OR 2.9 (1.1-7.4)). 
Past use was not associated with an increased risk of sudden cardiac death. 
Sensitivity analysis showed, that after exclusion of users of amiodarone, point esti-
mates did not change substantially (OR 3.3 (1.3-8.5)). Stratified analyses showed that 
the association between sudden cardiac death and use of antithyroid drugs tended to 
be higher in patients younger than 70 years (OR 16.1 (1.0-262.0)) than in patients older 
than 70 years (OR 1.8 (0.5-7.3)), but this difference was not statistically significant. 
Effect modification by gender could not be demonstrated. 
Discussion
In this study, we demonstrated in two independent populations that use of antithyroid 
drugs was associated with an increased risk of sudden cardiac death. There are two 
potential explanations for our findings. First, sudden cardiac death might be an adverse 
reaction to the antithyroid drugs. However this seems unlikely since different antithyroid 
drugs were involved and it lacks a biologically plausible mechanism. Second, patients 
may still have had inadequately treated hyperthyroidism with increased levels of free T4. 
Since TSH and free T4 levels were only available in a minority of patients, we could not 
verify this. Validation of the exposed sudden cardiac death cases demonstrated that the 
exposed cases with known TSH measurements, had low TSH levels a few days before 
the index date. This could indicate that these patients were still hyperthyroid at that 
time. Our findings could suggest that these deaths were caused by undertreatment of 
hyperthyroidism. 
Sudden deaths have been described after therapy with radioactive iodine. However, 
in the Rotterdam Study none of the exposed patients had received radioactive iodine. 
In IPCI, one of the exposed controls received radioactive iodine before the index-date 
and none of the exposed cases. Amiodarone may cause iodine-induced thyreotoxicosis 
(AIT), which might worsen arrhythmias and increase mortality.[44] However, excluding 
all users of amiodarone did not change the point estimates substantially. The association 
between antithyroid drugs and sudden cardiac death in our study tended to be higher 
in younger persons in the case-control study. We did not find effect modification by age 
in the Rotterdam Study, possibly since in a study of an elderly population there is less 
age variability. Participants who were treated with a higher dosage had a higher risk of 
sudden cardiac death, probably since these participants had more severe hyperthyroid-
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ism. Furthermore, participants who were treated less than 1 year had an increased risk, 
possibly due to depletion of susceptibles. 
Subclinical hyperthyroidism is associated with increased cardiovascular mortality 
among persons of 60 years or older.[14] Hyperthyroidism has been associated with 
ventricular arrhythmias and sudden cardiac death in several case reports.[17, 22-25, 45] 
Recently, we found an association of free T4 with a higher risk of QTc prolongation in 
males.[7] A potential explanation for this association is an increased activity of cardiac 
Na+/ K+ ATPase in thyroid hormone excess, leading to increased intracellular K+ with 
subsequent membrane hyperpolarization and an increase in QTc duration.[5, 6] In the 
Rotterdam Study, the association of antithyroid drugs and sudden cardiac death tended 
to be higher in males, which supports the association of free T4 and QTc prolongation in 
males, we found earlier. As far as we know, this is the first time that use of antithyroid 
drugs has been associated with sudden cardiac death in two large epidemiologic studies.
Our study has several strengths. First, the availability of data on a large group of 
participants in two independent study populations. We were able to take advantage of 
the fact that in most cases of sudden cardiac death extensive information of the facts 
surrounding the event was available, which allowed rigorous adjudication of sudden 
cardiac death events. Second, the complete coverage of drug dispensing records in the 
Rotterdam Study and of prescription data in IPCI allowed us to study the association 
between antithyroid drugs and sudden cardiac death. The population-based design of 
the Rotterdam Study probably limited the chance of selection bias. Selection bias is 
also unlikely in IPCI which covers the complete population in a circumscribed area and 
both cases and controls were selected from the same source population. There is no 
information bias, since we used pharmacy data and GP data which are automatically 
registered, prospectively and irrespective of disease status. Confounding was minimized 
by adjusting for all known cardiovascular risk factors of sudden cardiac death. However, 
our study has also some potential limitations. Not all acute deaths may have been of 
cardiac origin. We determined sudden cardiac death, however, on the basis of the full 
medical records and all circumstances surrounding the death were available. Recently, an 
evaluation comparing different methods to determine the incidence of sudden cardiac 
death suggested that this method provides a very reliable way of determining sudden 
cardiac death cases.[46] Because of the small number of users of antithyroid drugs in 
our analysis in the Rotterdam Study, we tested the validity of our findings by replication 
in the IPCI database. The fact that the association was not only demonstrated and 
subsequently replicated in two independent study populations but also that the point 
estimates were quite similar, confirms the validity of the association between current 
use of antithyroid drugs and sudden cardiac death. Second, we could not investigate 
the mechanism of the association between hyperthyroidism and sudden cardiac death. 
The patients using antithyroid drugs could have hyper-, hypo- or normothyroid values. 
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However, since the exposed sudden cardiac death cases with a thyroid measurement, 
had a decreased TSH measurement shortly before the index date, it is more likely due to 
the underlying hyperthyroidism than due to the antithyroid drugs. Earlier, we demon-
strated that free T4 is associated with QTc prolongation in males [7] and also that QTc 
prolongation is associated with an increased risk of sudden cardiac death.[12]
In conclusion, we demonstrated that use of antithyroid drugs seems to be associated 
with a threefold increased risk of sudden cardiac death. Although this might be due to 
antithyroid drug use, it could be more readily explained by underlying hyperthyroidism, 
since increased free T4 levels are associated with QTc prolongation and treated patients 
who developed sudden cardiac death still had low TSH levels shortly before death. This 
suggests that hyperthyroidism may be a risk factor for sudden cardiac death. 
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Abstract
Background
It is assumed that testosterone is an important regulator of gender-related differences 
in ventricular repolarization. Therefore, our aim was to study whether serum levels of 
testosterone are associated with QTc, QT and RR interval variation. 
Methods
Setting: Two independent population-based cohort studies. 
Participants: 445 male participants (≥55 yr) from the Rotterdam Study cohort and 1428 
male participants from the Study of Health in Pomerania (SHIP) with an electrocardio-
gram who were randomly sampled for assessment of serum testosterone at baseline, 
after exclusion of participants with testosterone altering drugs, QTc prolonging drugs or 
dig(it)oxin, left ventricular hypertrophy and left and right bundle branch block.
Endpoints: Length of the QTc, QT and RR intervals.
Analysis: Linear regression model, adjusted for the two individual studies and a pooled 
analysis of both studies.
Results
The pooled analysis of the Rotterdam Study and SHIP showed that the QTc interval 
gradually decreased among the tertiles (P value for trend 0.024). The third tertile of 
serum testosterone was associated with a lower QTc interval compared to the first tertile 
(-3.4 ms (-6.5;-0.3)). However, the third tertile of serum testosterone was not associated 
with a lower RR-adjusted QT interval compared to the first tertile (-0.7 ms (–3.1;1.8)). 
The RR interval gradually increased among the tertiles (P value for trend 0.002) and the 
third tertile of serum testosterone showed an increased RR interval compared to the first 
tertile (33.5 ms (12.2;54.8)).
Conclusions
In the pooled analysis of two population-based studies, serum testosterone levels were 
not associated with the RR-adjusted QT interval. Lower QTc intervals in men with higher 
serum testosterone levels were probably due to the association of serum testosterone 
with prolongation of the RR interval. 
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Introduction
There are well known gender-related differences in human cardiac repolarization.[1, 
2] This is demonstrated by a longer heart-rate corrected QT (QTc) interval in women, 
which is the traditional clinical measurement for assessing the duration of ventricular 
repolarization.[3] Prolongation of ventricular repolarization may result in early after 
depolarizations, which in turn may induce re-entry and thereby provoke Torsade de 
Pointes and fatal ventricular arrhythmias.[4-7] 
The gender differences in the QTc interval are not present in young children, whereas 
at the time of onset of puberty the duration of the QTc interval in boys shortens, which 
results in a longer QTc interval in adult women compared to men.[8-10] These gender 
differences decrease with age.[10] Since the period between puberty and approximately 
50 years of age coincides with the highest circulating levels of androgens in males, 
male sex hormones may play a role in the shorter QTc interval in men. Furthermore, 
virilized women exhibit QTc intervals similar to those of healthy men, whereas castrated 
men had QTc intervals similar to those of normal women.[11] Testosterone therapy also 
reduces QT dispersion in men with congestive heart failure.[12] 
These data suggest that testosterone might be an important regulator of ventricular 
repolarization, which might explain the gender-related differences in ventricular repolar-
ization. Therefore, our aim was to study whether testosterone is associated with QTc, QT 
and RR interval duration. Since bio-available testosterone decreases with age [13], we 
studied this association in two cohorts. First, in a cohort of elderly (the Rotterdam Study) 
and second, in a cohort with a younger mean age (the Study of Health in Pomerania 
(SHIP)). 
Methods
Setting and study design
Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study, which started with 
a baseline visit between 1990 and 1993. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, the Netherlands, approved the study. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years and over, were invited to participate 
(n=10,275). Of them, 7983 (78%) gave their written informed consent and took part 
in the baseline examination. Objectives and methods of the Rotterdam Study have been 
described in detail elsewhere.[14, 15] At baseline, all participants were visited at home 
for a standardized questionnaire, and 7151 were subsequently examined at the research 
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center. The cohort is continuously monitored for major morbidity and mortality through 
linkage with general practitioner and municipality records. Drug prescriptions dispensed 
to participants by automated pharmacies are routinely stored in the database since 1 
January 1991.
All male cohort members of the Rotterdam Study (n=3105), who had an ECG as well 
as serum testosterone and dehydroepiandrosterone sulfate (DHEAS) measurements at 
baseline were enrolled in the study population. Digitally stored ECGs were available for 
2200 male participants at the time of the first visit. Missing ECGs were mainly due to 
temporary technical problems with ECG recording. Androgen status was assessed in 
different random subsets of these males. Male participants with an ECG and with both 
a serum testosterone measurement and a DHEAS measurement (n=540) were included. 
Participants who received anabolic steroids (Anatomic Therapeutical Chemical (ATC) 
code A14A) (n=1) were excluded. None of the participants received sexual hormones 
(ATC code G03), testosterone 5a-reductase inhibitors (ATC code G04CB), sexual hor-
mone antagonists (ATC code L02B) or had a pacemaker. Participants who used digoxin 
(n=25), which is a QTc shortening agent, or QTc prolonging drugs (n=6) as well as 
persons with evidence of left ventricular hypertrophy (n=36) or left (n=13) and right 
bundle branch block (n=36) were excluded, since these conditions are associated with 
an altered QTc interval.[16, 17] Overall, 445 participants were included in the Rotterdam 
study population.
The Study of Health in Pomerania (SHIP)
SHIP is a cross-sectional population-based study in West Pomerania, a region in the north-
east of Germany. The total population of West Pomerania selected for SHIP comprised 
212,157 inhabitants. A two-stage cluster sampling method adopted from the WHO 
MONICA Project Augsburg, Germany yielded 12 five year age strata (20 to 79 years) for 
both genders, each including 292 individuals.[18] The sampling was performed from 
population registries where all German citizens are registered. Data collection started in 
October 1997 and was finished in March 2001. The net sample comprised 6267 eligible 
subjects. Finally, 4310 subjects (69%) participated. The study was monitored by a board 
of independent scientists. All participants gave written informed consent. The study 
conformed to the principles of the Declaration of Helsinki as reflected by an a priori 
approval of the Ethics Committee of the University of Greifswald. Use of medication at 
baseline was recorded by a computer-aided method using the ATC code.
All male cohort members of SHIP (n=2118) with ECG, testosterone and DHEAS mea-
surements at baseline were enrolled in the study population. Digitally stored ECGs were 
available for 1826 male participants at the time of the first visit. Male participants with 
an ECG and both a testosterone and a DHEAS measurement (n=1677) were included. 
Participants who received sexual hormones (ATC code G03) (n=3), testosterone 5a 
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reductase inhibitors (ATC code G04CB) (n=4) or sexual hormone antagonists (ATC 
code L02B) (n=3) were excluded. None of the participants reported to receive anabolic 
steroids (ATC code A14A). Furthermore, participants who used digoxin (n=5) or digi-
toxin (n=153), QTc prolonging drugs (n=13), persons with a pacemaker (n=15), as well 
as persons with evidence of left ventricular hypertrophy (n=4) or left (n=1) and right 
bundle branch block (n=48) were excluded. Overall, 1428 participants were included in 
the SHIP study population.
QTc, QT and RR interval 
The endpoints of the study were the lengths of the QTc, QT and RR intervals in ms. A 
12-lead resting ECG was recorded with an ACTA electrocardiograph (ESAOTE, Florence, 
Italy) at a sampling frequency of 500 Hz and stored digitally. All ECGs (both from the 
Rotterdam Study as well as from SHIP) were centrally processed in Rotterdam using the 
Modular ECG Analysis System (MEANS) to obtain ECG measurements, in agreement 
with the FDA guidance for clinical evaluation of QT/ QTc interval prolongation.[19] The 
MEANS program has been evaluated and validated extensively.[20-23] In one of these 
validation studies, ECGs with selected abnormalities were analyzed by 5 cardiologists 
and 11 different computer programs of which MEANS performed as one of the best.
[23] In a study in which QT intervals by manual measurement were compared with 
QT measurement by ECG machines, manual and automated measurements generated 
similar numerical results in 3 studies in healthy volunteers, which all included a positive 
control.[24] MEANS determines common onsets and offsets for all 12 leads together 
on one representative averaged beat, with the use of template matching techniques.
[21] The QT interval is determined from the start of the QRS complex until the end of 
the T wave. To adjust for heart rate, Bazett’s formula (QTc=QT/√RR) was used.[25] The 
RR interval was taken as the median of the RR intervals in the recording. Additionally, 
the MEANS program determines left ventricular hypertrophy and left and right bundle 
branch block.
Steroids
Rotterdam Study
At baseline, non-fasting blood samples were obtained. Time of sampling was recorded. 
Testosterone and DHEAS were estimated using coated tube or double antibody RIAs, 
respectively, purchased from Diagnostic Systems Laboratories.[26] 
SHIP
At baseline, non-fasting blood samples were obtained. Time of sampling was recorded. 
Testosterone and DHEAS were measured using competitive chemiluminescent enzyme 
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immunoassays on an Immulite 2500 analyzer (DPC Biermann GmbH, Bad Nauheim, 
Germany).
Covariates
Rotterdam Study
Hypertension was identified through the use of antihypertensive medication and/or 
the assessment of blood pressure measurements, according to the guidelines of the 
World Health Organisation.[27] Prevalence and incidence of myocardial infarction were 
assessed as previously described.[28, 29] Diabetes mellitus was defined as the use of 
blood glucose–lowering medication and/or a non-fasting serum glucose level of 11.1 
mmol/l or higher and/or fasting serum glucose levels ≥ 7mmol/l.[30] Prevalence and inci-
dence of heart failure were assessed by the presence of suggestive signs and symptoms 
as previously described.[31, 32] Potassium and calcium were measured by means of a 
Microlyte device. During the home interview, smoking status and use of alcohol were 
assessed. Creatinine clearance was computed with the Cockroft Gault method. Renal 
failure was defined by the internationally accepted criterion of a GFR below 60 ml/min.
[33] Gamma-glutamyl transferase (GGT), aspartate-amino transferase (ASAT), alanine-
amino transferase (ALAT) levels were used to determine hepatic failure.
SHIP
Hypertension was identified through the use of antihypertensive medication and/or the 
assessment of blood pressure measurements, according to the guidelines of the World 
Health Organisation.[27] Diabetes mellitus and myocardial infarction were defined 
as self-reported physician’s diagnosis. Determination of calcium was performed by a 
colorimetric assay and potassium by ion-selective electrodes (Roche/Hitachi 717; Roche 
Diagnostics GmbH, Mannheim, Germany). During the home interview, smoking status 
and use of alcohol were assessed. Creatinine clearance was computed with the Cockroft 
Gault method. Renal failure was defined by the internationally accepted criterion of a 
GFR below 60 ml/min.[33]GGT, ALAT and ASAT were used to determine hepatic failure.
Statistical analysis
The association between the QTc, QT, RR intervals and testosterone was assessed 
through linear regression with log-transformed testosterone and testosterone measure-
ments divided in tertiles. Since DHEAS was associated with both the QTc and the RR 
interval, we adjusted all analyses for DHEAS. Furthermore, all analyses were adjusted for 
age, time of blood withdrawal, hypertension, myocardial infarction, diabetes mellitus, 
potassium, calcium and in the Rotterdam Study also for heart failure. 
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First, a linear regression analysis was conducted with QTc, QT and RR interval as 
dependent and testosterone as independent variables for the Rotterdam Study and SHIP 
separately. Second, we conducted a pooled analysis of the Rotterdam Study and SHIP. 
Furthermore, we performed several sensitivity analyses: First, by stratification for age. 
Second, in additional analyses we adjusted for smoking, alcohol abuse, renal failure, 
hepatic failure and use of beta-blockers. All analyses were performed using SPSS for 
Windows version 15.0 (Chicago, Illinois, USA).
Results
Subject characteristics
The baseline characteristics of the participants are presented in table 1. The mean age 
of the study population of the Rotterdam Study was 68.0 years (standard deviation (SD) 
7.8 years). The mean testosterone level was 11.3 nmol/l (SD=3.7). The mean age of the 
study population of SHIP was 49.1 years (SD 16.0 years). Mean testosterone levels were 
17.0 nmol/l (SD=5.9).
Table 1 Baseline characteristics of study population
Rotterdam Study SHIP
Number of participants 445 1428
Age (years, mean, SD) 68.0 (7.8) 49.1 (16.0)
Mean QTc interval (ms) (SD) 423.2 (25.0) 423.5 (24.4)
Mean QT interval (ms) (SD) 398.2 (28.6) 394.1 (29.9)
Mean RR interval (ms) (SD) 896.2 (156.7) 876.0 (156.2)
Body Mass Index (kg/m2) (SD) 26.6 (3.4) 27.7 (4.2)
Diabetes mellitus (n, %) 50 (11.2) 95 (6.7)
Myocardial infarction (n, %) 84 (18.9) 59 (4.1)
Hypertension (n, %) 111 (24.9) 594 (41.6)
Heart failure (n, %) 7 (1.6) -
Mean potassium (mmol/l) (SD) 4.1 (0.3) 4.1 (0.3)
Mean calcium (mmol/l) (SD) 2.4 (0.1) 2.4 (0.1)
Mean DHEAS (mmol/l) (SD) 4.3 (2.7) 5.3 (3.3)
Mean testosterone (nmol/l) (SD) 11.3 (3.7) 17.0 (5.9)
SD=standard deviation
DHEAS= dehydroepiandrosterone sulfate
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Androgens and QTc interval
The mean duration of the QTc interval was approximately similar in both studies, the 
mean duration of the QT and RR interval was slightly longer in the Rotterdam study 
than in SHIP (table 1). Comparison of the highest testosterone tertile with the lowest 
tertile showed no significant association between testosterone and QTc (-5.9 ms (95%CI 
–13.8 ; 2.1) and -2.9 ms (95%CI –5.9 ; 0.1) respectively) nor with the QT interval (–2.4 
ms (95%CI -8.8 ; 4.0) and -0.6 ms (95%CI –3.0 ; 1.8) respectively) in the Rotterdam 
and SHIP study separately (table 2). The logarithmic transformation of testosterone was 
associated with the QTc interval in SHIP (-7.9 ms (95%CI –15.3 ; -0.6)).
In SHIP, the RR interval increased gradually with increasing testosterone levels (P value 
for trend 0.004) and the second and third tertiles of testosterone had longer RR intervals 
compared to the first tertile (24.0 ms (95%CI 3.8 ; 44.1) and 31.3 ms (95%CI 10.3 ; 
52.3) respectively). The logarithmic transformation of testosterone was associated with 
the RR interval in both the Rotterdam Study and SHIP (149.8 ms (95%CI 30.6 ; 269.1) 
and 55.9 ms (95%CI 5.2 ; 106.6) respectively).
Table 2 Association of testosterone with QTc, QT and RR interval 
Rotterdam 
Study 
(n=445)
Testosterone QTc-interval in ms 
(95% CI)1
QT-interval in ms 
(95% CI)2
RR-interval in ms 
(95% CI)1
Log-transformation -6.5 (-23.7 ; 10.8) 5.9 (-8.2 ; 20.1) 149.8 (30.6 ; 269.1)
Tertiles
1 Reference Reference Reference
2 3.8 (-4.1 ; 11.7) 5.5 (-0.8 ; 11.9) 29.2 (-27.3 ; 85.8)
3 -5.9 (-13.8 ; 2.1) -2.4 (-8.8 ; 4.0) 42.4 (-14.3 ; 99.2)
P value for linear trend 0.132 0.419 0.143
SHIP 
(n=1428)
Log-transformation -7.9 (-15.3 ; -0.6) -3.4 (-9.2 ; 2.4) 55.9 (5.2 ; 106.6)
Tertiles
1 Reference Reference Reference
2 -0.7 (-3.6 ; 2.2) 1.5 (-0.8 ; 3.9) 24.0 (3.8 ; 44.1)
3 -2.9 (-5.9 ; 0.1) -0.6 (-3.0 ; 1.8) 31.3 (10.3 ; 52.3)
P value for linear trend 0.061 0.623 0.004
CI = Confidence Interval
1 :  adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, dehydroepiandrosterone 
sulfate (DHEAS) and in the Rotterdam Study also for heart failure
2 :  adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, DHEAS, RR interval and 
in the Rotterdam Study also for heart failure
Testosterone in nmol/l. For the Rotterdam Study the tertiles were defined as (1) ≤ 9.9; (2) 10.0 – 12.6; (3) ≥ 12.7. For SHIP the tertiles were 
defined as (1) ≤  13.9; (2) 14.0 – 18.6; (3) ≥ 18.7.
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Pooled analysis
There was a gradual decrease of the QTc interval among the tertiles (P value for trend 
0.024), while the third tertile of testosterone was significantly associated with the QTc 
interval compared to the first tertile (-3.4 ms (95%CI –6.5 ; -0.3)) (table 3). Compared to 
the first tertile of testosterone, the third tertile was not associated with the QT interval 
(–0.7 ms (95%CI –3.1 ; 1.8)). 
There was a gradual increase of the RR interval among the tertiles (P value for trend 
0.002), while the third tertile of testosterone was significantly associated with the RR 
interval compared to the first tertile (33.5 ms (95%CI 12.2 ; 54.8)). Sensitivity analyses 
revealed no effect modification by age. Additional adjustment for smoking, alcohol, 
renal failure, hepatic failure or use of beta-blockers did not change the estimates.
Discussion
In this pooled analysis of two population-based studies, we found that serum testoster-
one levels were associated with shortening of the QTc interval and prolongation of the 
RR interval in men, whereas we did not find an association between serum testosterone 
levels and the uncorrected QT interval. Earlier, it has been suggested that the shorter 
QTc interval in men than in women may be explained by the fact that testosterone 
influences repolarization by its effect on Ca2+ and K+ channels, as well as on hERG-
encoded K+ channels.[34] Since the QT interval was not significantly associated with 
serum testosterone, our findings suggest that the difference in the QTc interval in men 
Table 3 Association of testosterone with QTc, QT and interval: pooled analysis of the Rotterdam Study and SHIP (n=1873)
Testosterone QTc-interval in ms
(95% CI)1
QT-interval in ms
(95% CI)2
RR-interval in ms
(95% CI)1
Log-transformation -8.1 (-14.8 ; -1.4) -3.1 (-8.4 ; 2.3) 62.5 (15.7 ; 109.2)
Tertiles
1 Reference Reference Reference
2 -0.7 (-3.6 ; 2.1) 0.5 (-1.8 ; 2.8) 10.8 (-9.1 ; 30.8)
3 -3.4 (-6.5 ; -0.3) -0.7 (-3.1 ; 1.8) 33.5 (12.2 ; 54.8)
P value for linear trend 0.024 0.529 0.002
CI = Confidence Interval
1:  adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, dehydroepiandrosterone 
sulfate (DHEAS) and cohort
2:  adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, RR interval, DHEAS and 
cohort 
Testosterone in nmol/l. The tertiles were defined as (1) ≤  12.5; (2) 12.6 – 17.3; (3) ≥ 17.4.
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is mainly due to the underlying association with the RR interval. Since QTc is calculated 
by Bazett’s formula, an increase in RR interval will lead to a shorter QTc interval. 
According to literature, the gender differences in the QTc interval decrease with age 
[10], this could be due to the fact that bio-available testosterone decreases with age.
[13] It is well known that women have a longer QTc interval than men,[2] whereas the 
uncorrected QT intervals are rather similar in men and women.[10] Since women have 
a faster heart rate, and therefore shorter RR intervals compared to men, women have 
a prolonged QTc interval when the same heart rate correction formula is applied. The 
gender differences in the RR interval remain after autonomic blockade, which suggests 
a possible gender-related difference in sino-atrial node function.[35] However, this dif-
ference appears to be related to a difference in maximum exercise capacity between 
men and women rather than to intrinsic sinus node gender-related differences.[35] 
Since androgen levels increase in response to exercise[36], the increased RR interval in 
men with high testosterone levels could be due to increased exercise capacity, which 
affects the sino-atrial node function. 
Our investigation has several strengths that include the population-based design 
of participating studies and the central ECG data management, which facilitates best 
comparability between both studies. Although we did not use the complete population 
in the Rotterdam Study, selection bias is unlikely because the characteristics of the study 
population were comparable to the baseline characteristics of the whole population of 
the Rotterdam Study. Furthermore, information bias is unlikely because data were gath-
ered prospectively and because the use of digital ECG recordings all measured using 
the automatic MEANS system likely reduced intra- and interobserver variability in the 
assessment of the QTc, QT and RR intervals. Confounding was minimized by adjusting 
for all known risk factors. However, our study has also some limitations. Because of the 
cross-sectional design we cannot exclude that QTc prolongation or RR interval short-
ening was already present in some participants before the decrease of testosterone. 
Therefore, the results from this study should be confirmed with longitudinal data from 
other large cohorts. Another limitation of our study is that repeated blood sampling in 
men with initially low serum testosterone levels is recommended to confirm androgen 
deficiency [37], but this and other epidemiologic studies [38-41] were based on a single 
measurement of serum testosterone. However, misclassification of men with low serum 
testosterone levels would be expected to underestimate, not overestimate associations. 
In conclusion, we demonstrated in a pooled analysis of two population-based stud-
ies that serum testosterone is not associated with a difference in the RR-adjusted QT 
interval and that the decreased QTc interval in men with higher levels is probably due to 
the association of serum testosterone with prolongation of the RR interval. 
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Abstract
Background
Since diabetes mellitus has been associated with QTc and RR interval variation, and 
hyperglycemia is an independent risk factor for cardiovascular disease, our aim was to 
study whether non-diabetic persons with impaired fasting serum glucose and hyperin-
sulinemia have QTc/QT-interval prolongation and RR-interval shortening, and whether 
these were associated with an increased risk of sudden cardiac death. 
Methods 
First, a cross-sectional analysis was conducted as part of the population-based Rotter-
dam Study including 1050 men and 1520 women (≥ 55 yr), without diabetes mellitus. 
Participants for whom an ECG, fasting serum glucose and fasting insulin measurements 
were available, were eligible for the study. Participants using digoxin or QTc prolong-
ing drugs, and participants with left ventricular hypertrophy and left and right bundle 
branch block were excluded. The endpoints of the study were the length of the QTc, QT 
and RR interval. The associations were examined by means of linear regression analysis. 
Second, in all 6020 participants of the Rotterdam Study with an ECG, the associations 
between the QTc, QT and RR interval and sudden cardiac death were examined by 
means of Cox regression analysis.
Results
Overall, there was a significant association between impaired fasting serum glucose 
and the QTc interval with an increase of 2.6 ms (95%CI: 0.3;5.0). Hyperinsulinemia was 
also associated with QTc prolongation (3.0 ms (0.8;5.3)). Impaired fasting glucose and 
hyperinsulinemia were significantly associated with a decrease of the RR interval (-33.7 
ms (-48.8;-18.6) and –44.4 ms (-58.7;-30.0) respectively). 
Participants in the fourth quartile of the QTc and QT interval had a significantly 
increased risk of sudden cardiac death compared to participants in the first quartile (HR 
2.87 (95%CI 2.02 – 4.06); HR 3.05 (1.99 – 4.67) respectively). Furthermore, there was a 
significant inverse association between the fourth quartile of the RR interval compared 
to the first quartile and the risk of sudden cardiac death (HR 0.49 (0.34 – 0.80)).
Conclusions
We demonstrated in this population-based study that impaired fasting glucose and 
hyperinsulinemia are associated with a significantly increased QTc-interval and with 
significant shortening of the RR interval. We demonstrated that both a prolonged QTc 
as well as a shortened RR interval are associated with an increased risk of sudden cardiac 
death.
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Introduction
Diabetes mellitus is a common disease in the elderly which adversely affects cardiac 
repolarization, probably by autonomic imbalance. It is associated with prolongation 
of the heart-rate corrected QT (QTc) interval which is the traditional measurement for 
assessing the duration of ventricular repolarization.[1, 2] QTc prolongation may result 
in early after depolarizations, which in turn may induce re-entry and thereby provoke 
torsade de pointes and fatal ventricular arrhythmias.[3-7] 
In diabetes, hyperglycemia is a risk factor for cardiovascular disease. Non-diabetic 
participants with impaired fasting glucose or hyperinsulinemia may have an increased 
risk of cardiovascular disease as well. Glucose intolerance, high fasting serum glucose 
levels and insulin levels have been associated with prolongation of the QTc interval 
in non-diabetic persons.[8, 9] In a small study of 35 non-diabetic offspring of type 2 
diabetic patients, it was demonstrated that during acute hyperinsulinemia, the QT 
interval remained unchanged, whereas the QTc interval increased.[10] Serum glucose 
and hyperinsulinemia have been demonstrated to be associated with the RR interval in 
non-diabetic patients.[11, 12] 
To our knowledge, no large studies about the association between serum glucose and 
insulin, and the uncorrected QT interval in non-diabetic persons have been published. 
Since diabetes mellitus has been associated with QTc and RR interval variation, and 
hyperglycemia is an independent risk factor for cardiovascular disease, our aim was to 
study whether non-diabetic participants with an impaired fasting glucose measurement 
and hyperinsulinemia have an increased risk of QTc prolongation and RR shortening 
and thereby an increased risk of sudden cardiac death. Therefore, we studied whether 
impaired fasting glucose and hyperinsulinemia are associated with the QTc, QT and RR 
interval in non-diabetic participants of a large prospective population-based study in 
elderly. Subsequently, we examined the association between the QTc, QT and RR interval 
and sudden cardiac death in the same population.
Methods
Setting
The Rotterdam Study is a prospective population-based cohort study, which started with 
a baseline visit between 1990 and 1993. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, the Netherlands, approved the study. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years and over, were invited to participate 
(n=10,275). Of them, 7983 (78%) gave their written informed consent and took part 
in the baseline examination. Objectives and methods of the Rotterdam Study have been 
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described in detail elsewhere.[13, 14] At baseline, all participants were visited at home 
for a standardized questionnaire, and 7151 were subsequently examined at the research 
center. Since the start of the study, follow-up visits took place in the period 1993 
through 1996 for the second visit, in the period between 1997 through 1999 for the 
third visit and in the period between 2002 through 2004 for the fourth visit. In addition 
to follow-up examinations, the cohort is continuously monitored for major morbidity 
and mortality through linkage with general practitioner and municipality records. Drug 
prescriptions dispensed to participants by automated pharmacies are routinely stored in 
the database since 1 January 1991. 
Study designs
We performed two analyses in the Rotterdam Study. First, we used a cross-sectional 
design to analyse the association between serum insulin and glucose as assessed at 
the third visit to the research center, and QT-, QTc-, and RR-interval with data also from 
the third visit. Hereto, both the ECG and blood sampling occurred at the same day at 
the third visit to the research center. The reason was that during rounds 1 and 2, no 
data were available on both serum insulin and serum glucose. Second, for studying the 
association between QT-, QTc-, and RR-interval and sudden cardiac death, we used a 
prospective cohort design with the whole Rotterdam Study for whom an ECG was avail-
able. This analysis included the participants from the first analysis as described above. 
Since fasting glucose and fasting insulin measurements were only available at the third 
visit, we could not directly assess the effect between fasting glucose, fasting insulin 
and sudden cardiac death due to the limited number of sudden cardiac death events 
occurring during follow-up since the third visit. 
Cross-sectional analysis of QT, QTc-, and RR-interval
All participants of the Rotterdam Study without diabetes mellitus, who had an ECG and 
a fasting glucose and fasting insulin measurement at the third visit were enrolled in our 
first analysis. Diabetes mellitus (type I or II) was defined as the use of blood glucose–low-
ering medication and/or a non-fasting serum glucose level of 11.1 mmol/l or higher and/
or fasting serum glucose levels ≥ 7mmol/l at the third investigation or any time prior to 
that moment.[15] Digitally stored ECGs were available for 3818 participants at the time 
of the third visit. Missing ECGs were mainly due to temporary technical problems with 
ECG recordings. 
Participants with diabetes mellitus (n=357), participants without a fasting glucose 
measurement (n=168) or a fasting insulin measurement (n=270) or insulin outliers (n=1 
(insulin=9292 pmol/l)), participants who were not fasting at blood sampling (n=160), par-
ticipants who used QTc prolonging drugs as defined on list 1 of the website based registry 
(http://www.azcert.org/ medical-pros/ drug-lists/ drug-lists.cfm) [16] (n=150), participants 
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who used digoxin (n=102), which is a QTc shortening agent, persons with a pacemaker 
(n=13), as well as persons with evidence of left ventricular hypertrophy (n=125) or left 
and right bundle branch block (n=73, n=131) were excluded, since these conditions are 
associated with an altered QTc interval.[17, 18] Overall, 2570 participants were included 
in this cross-sectional analysis.
Cohort study of sudden cardiac death
All cohort members of the Rotterdam Study with an ECG were enrolled in the study 
population. The study ended on one of the censoring dates (death or transferring 
out) or the end of the study period (1 January 2006). Overall, 6020 participants were 
included in the cohort analysis.
QTc, QT and RR interval 
The endpoints of the study were the length of the QTc, QT and RR interval in milliseconds 
(ms). A 12-lead resting ECG was recorded with an ACTA electrocardiograph (ESAOTE, 
Florence, Italy) at a sampling frequency of 500 Hz and stored digitally. All ECGs were 
processed by the Modular ECG Analysis System (MEANS) to obtain ECG measurements, 
in agreement with the FDA guidance for clinical evaluation of QT/ QTc interval prolonga-
tion.[19] The MEANS program has been evaluated and validated extensively.[20-23] In 
one of these validation studies, ECGs with selected abnormalities were analyzed by 5 
cardiologists and 11 different computer programs of which MEANS performed as one 
of the best.[23] MEANS determines common onsets and offsets for all 12 leads together 
on one representative averaged beat, with the use of template matching techniques.
[21] The QT interval is determined from the start of the QRS complex until the end 
of the T wave. To adjust for heart rate, Bazett’s formula (QTc=QT/√RR) was used.[24] 
Additionally, the MEANS program determines left ventricular hypertrophy and left and 
right bundle branch block.
Sudden cardiac death 
According to the most recent definition, sudden cardiac death was defined as: 1) a 
witnessed natural death attributable to cardiac causes, heralded by abrupt loss of 
consciousness, within one hour of onset of acute symptoms, or 2) an unwitnessed, 
unexpected death of someone seen in a stable medical condition <24 hours previously 
with no evidence of a non-cardiac cause.[25, 26] 
The ascertainment of sudden cardiac death cases has been described previously.[7] 
In short, information on vital status is obtained from municipal health authorities in 
Rotterdam and GPs. Two research physicians independently coded all reported events, 
blinded to exposure, and judged the likelihood of sudden cardiac death according to 
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the definition above. In cases of disagreement, consensus was sought and finally, a 
cardiologist reviewed all events. The index date was the date of death.
Fasting glucose and insulin status
At the third visit, fasting blood samples were drawn by venapuncture and the serum 
glucose levels were measured using the glucose hexokinase method (Instruchemie).[27] 
Serum insulin was determined by metric assay (Biosource Diagnostics). This assay has no 
cross-reactivity with either proinsulin or C-peptide.
Glucose status was classified into two categories: subjects with normal fasting glu-
cose (NFG) and subjects with impaired fasting glucose (IFG). IFG is a recently defined 
diagnostic category based on fasting plasma glucose concentration.[28] Analogous to 
the World Health Organization criteria of impaired glucose tolerance, it represents a 
metabolic stage intermediate between normal glucose homeostasis and diabetes mel-
litus and is associated with insulin resistance syndrome.[28, 29] NFG was defined as a 
fasting glucose level below 6.1 mmol/L. IFG was defined as a fasting serum glucose level 
between 6.1 and 6.9 mmol/L.[28]
Insulin status was classified into two categories: subjects with normal insulin levels 
(<100 pmol/l) and subjects with hyperinsulinemia (≥100 pmol/l).
Covariates
Clinical measures were obtained during the visits at the Rotterdam Study research cen-
ter. Hypertension was identified through the use of antihypertensive medication and/
or the assessment of blood pressure measurements, according to the guidelines of the 
World Health Organization.[30] Prevalence and incidence of myocardial infarction were 
assessed by hospital discharge diagnosis or in case a patient was not hospitalized, when 
signs and symptoms, analysis of the standard 12-lead ECG and cardiac enzyme data 
were diagnostic of a myocardial infarction.[31, 32] Prevalence and incidence of heart 
failure were assessed by the presence of suggestive signs and symptoms as previously 
described.[33, 34] Hypercholesterolemia was defined as a total serum cholesterol level 
above 6.2 mmol/l or the use of cholesterol-lowering drugs, hypertriglyceremia was 
defined as a triglycerides level above 1.695 mmol/l.[35]
Statistical analysis
The associations between the determinants impaired fasting glucose and hyperin-
sulinemia, and the outcomes QTc, QT and RR interval, were assessed through linear 
regression analysis. The relative risk of sudden cardiac death associated with the QTc, 
QT and RR interval was estimated by calculation of the hazard ratios using Cox propor-
tional hazards models. All analyses were adjusted for age and gender. In addition, all 
covariates that were associated with the outcome (p<0.10) were considered as potential 
Glucose and insulin and ventricular repolarization 147
confounders in both analyses. In the analyses assessing impaired fasting glucose and 
hyperinsulinemia, and QTc, QT, RR interval, the following covariates were considered as 
potential confounder: body mass index, waist-hip ratio, hypercholesterolemia, hypertri-
glyceremia, hypertension, myocardial infarction, heart failure and use of beta-blockers. 
In the analyses assessing the QTc, QT, RR interval and sudden cardiac death, the follow-
ing covariates were considered as potential confounder: diabetes mellitus, hypercholes-
terolemia, hypertension, myocardial infarction, heart failure, body mass index, use of 
QTc prolonging drugs, use of beta-blockers and use of digoxin. The multivariate models 
were built to include all covariates that changed the association between exposure and 
the outcome by more than 5%.
First, a linear regression analysis was conducted with the QTc, QT, RR interval as out-
comes and impaired fasting glucose and hyperinsulinemia as determinants. Second, in 
participants with a normal fasting glucose measurement, linear regression analysis was 
conducted with hyperinsulinemia as determinant. We performed a sensitivity analysis 
by additionally adjusting for determinants of the metabolic syndrome: hypertension, 
hypertriglyceremia, hypercholesterolemia, waist-hip ratio and BMI. 
Third, a Cox regression was conducted with sudden cardiac death as outcome and 
the QTc, QT and RR interval divided in quartiles as determinants. All analyses were 
performed using SPSS for Windows version 15.0 (Chicago, Illinois, USA).
Results
Subject characteristics
The characteristics of the participants at the third visit are presented in table 1. Overall, 
2570 participants were included, of whom 1520 were female and 1050 male. The 
mean age of the study population was 71.1 years (standard deviation (SD) 6.8 years). 
Mean fasting glucose was 5.5 mmol/l (SD=0.5), mean fasting insulin was 72.7 pmol/l 
(SD=41.9). Overall, 403 participants had impaired fasting glucose and 455 participants 
had hyperinsulinemia. 
QTc, QT and RR interval 
The mean duration of the QTc interval was significantly shorter in males (423.2 ms) than 
in females (432.5 ms) (p<0.0001). Moreover, the mean duration of the RR interval was 
significantly longer in males (933.4 ms) than in females (895.7 ms) (p<0.0001).
Overall, there was a significant association between impaired fasting glucose and 
the QTc interval with an increase of 2.6 ms (95%CI: 0.3 ; 5.0), after adjustment for 
age, gender and hypertension (table 2). Furthermore, hyperinsulinemia was also associ-
ated with QTc prolongation (3.0 ms (0.8 ; 5.3)). However, impaired fasting glucose and 
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hyperinsulinemia were not associated with an increase of the QT interval, adjusted for 
age, gender, RR interval and hypertension (0.0 ms (-2.0 ; 2.1)) and –0.1 (-2.0 ; 1.9) 
respectively).
Impaired fasting glucose and hyperinsulinemia were associated with a significant 
decrease of the RR interval after adjustment for age, gender and hypertension (-33.7 ms 
(-48.8 ; -18.6) and –44.4 ms (-58.7 ; -30.0) respectively). After adjusting for hyperten-
sion, hypertriglyceremia, hypercholesterolemia, waist-hip ratio and BMI, the results did 
not change substantially.
Normal fasting glucose status
In participants with normal fasting glucose, hyperinsulinemia was not associated with 
the QTc or QT interval (table 3). However, in subjects with normal fasting glucose, 
hyperinsulinemia was significantly associated with a decrease of the RR interval after 
adjustment for age, gender and hypertension (-54.4 ms (-71.1 ; -37.7)). 
QTc, QT, RR interval and sudden cardiac death
The baseline characteristics of all participants are presented in table 4. The mean age 
of the study population at baseline was 69.4 years, 59.6% was female. During the 
follow-up period, 209 persons were classified as definite sudden cardiac death and 54 
as probable sudden cardiac death.
Table 1 Characteristics of study population
Total (n=2570) Impaired fasting 
glucose (n=403)
Hyperinsulinemia 
(n=455)
Age (years, mean, SD) 71.1 (6.8%) 71.6 (6.9%) 71.6 (6.8)
Gender (female) 1520 (59.1%) 233 (57.8%) 290 (63.7%)
Mean QTc interval (ms) (SD) 428.3 (22.7%) 430.6 (24.0%) 431.4 (23.9%)
Mean QT interval (ms) (SD) 406.8 (29.7%) 403.8 (31.9%) 402.4 (29.3%)
Mean RR interval (ms) (SD) 910.2 (144.7%) 887.8 (153.1%) 877.2 (138.8%)
Body Mass Index kg/ m2 (mean, SD) 26.0 (3.4) 27.3 (3.6) 28.2 (3.6)
Waist-hip ratio (mean, SD) 0.9 (0.1) 0.9 (0.1) 1.0 (0.1)
Hypercholesterolemia (n, %) 220 (8.6%) 38 (9.4%) 40 (8.8%)
Hypertriglyceremia (n, %) 671 (26.1%) 139 (34.5%) 210 (46.2%)
Hypertension (n, %) 776 (30.2%) 172 (42.7%) 188 (41.3%)
Myocardial infarction (n, %) 231 (9.0%) 35 (8.7%) 47 (10.3%)
Heart failure (n, %) 64 (2.5%) 9 (2.2%) 19 (4.2%)
Use of beta-blockers (n, %) 374 (14.6%) 90 (22.3%) 89 (19.6%)
Mean fasting glucose (mmol/l) (SD) 5.5 (0.5%) 6.4 (0.2%) 5.8 (0.5%)
Mean fasting insulin (pmol/l) (SD) 72.7 (41.9%) 97.9 (52.6%) 141.3 (46.5%)
SD=standard deviation
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Participants in the fourth quartile of the QTc/ QT interval had a significant increased 
risk of sudden cardiac death compared to participants in the first quartile (HR 2.87 
(95%CI 2.02 – 4.06); HR 3.05 (1.99 – 4.67) respectively). (table 5) Furthermore, there 
was a significant inverse association between the fourth quartile of the RR interval com-
pared to the first quartile and the risk of sudden cardiac death (HR 0.49 (0.34 – 0.80)).
Discussion
In this population-based study, we demonstrated that non-diabetic participants with an 
impaired fasting glucose and hyperinsulinemia had a significantly increased QTc interval 
and a significantly shorter RR interval than participants with normal fasting glucose and 
insulin measurements. Fasting glucose and fasting insulin were not associated with the 
QT interval after adjustment for the RR interval. Furthermore, we demonstrated that an 
increased QTc/ QT interval and decreased RR interval are associated with a significantly 
increased risk of sudden cardiac death. Although a QTc interval prolongation of 2-3 ms in 
one individual usually remains without clinical consequences, an average shift of 2-3 ms 
in a Gaussian distribution on a population level will inevitably push more individuals into 
Table 2 Association of fasting glucose and insulin with the QTc, QT and RR interval in non-diabetic participants
Number of 
participants
QTc prolongation 
in ms (95% CI)1
QT prolongation 
in ms (95% CI)2
RR prolongation 
in ms (95% CI)1
Fasting glucose 2570
Normal fasting glucose (≤ 6.0) 2167 Reference Reference Reference
Impaired fasting glucose (6.1-6.9) 403 2.6 (0.3 ; 5.0) 0.0 (-2.0 ; 2.1) -33.7 (-48.8 ; -18.6)
Fasting insulin 2570
Normal insulin (<100) 2115 Reference Reference Reference
Hyperinsulinemia (≥100) 455 3.0 (0.8 ; 5.3) -0.1 (-2.0 ; 1.9) -44.4 (-58.7 ; -30.0)
CI = Confidence Interval
1 : adjusted for age, gender,  hypertension
2 : adjusted for age, gender, RR interval and hypertension
Glucose in mmol/l
Insulin in pmol/l
Table 3 Association of insulin with the QTc, QT and RR interval in non-diabetic partcipants with a normal fasting glucose measurement
Normal fasting glucose Number of 
participants
QTc prolongation 
in ms (95% CI)1
QT prolongation 
in ms (95% CI)2
RR prolongation 
in ms (95% CI)1
Fasting insulin
Normal insulin (<100) 1855 Reference Reference Reference
Hyperinsulinemia (≥100) 312 2.5 (-0.2 ; 5.1) -1.5 (-3.8 ; 0.7) -54.4 (-71.1 ; -37.7)
CI = Confidence Interval
1 : adjusted for age, gender and hypertension
2 : adjusted for age, gender, RR interval and hypertension
Insulin in pmol/l
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the upper percentiles of the QTc interval with its increased risk of ventricular arrhythmias 
and sudden cardiac death. 
Our findings suggest that the association of glucose and insulin with the QTc interval 
is due to the underlying shortening of the RR interval, since QTc is calculated by Bazett’s 
formula using the square root of the RR interval in the denominator. However, we 
confirmed that both an increased QTc as well as a shortened RR interval are associated 
with an increased risk of sudden cardiac death, as has been demonstrated before.[7, 
36-38] Our findings cannot be explained by the metabolic syndrome, since additional 
adjustment for the determinants of the metabolic syndrome did not change the results 
substantially. We demonstrated that the association of hyperinsulinemia with the RR 
interval was even more pronounced in participants with a normal fasting glucose. This 
suggests that in subjects with nonsymptomatic insulin resistance syndrome, increased 
sympathetic nervous system activity and autonomic imbalance occur. 
Impaired fasting glucose and hyperinsulinemia have been associated with the QTc 
interval in non-diabetic persons [8, 9]. However, a relation with the QT interval has only 
been demonstrated in a small study of 35 non-diabetic offspring of type 2 diabetic 
patients.[10] That study showed that during acute hyperinsulinemia, the QT interval 
remained unchanged, whereas the QTc interval increased. Impaired fasting glucose and 
hyperinsulinemia have been demonstrated to be associated with the RR interval in non-
diabetic patients.[11, 12] Several mechanisms by which impaired fasting glucose and 
hyperinsulinemia may affect the QTc and RR interval have been reported, amongst others 
increased sympathetic activity, autonomic imbalance, impairment of the hERG channel, 
Table 4 Baseline characteristics of sudden cardiac death study population
Characteristic n=6020
Mean age (years) (SD) 69.4 (9.2)
Gender (female) 3585 (59.6%)
Diabetes mellitus (n, %) 652 (10.8%)
Hypercholesterolemia (n, %) 2539 (42.2%)
Hypertension (n, %) 2025 (33.6%)
Myocardial infarction (n, %) 715 (11.9%)
Heart failure (n, %) 203 (3.4%)
Mean Body Mass Index (kg/ m2) (SD) 29.3 (15.1)
Use of QTc prolonging drugs (n, %) 348 (5.8%)
Use of beta-blockers (n, %) 1159 (19.3%)
Use of digoxin (n, %) 390 (6.5%)
Mean QTc interval (ms) (SD) 434.7 (28.5)
Mean QT interval (ms) (SD) 405.8 (34.7)
Mean RR interval (ms) (SD) 881.3 (156.1)
SD Standard Deviation
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raised production of free radicals, disturbed myocardial membrane function or a reduc-
tion of Na+/K+-ATPase activity.[39-41] Although the exact underlying mechanism may 
be unknown, increased sympathetic activity caused by hyperinsulinemia may decrease 
the RR interval.[42] Furthermore, the insulin resistance syndrome can be considered as a 
pre-stage of diabetes mellitus, which suggests the early presence of autonomic nervous 
dysfunction.[43]
Our study has several strengths. An advantage of the Rotterdam Study is its 
population-based character. Although we limited our study population, selection bias 
is unlikely because the characteristics of the study population were comparable to the 
baseline characteristics of the whole population of the Rotterdam Study. Furthermore, 
information bias is unlikely because data were gathered prospectively and because of 
the use of digital ECG recordings. The digital ECGs were all automatically interpreted 
using the MEANS system which reduced intra- and interobserver variability in the assess-
ment of the QTc, QT and RR intervals. Confounding was minimized by adjusting for all 
known risk factors. However, our study has also some limitations. Because of the cross-
sectional design we cannot exclude that RR interval shortening was already present in 
some patients before the increase of glucose and insulin. Therefore, the results from 
this study should be confirmed with longitudinal data from other large cohorts. Finally, 
our study population consisted of participants aged 55 years and older. Whether our 
findings can be generalized to other age groups requires further study. 
Table 5 Association of QTc, QT and RR interval with sudden cardiac death
Quartiles
SCD
(n=263)
HR (95% CI)1 HR (95% CI)2
QTc interval
1 51 Reference Reference
2 59 1.39 (0.95 - 2.03) 1.37 (0.94 – 2.00)
3 57 1.53 (1.05 – 2.25) 1.48 (1.01 – 2.16)
4 96 3.42 (2.42 - 4.84) 2.87 (2.02 – 4.06)
QT adjusted for RR 
interval
1 72 Reference Reference
2 56 1.21 (0.83 – 1.77) 1.14 (0.78 – 1.66)
3 61 2.04 (1.36 – 3.07) 1.82 (1.21 – 2.75)
4 74 3.67 (2.40 – 5.60) 3.05 (1.99 – 4.67)
RR interval
1 90 Reference Reference
2 62 0.58 (0.42 – 0.80) 0.63 (0.46 – 0.88)
3 63 0.61 (0.44 – 0.84) 0.68 (0.49 – 0.94)
4 48 0.46 (0.32 – 0.66) 0.49 (0.34 – 0.80)
SCD = sudden cardiac death; HR = Hazard Ratio
1 Adjusted for gender and time-depending age.
2 QTc interval additionally adjusted for myocardial infarction, and use of QTc prolonging drugs and digoxin; QT interval additionally adjusted for 
time-depending myocardial infarction and use of QTc prolonging drugs; RR interval additionally adjusted for use of beta-blockers and digoxin.
Quartiles: QTc (1) ≤416 ms; (2) 417-431 ms; (3) 432-449; (4) ≥450 ms; QT (1) ≤382 ms; (2) 383-403 ms; (3) 404-425 ms; (4) ≥426 ms; RR (1) 
≤770 ms; (2) 771-869 ms; (3) 870-979 ms; (4) ≥940 ms.
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In conclusion, we demonstrated in this population-based study that impaired fasting 
glucose and hyperinsulinemia are significantly associated with an increased QTc-interval 
but not with an increase of the QT interval. This is explained by a shortening of the RR 
interval, probably due to an increased sympathetic activity. We demonstrated that both 
an increased QTc/ QT as well as a shortened RR interval are associated with an increased 
risk of sudden cardiac death.
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Sudden cardiac death is a major clinical and public health problem. Therefore, it is 
important to identify persons at risk for sudden cardiac death and to be aware of all 
factors associated with an increased risk. Although many causes of QTc prolongation 
and thereby sudden cardiac death have been identified, not all risk factors have been 
determined. The general objective of this thesis was to study the effect of certain drugs 
and endocrine factors on QTc prolongation and sudden cardiac death. In this chapter, 
the main findings of this research and the main methodological considerations of these 
studies are presented. Furthermore, potential clinical implications and suggestions for 
future research are discussed.
Main findings
Drugs and repolarization disturbances
Nowadays, an increasing number of drugs, especially non-cardiac drugs, are known 
to delay cardiac repolarization and to induce Torsade de Pointes.[1] Therefore, it is 
recommended that drugs are examined for their effect on ventricular repolarization 
before marketing. One of the non-clinical methods is to evaluate the inhibition of Ikr, 
encoded by the human-ether a go-go related (hERG) gene, which is the most common 
mechanism responsible for drug-induced prolongation of the QT interval in humans.[2] 
In addition, the ‘thorough QT/ QTc study’ is conducted, which is a premarketing clinical 
trial, specifically requested by registration authorities to evaluate the effect on cardiac 
repolarizarion. Additional evaluation in subsequent clinical studies can be performed in 
later stages of development. In addition to non-clinical and clinical data, adverse event 
data can be another source of information on proarrhythmic potential, both during 
clinical studies as well as post-marketing. The gathered information can eventually lead 
to delayed or denied marketing authorization, changes in the labelling of the sum-
mary of product characteristics, restriction in use or withdrawal from the market.[3] 
Pre-registration assessment of the potential for QTc prolongation has several limita-
tions, such as the limited size of the study population, selection of participants, who 
are relative healthy and often do not have comorbidities or use concomitant drugs, and 
the limited duration of trials.[4, 5] Since not all safety-relevant information is available 
before marketing, post-marketing information is important for the safe use of drugs. 
In recent years, several lists have been published of non-cardiac drugs associated 
with QTc prolongation and cardiac arrhythmias.[6-9] An internet-based registry includes 
a list of drugs based on information from the International Registry of Drug-Induced 
Arrhythmias, literature, change in labels of (new) drugs and the Food and Drug Admin-
istration’s (FDA) database for adverse drug event reports.[9] In addition, De Ponti et al. 
have published a list of non-anti-arrhythmic drugs with pro-arrhythmogenic effects, 
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based on a structured literature search including published (non-) clinical evidence and 
official warnings in the labelling.[6, 7] 
It is often unknown whether non-listed drugs of similar therapeutic or chemical 
classes as listed ones do not also provoke QTc prolongation or whether they are not 
listed due to insufficient data. For instance, only some psychotropic drugs have been 
associated with QTc interval prolongation whereas others were not, maybe because 
it was never investigated. Therefore, we studied whether listed as well as non-listed 
psychotropic drugs are indeed associated with QTc prolongation and evaluated whether 
this is a class effect or an individual drug effect. 
In the Rotterdam Study, we found that use of some antipsychotics (especially lithium, 
olanzapine and thioridazine) and almost all tricyclic antidepressants are associated 
with a significant increase in QTc interval (chapter 2.1). The results of our study are 
in agreement with previously reported information on these drugs.[7, 10-12] Most 
of these drugs were listed by either de Ponti or the internet-based registry. However, 
maprotiline, which was clearly associated with an increase in QTc interval, is not listed 
on the internet-based registry. On the other hand, for many of the listed drugs we 
could not confirm a significant increase in the QTc interval, which may have been due to 
limited power due to a low number of exposed persons per individual drug. In general, 
however, the direction of change was as expected. The only class that was associated 
with an overall increase of the QTc interval concerned tricyclic antidepressant drugs. In 
this class, most of the individual drugs that were prescribed (amitriptyline, imipramine 
and maprotiline) were associated with a significant increase of the QTc interval. These 
drugs not only block the human Ether-à-go-go Related Gene (hERG)-encoded potas-
sium channels but also the cardiac sodium channels.[8, 13, 14] Most drugs that prolong 
the QTc interval act by blocking the rapid component of the delayed rectifier potassium 
channel (Ikr) encoded by hERG; only few drugs are known to prolong the QTc interval 
by modifying INa.[15-17] Given the structural similarity between Na
+ channels and K+ 
channels, it is not surprising that many Na+ channel-blocking drugs also bind to K+ 
channels to prevent K+ efflux.[16] In conclusion, most of the drugs associated with QTc 
prolongation were listed by either de Ponti or the internet-based registry. However, 
maprotiline, which was clearly associated with an increase in QTc interval, is not listed 
on the internet-based registry. On the other hand, for many of the listed drugs we 
could not confirm a significant increase in the QTc interval, which may have been due to 
limited power by the low number of exposed persons per individual drug. 
Drug-genetic interaction in QTc prolongation
Several calcium channel blockers are included in the internet based registry (isradipine) 
or the list of De Ponti et al. (diltiazem, isradipine and verapamil).[7, 9] In addition, it has 
been reported recently that common NOS1AP variants are associated with QTc interval 
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prolongation.[18, 19] The NOS1AP gene encodes the nitric oxide synthase 1 (NOS1) 
activating protein.[18] NOS1 has a role in cardiac contractility, and it is hypothesized that 
nitric oxide signalling may be involved in cardiac repolarization.[20, 21] Since both NOS1 
and calcium channel blockers suppress L-type calcium channels, these QTc prolonging 
genetic variants and drugs might interact,[22-24] resulting in even further increased 
QTc prolongation. In the Rotterdam Study, we found that current use of verapamil was 
associated with a significant QTc interval prolongation. In addition, the minor alleles of 
both NOS1AP SNPs significantly potentiated the QTc interval prolonging effect of vera-
pamil (chapter 2.2). Furthermore, regression coefficients indicated that a similar effect 
might exist for isradipine, although the SNPs did not modify the effect on QTc interval 
on a multiplicative scale in association with isradipine. Our findings might be explained 
by the fact that verapamil causes a high-affinity blockage of the hERG-current, whereas 
amlodipine, diltiazem, isradipine, and nifedipine block the hERG current weakly, or not 
at all.[8, 25-27] The concentration of verapamil which is required to block the hERG-
encoded potassium channels overlaps with the concentration that blocks the calcium 
channel, whereas for the other calcium channel blockers this concentration is much 
lower than the concentration needed to block the hERG-encoded potassium channels.
[27] Although the mechanism by which NOS1AP influences the QT interval and interacts 
with verapamil is not known, it may involve calcium and potassium currents in the 
cardiomyocyte. NOS1AP has been found to activate NOS1.[28] NOS1 stimulates Ca2+ 
release in sarcoplasmic reticulum, which leads to increased intracellular calcium.[29] The 
elevation of intracellular Ca2+ suppresses the Ca2+ entry pathway, the L-type calcium 
channels.[30] Furthermore, elevations in intracellular calcium selectively enhances the 
delayed rectifier current, which leads to increased outflow of potassium.[30] Verapamil 
suppresses L-type calcium channels, which are also suppressed by NOS1.[27] Moreover, 
verapamil blocks the hERG-encoded potassium channels.[8, 25, 26] Thus, the physiologi-
cal feedback system, i.e. the Ca2+ sensitivity of the potassium current, is disturbed due 
to the high-affinity hERG-current blockade caused by verapamil. This suggests a model 
in which increased intracellular calcium and slow outflow of potassium in participants 
with minor alleles of NOS1AP using verapamil, leads to additional QTc prolongation.
Drugs and ventricular arrhythmias or sudden cardiac 
death
Virtually all QTc prolonging drugs act by blocking the rapid component of the delayed 
rectifier potassium channel (Ikr) encoded by hERG.[15] However, some QTc prolonging 
drugs that do not seem to cause sudden cardiac death, such as amiodarone [31], also 
block this current, whereas on the other hand some drugs that prolong the QTc interval 
with only few milliseconds were implicated in the occurrence of cardiac arrhythmias 
(e.g. terfenadine).[8, 32, 33] Terfenadine is a potent IKr blocker but usually it does not 
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prolong the QTc interval because it is readily transformed into its metabolite which is 
without an effect on QT interval. Terfenadine has been withdrawn from the market in 
several countries because of the possible occurrence of interactions with diseases and 
drugs that inhibit metabolism by cytochrome P450 CYP3A4, and due to the availability 
of alternatives.[1, 15] 
In 2003, it was shown that drugs with a small margin (i.e. drugs that block Ikr 
in concentrations close to the therapeutic plasma concentration) had a high risk of 
serious cardiac arrhythmia while drugs with a high margin (i.e. those of which only 
high-therapeutic plasma concentrations block potassium channels) had a lower risk.
[8] This margin between hERG-encoded Ikr channels binding capacity and free plasma 
concentration might be a useful tool in the prediction of the risk of Torsade de Pointes, 
and might be more important as an indicator of risk for cardiac arrhythmias. 
Although most QTc prolonging drugs act by blocking Ikr, few drugs are known to 
prolong the QTc interval by modifying INa. Sodium channel-blocking drugs can cause 
slowed intraventricular conduction, with the development of a re-entrant circuit, result-
ing in ventricular tachycardia or ventricular fibrillation. Examples of drugs with sodium 
channel-blocking activity are certain antihistamines, beta-blockers, tricyclic antidepres-
sants and phenothiazines.[16, 17] In chapter 3, we studied the effect of various drug 
classes (Ikr and INa blocking) on ventricular arrhythmia and sudden cardiac death. We 
studied the Ikr blocking (non-cardiovascular hERG-encoded potassium channel inhibit-
ing) drugs in general and domperidone in specific, and we studied the INa blocking 
anticonvulsants.
hERG-encoded potassium channel inhibiting drugs have been associated with an 
increased number of reports of serious ventricular arrhythmias and sudden death in 
the adverse drug reactions database of the World Health Organization.[34] Although 
important, this resource has limitations because reports are voluntarily submitted to 
pharmacovigilance centres and often do not contain a full medical history, whereas 
data on other risk factors may be incomplete or lacking. Moreover, since reporting of 
adverse drug reactions is voluntary, not all adverse drug reactions are reported and not 
all adverse reactions are recognized by the doctor. In this thesis, we demonstrated on 
the basis of IPCI data that current use of non-cardiovascular hERG-encoded potassium 
channel inhibiting drugs in the general population was associated with an increased 
risk of sudden cardiac death (chapter 3.1). Furthermore, we were able to confirm that 
drugs with a high hERG-encoded potassium channels inhibiting capacity had a higher 
risk of sudden cardiac death than patients using drugs with a low potassium channels 
inhibiting capacity.
A specific study was conducted on domperidone since this drug was available as over 
the counter drug, is widely used and was associated with a significant almost 4-fold 
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increase in risk of sudden cardiac death in a previous study that did, however, not focus 
on the drug and did not model the effect of the drug specifically. [35] The study on 
domperidone was stratified by insurance type to avoid differential misclassification of 
exposure and since there was heterogeneity between the effects in publicly and privately 
insured patients. In the IPCI database, we found that current use of domperidone and 
in particular high doses, were associated with a substantially increased risk of sudden 
cardiac death (chapter 3.2). This is in agreement with the relatively high ETCPunbound/ 
IC50 ratio (0.119).[8] We were not able to identify cases of ventricular arrhythmia with 
current domperidone exposure, due to both the limited number of confirmed cases of 
ventricular arrhythmia and the low exposure prevalence to prescribed domperidone. 
Since prodromal symptoms of sudden cardiac death, such as nausea and vomiting, can 
be mistakenly diagnosed as symptoms due to gastric pathology, we considered GP visits 
to be a confounder in this study. 
Anticonvulsants (ACs) may influence cardiac conduction directly by blocking the 
cardiac sodium current. In addition, ACs act centrally in the brain and thereby influence 
the autonomic control of the heart, while autonomic dysfunction is associated with 
lethal cardiac arrhythmias.[36] In collaboration with experts from the Academic Medical 
Center, we found in IPCI that current use of ACs in general (especially carbamazepine) 
is associated with a more than 2-fold increased risk of sudden cardiac death (chapter 
3.3). Current use of sodium-channel blocking ACs was associated with an almost 3-fold 
increased risk of sudden death. Conversely, ACs without sodium channel blocking 
properties exhibited a lower and non-significant association with sudden cardiac death. 
Experimental studies showed that phenytoin, fenobarbital and lamotrigine have the 
ability to block hERG-encoded potassium channels.[37, 38] However, the relatively low 
ETCPunbound/ IC50 ratio (0.0436) of phenytoin, for instance, suggests that only high-
therapeutic plasma concentrations block hERG-encoded potassium channels.[8] After 
exclusion of these drugs, the use of sodium channel blocking ACs was still strongly 
associated with sudden cardiac death. A substantial proportion of deaths in patients 
with epilepsy is sudden and unexpected.[39] However, besides patients using ACs for 
epilepsy, we also included patients using ACs for other indications, e.g., neuropathic 
pain. Since our cases and controls were derived from the general population, most of 
the included epilepsy patient had stable epilepsy and used a single AC, thereby reducing 
confounding by severity of epilepsy and polytherapy of ACs. The risk of sudden cardiac 
death in phenytoin users was higher in the study described in chapter 3.3 than in 3.1, 
since only definite cases of sudden cardiac death were presented in chapter 3.3 in 
contrast with the study described in chapter 3.1 presenting both definite and probable 
cases due to the limited number of users for some drugs.
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Endocrine factors and repolarization disturbances and 
fatal ventricular arrhythmias
Gender-related differences in human cardiac repolarization are well known and illus-
trated by a longer QTc interval in women.[40, 41] In literature, it is suggested that tes-
tosterone might be an important regulator of ventricular repolarization, and this in turn 
might explain the gender-related differences in ventricular repolarization. In both the 
Rotterdam Study as well as in SHIP, we found that serum testosterone levels were associ-
ated with a shorter QTc interval and prolongation of the RR interval in men, whereas 
we did not find an association between serum testosterone levels and the uncorrected 
QT interval (chapter 5.1). Since the QT interval was not significantly associated with 
serum testosterone, our findings suggest that the difference in the QTc interval in men 
is mainly due to the underlying association with the RR interval. Since QTc is calculated 
by Bazett’s formula, an increase in RR interval will lead to a shorter QTc interval. Our 
findings are in agreement with earlier findings.[42] According to literature, the gender 
differences in the QTc interval decrease with age which might be due to the fact that 
bio-available testosterone decreases with age.[43] In the Rotterdam Study, we detected 
a significant difference in the QTc interval between males and females until the age of 
80 years (figure 1).
In the Rotterdam Study, we found an association between free T4 levels and prolonga-
tion of the QTc interval (chapter 4.1). We did not find an association between TSH and 
the QTc interval. A potential explanation for this finding is that an association between 
TSH and QTc would be indirect, while free T4 is more directly related to thyroid hormone 
activity on the heart. TSH binds to the TSH-receptor on thyroid cells, resulting in stimula-
tion of thyroid hormone production but has probably not an effect on QTc of its own.
[44] In this study, we did not present analyses with the QT interval adjusted for the RR 
interval as outcome, whereas we did show these analyses in chapters 5.1 and 5.2, which 
were conducted later. These additional analyses showed that both prolongation of the 
QTc-, as well as the QT interval adjusted for the RR interval were associated with higher 
free T4 levels.
Thyroid hormone may affect ventricular repolarization but the literature differs 
with respect to the direction of this change. Hypothyroidism has been associated with 
prolongation of the QTc interval,[45, 46] whereas hyperthyroidism has been found to 
be associated with decreased as well as increased repolarization times.[47-56] A pos-
sible explanation for the association of hyperthyroidism with QTc prolongation can be 
provided by an increase in the activity of cardiac Na+/ K+ ATPase due to thyroid hormone 
excess, leading to increased intracellular K+ with subsequent increased repolarisation 
duration.[54, 57] The effect appeared to be strongest in men. In hyperthyroid men, 
impaired sexual function, gynaecomastia, asthenospermia and low testicular volume 
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are attributed to lowered bio-available testosterone.[58, 59] In chapter 5.1 we dem-
onstrated that men with a higher level of testosterone have a shorter QTc interval. 
The decreased level of bio-available testosterone in hyperthyroid men results in less 
shortening of the QTc interval. 
Since free T4 levels were associated with an increased QTc interval duration, we 
hypothesized that hyperthyroidism could be associated with an increased risk of sudden 
cardiac death. Since thyroid hormone levels were only available in a minority of patients, 
we could not verify this. Therefore, we investigated whether use of antithyroid drugs 
(as a direct cause or as an indicator of poorly controlled hyperthyroidism) is associated 
with an increased risk of sudden cardiac death. In both the Rotterdam Study as well 
as in the IPCI database, we found that current use of antithyroid drugs was associated 
with an increased risk of sudden cardiac death (chapter 4.2). There are two potential 
explanations for our findings. First, sudden cardiac death might be an adverse reac-
tion to the antithyroid drugs themselves. However, this seems unlikely, since different 
types of antithyroid drugs were equally involved; also, this theory would be devoid of 
a biologically plausible mechanism. Second, patients may still have had inadequately 
treated hyperthyroidism early during treatment, consequently with increased levels of 
free T4. Validation of the exposed cases of sudden cardiac death demonstrated that the 
exposed cases with known TSH measurements had low TSH levels a few days before 
the index date. This confirmed the second explanation, i.e. that these patients were still 
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hyperthyroid at the moment of sudden cardiac death. Our findings suggest that these 
deaths were caused by undertreatment of hyperthyroidism.
Hyperthyroidism has been associated with ventricular arrhythmias and sudden car-
diac death in several case reports.[53, 60-64] In the Rotterdam Study, the association 
between antithyroid drugs and sudden cardiac death tended to be higher in males, 
which supports the association of free T4 and QTc prolongation in males which we 
described earlier. Because of the small number of users of antithyroid drugs in our 
analysis in the Rotterdam Study, we tested the validity of our findings by replication in 
the IPCI database. The fact that the association was observed in two independent study 
populations and that the point estimates were quite similar, confirms the validity of the 
association between current use of antithyroid drugs and sudden cardiac death. 
Diabetes mellitus is associated with QTc prolongation.[65, 66] Since hyperglycemia is 
an independent risk factor for cardiovascular disease, we studied whether non-diabetic 
participants with an impaired fasting glucose measurement and hyperinsulinemia have 
an increased risk of QTc prolongation and RR shortening and thereby an increased risk 
of sudden cardiac death. In the Rotterdam Study, we demonstrated that non-diabetic 
participants with an impaired fasting glucose and hyperinsulinemia had a significantly 
increased QTc interval and shorter RR interval than participants with normal fasting 
glucose and insulin measurements (chapter 5.2). Fasting glucose and fasting insulin 
were not associated with the uncorrected QT interval. These findings suggest that the 
association of glucose and insulin with the QTc interval is due to the shortening of the 
RR interval. However, in the same population both the QTc as well as the RR interval 
were associated with an increased risk of sudden cardiac death, which is in line with 
earlier findings.[67-70] Although the exact underlying mechanism is unknown, it is 
likely that increased sympathetic activity caused by hyperinsulinemia may increase heart 
rate and therefore decrease the RR interval.[71] 
Methodological considerations
In the following sections we will discuss some methodological considerations that apply 
to the internal and external validity of the studies described in this thesis.
Setting
All studies described in this thesis were performed using population-based data sources. 
Most studies were performed using data from the Rotterdam Study, a large popula-
tion-based cohort study of elderly.[72, 73] The strengths of this study are its general 
population based setting, the large number of participants, the consistent assessment 
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of measurements for every subject, long-duration of follow-up, and the availability of 
extensive information about various clinical characteristics of all participants gathered 
at every follow-up round. In addition, through linkage with GP and municipal mortality 
records, the total cohort is continuously monitored for major morbidity and mortality. 
Furthermore, virtually all participants fill their prescriptions in automated pharmacies 
linked to one computer network. From 1 January 1991 onwards, data on all dispensed 
drugs, including the prescribed daily dose, is available in computerized format on a 
day-to-day basis. All information is gathered irrespective of the outcome under study. 
For the studies on thyroid hormone and testosterone levels, we used a subcohort of 
the Rotterdam Study. However, the samples were measured randomly and the baseline 
characteristics of these subcohorts were comparable to the baseline characteristics of 
the complete study cohort.
Most other studies were performed using data from the Integrated Primary Care 
Information (IPCI) project, a longitudinal observational database, containing data from 
computer-based medical patient records of a large group of general practitioners (GPs) 
in the Netherlands, for a population based case-control study.[74, 75] The database 
contains the complete medical records on more than 1,000,000 patients. The electronic 
records contain coded and anonymous data on patient demographics, symptoms (in 
free text), diagnoses (using the International Classification for Primary Care (ICPC) [76] 
and free text) from GPs and specialists, referrals, laboratory findings, hospitalisations, 
and drug prescriptions, including their indications and dosage regimens. The strength of 
the database is that it contains a representative sample of the Dutch general population. 
In the Dutch health care system, the GP has a pivotal role by acting as a gatekeeper 
for all medical care. Therefore, the medical records of each individual patient can be 
assumed to contain all relevant medical information.
One study was partly conducted with data from the Study of Health in Pomerania 
(SHIP), which is a population-based study in West Pomerania, a region in the northeast 
of Germany.[77] The strengths of this study are its general population based setting 
and the availability of extensive information about various clinical characteristics of all 
participants gathered at every follow-up round.
Design
Most studies described in this thesis were designed as prospective population-based 
cohort studies, some studies as population-based case-control studies. Each of the indi-
vidual studies has its specific strengths and limitations. The Rotterdam Study contains 
a wide range of clinical characteristics and individual drug exposure for a large number 
of participants. However, the exposure of some individual drugs may be limited. In the 
studies assessing drug use at the time of an ECG, multiple follow-up ECGs per partici-
pant were available (chapter 2). This allowed us to assess the effect of a drug within 
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a person over time, which facilitates more detailed analyses. In the studies assessing 
the influence of endocrine factors on the QTc interval, only a single measurement was 
available (chapters 4.1 and 5). Due to this cross-sectional design, we cannot exclude 
that QTc or RR interval variation was already present in some participants before the 
change in thyroid hormone, testosterone, glucose or insulin levels. In the study assessing 
the effect of antithyroid drugs on sudden cardiac death, we took changes in exposure 
status into account by using a Cox-regression model with individual drug use as time-
dependent variables, since the pharmacy data provided us information about drug 
use at each point in time during follow-up (chapter 4.2). The IPCI database contains 
all relevant medical information and prescription information from the GP for a large 
number of patients. In the studies assessing the relationship between drug use and 
ventricular arrhythmias or sudden cardiac death, we were able to assess the drug use 
at the day of sudden cardiac death, since the prescription data provided us information 
about drug use at each point in time (chapters 3 and 4.2). 
Bias and confounding
In observational studies, selection bias, information bias and/ or confounding may 
influence the validity. The population-based design of the studies probably limited 
the chances of selection bias. In the Rotterdam Study and SHIP, there is a chance that 
non-participants to the study or to (part of) the examinations at the research center 
had more - or more serious - co-morbidity. Since we also have information from GPs, 
pharmacies and specialists from the participants that are not able to visit the research 
center, the chance of selection bias is limited. In the studies performed within the IPCI 
database, selection bias is unlikely, since both cases and controls were originating from 
the same IPCI population, and the controls were randomly selected from the source 
population.
Since all information in the three study bases was gathered prospectively and 
irrespective of disease status, without knowledge of drug-use, genotype or endocrine 
measurements, the chance of information bias is unlikely. However, misclassification of 
exposure may however have occurred for various reasons. In the studies investigating 
drug use as exposure, the legend duration for a calculated prescription may not reflect 
actual use. Furthermore, in the Rotterdam Study we used pharmacy data and in none of 
the sources we had information whether the drugs were actually taken. However, this 
will probably lead to non-differential misclassification. Over the counter drug use may 
cause misclassification since this will not be registered in the pharmacy or GP databases. 
This was relevant for the study on domperidone, where we observed strong hetero-
geneity in the effect of domperidone in publicly and privately insured persons, which 
generally have different patterns of OTC drug use. To limit differential misclassification 
we stratified by insurance. In the studies investigating endocrine factors as exposure, 
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misclassification may have occurred, since we used a single measurement. However, if 
exposure misclassification occurred in one of the studies it is probably non-differential. 
We cannot exclude that some misclassification of outcome occurred. However, this 
is unlikely in the studies with the QTc interval as outcome, since the use of digital ECG 
recordings, all measured using the MEANS system (in both the Rotterdam Study as 
well as in SHIP), likely reduced intra- and interobserver variability in the assessment of 
the QTc interval. In the studies with sudden cardiac death as outcome, we may have 
missed some deaths, although this will be minimal, since death is consistently registered 
by GPs. Second, since an autopsy was not available in all acute deaths, we cannot be 
certain that all acute deaths have been of cardiac origin. We determined sudden cardiac 
death, however, on the basis of the full medical records and most circumstances sur-
rounding death were available. Recently, an evaluation comparing different methods to 
determine the incidence of sudden cardiac death suggested that this method provides a 
very reliable way of determining cases of sudden cardiac death.[78] 
Confounding is an important issue in epidemiological studies. Although we adjusted 
for all known confounders, residual confounding may exist. In the study on domperi-
done and the risk of ventricular arrhythmias, we considered GP visits to be a confounder, 
since prodromal symptoms of sudden cardiac death, such as nausea and vomiting, 
can be mistakenly diagnosed as symptoms due to gastric pathology. Many potential 
confounders are well recorded in the three studies, such as use of concomitant drugs, 
comorbidities, and lifestyle factors. However, some factors potentially associated with 
sudden cardiac death, such as smoking, alcohol abuse or body weight, are not complete 
in the IPCI database. 
Confounding by indication is an important factor to consider in pharmaco-epidemi-
ological studies.[79] As shown in the study on use of antithyroid drugs and the risk of 
sudden cardiac death, it can be difficult to determine whether the drugs or the underly-
ing indication for use are associated with an increased risk of sudden cardiac death. 
Clinical implications
In the studies described in this thesis, we were able to identify several risk factors for QTc 
prolongation and/ or sudden cardiac death. Prescribers should be aware which drugs 
are associated with an increased risk of QTc prolongation and sudden cardiac death, in 
order to be able to make a proper benefit-risk assessment. Preferably, a physician should 
not prescribe two or more QTc prolonging drugs concomitantly. Nonetheless, when this 
is required, it is advised to record an ECG to examine the length of the QTc interval. 
However, in a recent study it was shown that doctors who overrule high-level drug-drug 
interaction alerts on QTc prolongation rarely record an ECG as a safety measure. If ECGs 
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were recorded before and after QTc overrides, clinically relevant QTc prolongation was 
found in one-third of the cases with an average change in QTc interval of 31 ms.[80] In 
an ideal situation, QTc prolonging drugs should not be prescribed to patients with an 
increased risk of sudden cardiac death, unless for life-threatening indications. 
Genotyping variants in the NOS1AP gene might reduce the risk of QTc prolonga-
tion due to use of verapamil and potentially other QTc prolonging drugs. However, a 
disadvantage would be that genotype information may not only inform physicians and 
patients about the risk of adverse events, but also about the risk of future non-drug-
related diseases which are associated with such variants. This may raise ethical issues.
Also, from a regulator’s point of view, it is important to know which drugs have the 
potential to prolong the QTc interval. For example, we confirmed that thioridazine was 
associated with a significant increase in the QTc interval. This drug has been withdrawn 
in 2005 due to QTc prolongation, cardiac arrhythmias and sudden death.[12] The over-
the-counter availability of domperidone has been the subject of discussion due to the 
increased risk of sudden cardiac death. In line with regulatory recommendations, most 
new drugs are tested for their ability to block hERG-encoded potassium channels.[81] We 
have shown that the margin between binding capacity and free plasma concentration 
of potentially hERG-encoded potassium channels blocking drugs might be an important 
indicator of the risk of sudden cardiac death. Regulators could use this margin to decide 
whether a drug is safe enough to be registered or whether QTc prolongation or sudden 
cardiac death should be labelled in the safety section of the product information.
Furthermore, physicians should be aware of the fact that certain endocrine factors 
are associated with an increased risk of QTc prolongation. First, our findings suggest that 
in patients with increased thyroid hormone levels euthyroid values should be reached 
as soon as possible to decrease the risk of sudden cardiac death. Second, patients with 
several risk factors for sudden cardiac death, including increased thyroid hormone levels 
or an impaired fasting serum glucose, can be identified to be able to take preventive 
measures, such as avoiding use of QTc prolonging drugs if possible. 
Future research
A number of studies described in this thesis show results based on a limited number of 
exposed individuals. In two different studies, we presented data from two independent 
populations to confirm our findings. However, there is still a need for replication in other 
populations for the remaining study results. 
To gain better insight into the risk of individual drugs in addition to class effects, data 
from several populations should be pooled, which will increase the number of exposed 
individuals. In Europe, there are initiatives to combine population databases for the early 
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detection of adverse events.[82] This will increase the power to detect an adverse event 
during the use of an individual drug, including the effect of duration of use and dosage. 
Also, with a larger population the role of different drugs can be studied within subpopu-
lations with risk-increasing co-morbidity such as diabetes mellitus, thyroid disorders, and 
other cardiovascular and endocrinological diseases. Furthermore, it is hypothesized that 
adverse events will be detected earlier than in spontaneous reporting systems, which 
depend on voluntary reporting by physicians, pharmacists and patients. 
Pharmacogenetic studies are currently conducted to identify genetic high risk groups 
for adverse events. However, most studies are conducted in populations with limited 
exposure of genetic variants in combination with use of specific drugs. Nevertheless, the 
combination of a rare genetic trait and a rarely used drug may remain difficult to inves-
tigate. Collaborations of several studies in Europe and the United States of America, 
e.g. the CHARGE Consortium, have the intention to pool data to increase the power to 
identify genetic high risk groups for adverse events.[83] 
Finally, since thyroid hormone levels were only available in a subcohort of the Rot-
terdam Study, we could not directly study the association between thyroid hormone and 
sudden cardiac death. Future research studying the direct association and the underlying 
mechanism will be necessary.
Main conclusions
In the past decade, one of the most frequent causes of withdrawal or restriction of mar-
keted drugs was QTc interval prolongation. Nevertheless, in a clinical setting it was recently 
shown that automatically generated warnings about QTc prolonging drugs interaction 
rarely result in the preferred approach to subsequently record an ECG.[80] Identification 
of QTc prolonging drugs in order to restrict the use or to withdraw a drug from the market 
when it causes cardiac arrhythmia, may therefore improve the safe use of drugs.
The studies on drugs and repolarization disturbances confirmed the important role of 
antidepressants and antipsychotics as potential contributors to QTc-prolongation. Espe-
cially tricyclic antidepressant drugs appear to prolong the QTc interval, and this seems to 
be a class effect. In addition, we demonstrated that the minor alleles of both NOS1AP 
SNPs significantly potentiate the QTc prolonging effect of verapamil. 
The studies on drugs and ventricular arrhythmia showed that current use of non-
cardiovascular hERG-encoded potassium channels inhibiting drugs in the general popu-
lation (both over-the-counter as well as prescription only drugs) was associated with an 
increased risk of sudden cardiac death. We demonstrated that hERG-encoded potassium 
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channels inhibiting capacity tended to be associated with an increased risk of sudden 
cardiac death. Furthermore, we demonstrated that use of anticonvulsants with sodium 
channel-blocking activity is associated with an increased risk of sudden cardiac death.
The studies on thyroid disturbances and repolarization disturbances and fatal ventricular 
arrhythmias demonstrated that high levels of free T4 are associated with substantial QTc 
prolongation in men. Subsequently, we showed in two independent populations that 
use of antithyroid drugs was associated with a threefold increased risk of sudden cardiac 
death. Although this might be directly caused by antithyroid drug use, it might be more 
readily explained by underlying poorly controlled hyperthyroidism, since treated patients 
who developed sudden cardiac death still had low TSH levels shortly before death. 
The studies on other endocrine factors and repolarization disturbances showed that 
serum testosterone levels were associated with both the QTc as well as the RR interval. 
However, we could not demonstrate an association with the QT interval. Lower QTc 
intervals in men with higher serum testosterone levels were probably due to the asso-
ciation of serum testosterone with prolongation of the RR interval. Furthermore, we 
demonstrated that impaired fasting glucose and hyperinsulinemia are associated with a 
significantly increased QTc interval and shortening of the RR interval. We demonstrated 
in the same population that both the QTc/ QT as well as the RR interval are associated 
with an increased risk of sudden cardiac death.
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Abstract
Background
A recent genome-wide association study identified a haplotype block on chromosome 
4q25 associated with atrial fibrillation (AF). We sought to replicate this association in 
four independent cohorts.
Methods 
The Framingham Heart Study and Rotterdam Study are community-based longitudinal 
studies. The Vanderbilt AF Registry and German AF Network (AFNet) are case–control 
studies.
Results
Participants with AF (n=3508) were more likely to be male and were older than refer-
ent participants (n=12 173). Single nucleotide polymorphism (SNP) rs2200733 was 
associated with AF in all four cohorts, with odds ratios (ORs) ranging from 1.37 in 
Rotterdam [95% confidence interval (CI) 1.18–1.59; P=3.1 * 10-5] to 2.52 in AFNet 
(95% CI 2.22–2.84; P=1.8 * 10-49). There also was a significant association between AF 
and rs10033464 in Framingham (OR 1.34 (1.03–1.75); P=0.031) and AFNet (OR 1.30 
(1.13–1.51); P=0.0002), but not Vanderbilt (OR 1.16 (0.86–1.56); P=0.33). A meta-
analysis of the current and prior AF studies revealed an OR of 1.90 (1.60–2.26; P=3.3 * 
10-13) for rs2200733 and of 1.36 (1.26–1.47; P= 6.7 * 10-15) for rs10033464.
Conclusions
The non-coding SNPs rs2200733 and rs10033464 are strongly associated with AF in four 
cohorts of European descent. These results confirm the significant relations between AF 
and intergenic variants on chromosome 4.
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Introduction
Atrial fibrillation (AF) is the most commonly sustained arrhythmia affecting over two 
million Americans, a number that is expected to increase to between 6 and 12 millions 
by the year 2050.[1, 2] AF is a major source of morbidity and mortality. It is associated 
with a five-fold increased risk of stroke [3], a doubling in risk of dementia [4], and an 
increased risk of heart failure (HF).[5, 6] 
Multiple risk factors for AF exist, including hypertension (HTN), valvular heart disease 
[7], HF, and a family history of the arrhythmia.[8-10] In the past 5 years, data have 
emerged to support a genetic contribution to AF. Several genetic loci for AF have been 
identified [11-13], although the genes responsible for AF at these loci remain unknown. 
Mutations in the cardiac sodium channel [14, 15], potassium channel complexes [16-
19], and gap junction proteins [20] have been reported to cause AF; however, these ion 
channel variants appear to account for only a small fraction of AF cases.[21] Finally, with 
the exception of the association between a common variant in KCNH2 and AF [22], 
most case–control association studies to date have been underpowered and have not 
been replicated.
Recently, a genome-wide association study in Icelanders identified a haplotype block 
on chromosome 4q25 containing variants that predispose to AF.[23] In this block, two 
single nucleotide polymorphisms (SNPs), rs2200733 and rs10033464, are in strong link-
age disequilibrium and define three haplotypes. The haplotype identified by rs2200733 
was found to confer a relatively higher risk [odds ratio (OR) = 1.72] of AF or atrial flutter, 
whereas the haplotype identified by rs10033464 conferred a more modest risk (OR = 
1.39) compared with the common sequence. The association of these SNPs with AF was 
replicated in two small cohorts of Northern Europeans and in a study of people of Asian 
descent. The 4q25 haplotype block is located in a ‘genomic desert’ of approximately 
1.5 million base pairs without any known genes. The closest gene, PITX2, is more than 
50 000 bp away from these variants.
PITX2 is a transcription factor critical for determining left–right asymmetry and for 
the differentiation of the left atrium.[24] Furthermore, it is necessary for the develop-
ment of the pulmonary myocardium [25], the source of ectopic, electrically active foci 
associated with paroxysmal AF in many individuals. The pulmonary myocardium is the 
therapeutic target of pulmonary vein ablation procedures that have become increasingly 
frequent in the management of AF.[26]
In our study, we sought to determine whether the association between the 4q25 
haplotype block and AF replicated in two community-based and two case–control 
studies with large numbers of AF participants. In an exploratory analysis, we studied 
whether there was effect modification by age.
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Methods
Description of study cohorts
The Framingham Heart Study (FHS) is a longitudinal observational, community-based 
cohort initiated in 1948 to prospectively investigate cardiovascular disease and its risk 
factors, as previously described.[27] Participants were diagnosed with AF, if AF or flutter 
was present on an electrocardiogram obtained from the hospital or physician records 
or from routine Framingham clinic examination (every 2 years in the Original Cohort 
and every 4–8 years in the Offspring Cohort). AF cases were available through 21 April 
2007. All protocols were approved by the Boston University Medical Center Institutional 
Review Board, and participants provided written informed consent.
The Rotterdam Study (RS) is a community-based study founded in 1990. The Medical 
Ethics Committee of Erasmus University Rotterdam approved the study, and participants 
signed consent. Inhabitants of a suburb of Rotterdam (n = 10 275) aged 55 years and 
older were invited, and 7983 participants (78%) were examined. The participants were 
interviewed at their home and were examined during two visits at the research centre 
for baseline data collection. The participants were re-examined twice during three 
follow-up rounds. The first round was performed between July 1993 and 31 December 
1994. The second round started in April 1997 and ended 31 December 1999. The third 
round started in January 2002 and ended 31 July 2004. Three methods were used to 
assess cases of AF or atrial flutter, as described previously [28]: (i) at baseline and during 
follow-up examinations, 10 s 12-lead ECGs were recorded at the research centre with 
an ACTA Gnosis IV ECG recorder (EsaOte, Florence, Italy), stored digitally, and analysed 
with the Modular ECG Analysis System (MEANS).[29] To verify the diagnosis of AF, all 
ECGs with a diagnosis of AF or flutter or any other rhythm disorder were re-coded 
independently by two physicians who were blinded to the MEANS diagnosis. The judge-
ment of a cardiologist was considered decisive in the case of persistent disagreement; 
(ii) general practitioners information; and (iii) hospital discharge diagnoses were also 
obtained from the Landelijke Medische Registratie system.
The Vanderbilt AF Registry consists of consecutive patients with documented AF age 
>18 years, who were prospectively enrolled since October 2002 from the Vanderbilt 
Cardiology and Arrhythmia Clinics, the emergency department, and in-patient services. 
At enrolment, participants were asked a detailed medical and drug history and were 
asked to complete a symptom questionnaire.[30] Participants were excluded if AF was 
diagnosed in the setting of recent cardiac surgery or were unable to give informed 
consent or report for follow-up. An echocardiogram was obtained on all patients at 
the time of registry enrolment. The study protocol was approved by the Vanderbilt 
University Institutional Review Board, and participants were enrolled following informed 
written consent. Participants with AF (n=556) were enrolled and age- and sex-matched 
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to referent participants (n=598). The controls were participants who underwent cardiac 
surgery with no personal or family history of AF and had no AF documented after 
surgery.
The German Competence Network for Atrial Fibrillation (AFNet) is a national registry 
of AF patients comprising 10 000 probands. DNA samples are currently collected from 
patients with AF onset before age 60 years. In this analysis, all samples available by 1 
October 2007 (n=906) from the nation-wide German Competence Network for Atrial 
Fibrillation were combined with AF patients collected at the Medical Department I of the 
University Hospital Munich, Campus Grosshadern of the Ludwig-Maximilians University 
Munich, the Medical Department I of the Technical University Munich Hospital, and the 
Deutsches Herzzentrum Munchen (in total, n=1715). Cases were selected if the diag-
nosis of AF was made on an electrocardiogram analysed by a trained physician. Patients 
with signs of moderate-to-severe HF, moderate-to-severe valve disease, or with hyper-
thyroidism were excluded from the study. Control probands were from a population-
based epidemiological survey of persons living in or near the city of Augsburg, Southern 
Germany (KORA S4), conducted between 1999 and 2001.[31] The survey population 
consisted of German nationality residents born between 1 July 1925 and 30 June 1975 
identified through the registration office. A sample of 6640 participants was drawn with 
10 strata of equal size according to sex and age and 4261 individuals (66.8%) agreed 
to participate. Exclusion criteria for control probands were reported history of AF, signs 
or symptoms of AF on physical examination, or absence of sinus rhythm upon 12-lead 
resting ECG that all probands received. All studies involving humans were performed 
according to the declarations of Helsinki and Somerset West, were approved by local 
medical Ethics Committees, and participants signed informed consent.
Genotyping
SNP genotyping in the FHS and RS was performed using an ABI TaqMan assay.[32] 
Genotyping of samples from Vanderbilt University and AFNet was performed using PCR, 
iPlex single base primer extension, and matrix assisted laser desorption/ionization–time 
of flight mass spectrometry in a 384-well format (Sequenom, San Diego, CA, USA), as 
described previously.[33] Subjects were considered to have failed genotyping if we were 
unable to detect a PCR product or to distinguish between the alleles in at least two 
separate experiments.
Statistical analysis
Exact Hardy–Weinberg equilibrium (HWE) tests were applied to all SNPs in the referent 
participants. In the Framingham sample, a subset of unrelated participants was used to 
test for deviation from HWE. SNP-age interactions were assessed using age as a continu-
ous variable. All calculations were performed using R (FHS), SPSS (RS), SAS (Vanderbilt 
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AF Registry), and STATA SE 8.0 statistical package (AFNet). Logistic regression was used 
to adjust for participants’ age and sex. In the community-based studies, a multi-variable 
analysis was performed using logistic regression to adjust for participants’ age, sex, 
body mass index, and history of HTN, HF, myocardial infarction, and diabetes mellitus. A 
two-sided P-value of less than 0.05 was considered significant. Only subjects who failed 
genotyping were excluded from the analysis. Meta-analyses of the relations between 
AF and rs2200733 and rs10033464 were performed. Given the differences in study 
design, the community-based samples (FHS and RS) and case–control studies (AFNet 
and Vanderbilt AF Registry) were analysed separately. A meta-analysis was performed to 
determine the association between AF and rs2200733 or rs10033464 using all available 
case–control studies for AF.[23]
Results
A total of 3508 participants with AF and 12 173 referent participants were available from 
four cohorts of European descent (Table 1). Participants with AF were older (P ≤ 0.001) 
and were more likely to be male in the FHS, RS, and AFNet (P ≤ 0.001). By design, there 
was a similar number of men among those with and without AF in the Vanderbilt AF 
Registry (67.8 vs. 66.6%, P=NS). Genotype call rates and HWE were similar in subjects 
without AF (Table 2). Minor allele frequencies for rs2200733 are illustrated in Figure 1. 
In an analysis adjusted for age and sex, rs2200733 was strongly associated with AF 
(Table 3), with ORs ranging from 1.37 (95% CI 1.18–1.59; P = 3.1 * 10-5) in the RS to 
2.52 (95% CI 2.22–2.84; P=1.8 * 10-49) in AFNet. A multi-variable analysis adjusting 
for age, sex, HTN, HF, diabetes, and body mass index was performed in the population-
based studies. The association between rs2200733 and AF remained significant with an 
OR of 1.47 (95% CI 1.11–1.94; P = 0.0067) in the FHS and 1.36 (95% CI 1.17–1.59; P 
= 9.3 * 10-5) in the RS. Exclusion of subjects with missing data for at least one co-variate 
Table 1 Characteristics of the study cohorts
Framingham Heart 
Study
Rotterdam Study Vanderbilt AF 
Registry
German AF network
AF Non-AF AF Non-AF AF Non-AF AF Non-AF
Number of 
participants
327 2006 910 5496 556 598 1715 4073
Age (years) 
mean± SD 
82.2 ±9.9 71.4±12.8* 73.4±8.4 68.8±9.1* 54.2±13.7 56.6±14.2# 61.7±12.1 49.2±13.9*
Men, number 
(%)
189 
(57.8)
833 
(41.5)*
415 
(45.6)
2178 
(39.6)#
377 
(67.8)
398 
(66.6)
1328 
(72.2)
2005 
(49.2)*
For comparisons between participants with and without AF: * P<0.0001 and # P=0.0001
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Table 2 Distribution of genotypes by cohort for single nucleotide polymorphisms rs2200733 or rs10033464 
rs2200733 rs10033464
CC CT TT
Call 
rate 
(%)
HWE GG GT TT
Call 
rate 
(%)
HWE
Framingham Heart 
Study
    AF 229 83 12 99.1 0.15 253 70 2 99.4 0.40
    Non-AF 1527 418 29 98.2 0.82 1676 305 24 99.9 0.08
Rotterdam Study
    AF 676 215 19 97.4 0.68 674 162 12 99.6 0.48
    Non-AF 4392 1030 74 97.5 0.14 4194 855 52 99.6 0.25
Vanderbilt AF Registry
    AF 398 130 24 98.8 0.004 439 106 7 98.1 0.83
    Non-AF 453 99 6 98.4 0.81 452 99 4 98.8 0.81
German AF network
    AF 1015 598 93 99.5 0.69 1328 351 22 99.1 0.83
    Non-AF 3116 853 45 98.6 0.11 3315 675 29 98.7 0.40
AF=atrial fibrillation; HWE=P-value for exact Hardy-Weinberg equilibrium test
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Figure 1 Comparison of the minor allele frequency for single nucleotide polymorphisms 
rs2200733 in participants either with (filled circle) or without (open circle) AF. 95% confidence 
intervals are indicated by the error bars. 
Figure 1 Comparison of the minor allele frequency for single nucleotide polymorphisms rs2200733 in participants either with (filled circle) or 
without (open c rcle) AF. 95% c nfidence intervals are indicated by the rror bars.
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did not alter our findings (FHS n=28, OR1.47, 95% CI 1.11–1.94; RS n=468,OR 1.37, 
95% CI 1.18–1.60). In a meta-analysis of the relations between rs2200733 and AF in 
the community-based studies (Framingham and Rotterdam), the OR was 1.38 (95% 
CI 1.21–1.57; P=1.41 * 10-6), compared with 2.09 (95% CI, 1.41–3.10; P=2.4 * 10-4) 
in the case–control studies (Vanderbilt AF Registry and AFNet). A meta-analysis of the 
case–control studies from both the current and prior [23] reports reveals an OR of 1.90 
(95% CI 1.60–2.26; P = 3.3 * 10-13). The association between AF and SNP rs10033464 
was weaker (Table 3) and did not achieve statistical significance in the Vanderbilt AF 
Registry cohort. In a multi-variable analysis, rs10033464 was not significantly associ-
ated with AF in the FHS, with an OR of 1.22 (95% CI 0.92–1.62; P = 0.18) or the RS 
1.17 (95% CI 0.98–1.39; P = 0.093). A meta-analysis of the association between AF 
and rs10033464 in the case–control studies, with inclusion of the current and previous 
reports [23] reveals an OR of 1.36 (95% CI 1.26–1.47; P = 6.7 * 10-15). In an exploratory 
analysis, we observed a significant interaction between rs2200733 genotype and age in 
the FHS (P = 0.0065), but not in the RS (P = 0.62). There was no significant interaction 
between rs10033464 genotype and age in the FHS (P = 0.24) or in the RS (P = 0.47). 
In order to compare with prior reports, we have presented these data dichotomized at 
60 years of age in Table 4. A higher OR was noted between SNP rs2200733 and AF 
in participants <60 years in the FHS and AFNet, whereas the opposite was true in the 
Vanderbilt AF Registry with a higher OR in participants over 60 years. 
In the RS, there were 575 cases of incident AF. After adjustment for age and sex, the 
association between AF and rs2200733 was significant (OR 1.39, 95% CI 1.17–1.65; P 
= 2.1 * 10-4). Among the 2006 participants available in the FHS, there were 184 incident 
cases of AF. Acknowledging low power to detect an association in Framingham we did 
not observe a significant odds of incident AF with SNPs rs10033464 or rs2200733 (OR, 
95% CI, P-value: 1.11, 0.81–1.52, 0.52; and 1.21, 0.89–1.64, 0.23, respectively).
Table 3 Association between the single nucleotide polymorphisms rs2200733 or rs10033464 with atrial fibrillation
Adjusted for age and gender Adjusted for age, gender, HTN, HF, MI, BMI, DM
rs2200733 rs10033464 rs2200733 rs10033464
Odds Ratio 
(95% CI)
P-value Odds Ratio 
(95% CI)
P-value Odds Ratio 
(95% CI)
P-value Odds Ratio 
(95% CI)
P-value
Framingham 
Heart Study
1.40 
(1.07 – 1.82)
0.01 1.34 
(1.03 – 1.75)
0.031 1.47 
(1.11 – 1.94)
0.007 1.22 
(0.92 – 1.62)
0.18
Rotterdam 
Study
1.37 
(1.18 – 1.59)
3.1 * 10-5 1.17 
(0.99 – 1.38)
0.07 1.36 
(1.17 – 1.59)
9.3 * 10-5 1.17 
(0.98 – 1.39)
0.09
Vanderbilt AF 
Registry
1.68 
(1.29 – 2.18)
0.0001 1.16 
(0.86 – 1.56)
0.33 - - - -
German AF 
network
2.52 
(2.22 – 2.84)
1.8 * 10-49 1.30 
(1.13 – 1.51)
0.0002 - - - -
HTN=hypertension; HF=heart failure; MI=myocardial infarction; DM=diabetes mellitus
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Discussion
In the last 2 years, an increasing number of genome-wide association studies have 
emerged in the literature identifying genetic variants associated with macular degenera-
tion [35], coronary disease [36], QT interval [37] and recently AF.[23] Although the prior 
studies provide an opportunity to identify variants associated with apparently complex 
traits in a population, upon the completion of these studies, two primary issues remain. 
First, given the inherent limits of multiple hypothesis testing in genome-wide association 
studies, can the findings from any one study be broadly replicated? Secondly, how do 
we go from association to mechanism or how precisely do these chromosomal variants 
lead to AF? In our current report, we address the reproducibility of the findings in the 
original study. 
We found that two SNPs—rs2200733 and rs10033464—were significantly associ-
ated with AF in four cohorts of Northern European descent after accounting for age 
and sex of the participants. Meta-analyses of the relations between AF and both SNPs in 
all available case–control studies provided a convincing OR of 1.90 (P = 3.3 * 10-13) for 
rs2200733 or 1.36 (P = 6.7 * 10-15) for rs10033464.
Although the potential mechanism of action of the genetic locus identified by these 
two non-coding SNPs is unknown and may be mediated through effects of distant 
genes, it is interesting to note that the closest gene, located ~ 50 000 bp centromeric, is 
the transcription factor, PITX2. Mouse knockouts of this gene have demonstrated a criti-
cal role for one isoform, PITX2c, in left–right asymmetry[24] and specifically the develop-
ment of the left atrium.[38, 39] The loss of PITX2c leads to right atrial isomerisation and 
a failure to suppress a default pathway for sinus node formation in the left atrium of 
the embryo.[40] Finally, in a recent elegant study, PITX2c has been demonstrated to be 
necessary for the development of the pulmonary myocardium or the sleeve of cardio-
myocytes extending from the left atrium to the initial portion of the pulmonary vein.
[25] Clinical and animal studies have demonstrated that ectopic foci of electrical activity 
arising from within the pulmonary veins and posterior left atrium play a substantial role 
Table 4 Relations between age of participants and risk of atrial fibrillation for single nucleotide polymorphisms rs2200733 or rs10033464 
rs2200733 rs10033464 
Age<60, Odds Ratio 
(95% CI), AF/non-AF
Age≥60, Odds Ratio 
(95% CI), AF/non-AF
Age<60, Odds Ratio 
(95% CI), AF/non-AF
Age≥60, Odds Ratio 
(95% CI), AF/non-AF
Framingham 
Heart Study
2.13 (1.13 – 4.00), 
29/1973
1.29 (0.98 – 1.72), 
295/1973
1.48 (0.68 – 3.23), 
30/2005
1.34 (1.01 – 1.78), 
295/2005
Rotterdam 
Study
1.34 (0.75 – 2.39), 
52/1007
1.33 (1.14 – 1.55), 
858/4489
1.60 (0.90 – 2.86), 
49/942
1.16 (0.97 – 1.38), 
802/4181
Vanderbilt AF 
Registry
1.44 (1.02 – 2.01), 
264/304
2.03 (1.34 – 3.07), 
168/254
1.12 (0.76 – 1.64), 
264/302
1.17 (0.73 – 1.86), 
168/253
German AF 
network
2.71 (2.34 – 3.15), 
697/2868
1.99 (1.68 – 2.36), 
1009/1146
1.35 (1.12 – 1.63), 
691/2872
1.31 (1.07 – 1.60), 
1010/1147
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in initiating and maintaining fibrillatory activity.[26, 41] Furthermore, electrical isolation 
of the pulmonary veins and left atrial region is the goal of catheter ablation procedures 
that increasingly have been used to treat AF in the last decade.
The association between genetic variants on chromosome 4q25 and AF that we have 
observed implicates a novel pathway in the genesis of arrhythmia. AF has been reported 
to be associated with mutations in ion channel proteins, alterations in ion channel flux, 
and action potential shortening.[42] It is interesting to hypothesize that these variants 
may dysregulate PITX2 during cardiogenesis or beyond, thus perturbing the normal 
structure or function of the left atrium and pulmonary veins and ultimately predisposing 
to AF.[43, 44] It is important to note that such reasoning is currently speculative and at 
present, no direct mechanistic relationship between these variants and PITX2 has yet 
been demonstrated.
Although there was a strong association between rs2200733 and incident AF in 
the RS, the association was not statistically significant in the FHS. Although the failure 
to replicate the Rotterdam findings may simply be due to the limited number of inci-
dent cases (n = 184) in the Framingham cohort, the relatively low risk associated with 
rs2200733, even in the case–control studies, suggests that the broad use of such a SNP 
in predictive testing is of limited clinical value. Similarly, the variability noted in the ORs 
for the association between SNP rs2200733 and AF in younger vs. older subjects may 
be due to the limited number of younger subjects available in all studies but the German 
AF Network. Future studies to determine whether this SNP is associated with the age 
of onset of AF or other outcomes from AF such as the risk of HF, stroke, mortality, 
responses to drugs, or catheter ablation procedures will be helpful.
As each of the four studies we sampled consists of participants of European descent, 
the generalizability of our results to other races and ethnicities is uncertain. In addition, 
we had low statistical power to test for gene–environment or gene–gene interactions.
In conclusion, we report that two variants on chromosome 4q25 are strongly associ-
ated with AF. Although variation at this locus does not appear to be suitable for clinical 
testing, it does provide a starting point for exploration of a novel pathway for this 
morbid arrhythmia.
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Abstract
We conducted meta-analyses of genome-wide association studies for atrial fibrillation 
(AF) in participants from five community-based cohorts. Meta-analyses of 896 prevalent 
(15,768 referents) and 2,517 incident (21,337 referents) AF cases identified a new locus 
for AF (ZFHX3, rs2106261, risk ratio RR = 1.19; P = 2.3 * 10-7). We replicated this 
association in an independent cohort from the German AF Network (odds ratio = 1.44; 
P = 1.6 * 10-11; combined RR = 1.25; combined P = 1.8 * 10-15).
Introduction
With increasing longevity of individuals in developed countries, late-onset chronic 
cardiovascular diseases such as AF have become important public health problems. AF 
is an electrical disorder of the heart’s upper chambers characterized by an irregular 
heart rhythm. The overall lifetime risk of AF is almost 25% in the US and Europe.[1, 2] 
Furthermore, the incidence of AF is increasing over time; in the US it is projected that 
up to 15.9 million individuals may be affected by 2050.[3] The growing number of 
individuals with AF is of concern because of its association with significantly increased 
risks of stroke, heart failure and death.[4] 
AF is a complex disease with many etiologies, including cardiovascular disease and 
its risk factors. Recently it was reported that, even for typical forms of AF, individuals 
with an affected relative are at higher risk of AF.[5] Moreover,a genome-wide associa-
tion study (GWAS) identified SNPs in the chromosome 4q25 region that are associated 
with increased AF risk.[6] We hypothesized that additional common genetic variation 
contributes to the development of AF. 
Methods
We conducted and combined meta-analyses of prevalent AF and incident AF, using 
existing GWAS data from the Cohorts for Heart and Aging Research in Genomic Epi-
demiology (CHARGE) AF Consortium. CHARGE included the following five community-
based cohorts[7]: Age, Gene/Environment Susceptibility Reykjavik Study (AGES); 
Atherosclerosis Risk in Communities (ARIC); Cardiovascular Health Study; Framingham 
Heart Study; and Rotterdam Study. Genotyping inclusion criteria were unbiased toward 
AF, as genotyping was performed as a core effort for many phenotypes in each cohort. 
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The CHARGE AF Consortium included analyses from five community-based cohorts that 
collected AF cases systematically in longitudinal follow-up and had GWAS data. All 
participants included in this analysis were of European descent. In CHARGE cohorts 
(and AFNET and KORAS4) written informed consent was obtained from each subject, 
including consent to use DNA for genetic analyses of cardiovascular disease. Consent 
precluded participant-specific meta-analysis. African American participants from ARIC 
and CHS studies were not analyzed for the present study. 
AGES represents the later follow-up of the midlife Reykjavik (Iceland) Study founded 
in1967.[8] AGES was designed to examine the genetic epidemiology of four pheno-
types known to alter with advancing age: vascular, neurocognitive, musculoskeletal and 
body composition. The AGES examinations were conducted between 2002 and 2006 
on 5,764 survivors of the Reykjavik Study.
The ARIC study was initiated in 1987 to examine atherosclerosis in middle-aged 
adults and completed enrollment of 15,792 participants. ARIC was conducted in four 
US communities (Forsyth County, NC; Jackson, MS; Minneapolis suburbs, MN; and 
Washington County, MD). Participants were examined about every three years four 
times and followed for events.[9] Only white ARIC participants were included in the 
analyses.
CHS is a prospective population-based cohort study of CVD in adults 65 years and 
older. The four Field Centers (Forsyth County, NC; Sacramento County, CA; Washington 
County, MD; Pittsburgh, PA) completed enrollment of 5888 participants in 1989-1990 
and 1992-1993.[10]
FHS is a community-based observational, cohort initiated in 1948 to prospectively 
investigate CVD and its risk factors. The Original cohort (n=5209) received biennial 
exams.[11] The Original Cohort children (& spouses), termed the Offspring cohort 
(n=5214), were recruited in 1971, and were examined every four to eight years.[12]
The community-based RS was founded in 1990 to examine the determinants of 
disease and health in the elderly with a focus on CVD, neurogeriatric, bone and eye 
diseases. Inhabitants of a Rotterdam suburb (n=10,275) age ≥55 years were invited and 
7,983 participants (78%) were examined. The participants were examined up to four 
times approximately every three years.[13]
AF Ascertainment
Studies included initial, paroxysmal, persistent, and permanent atrial fibrillation and 
atrial flutter (ARIC did not include atrial flutter). Prevalent AF was considered present 
if AF was observed on baseline electrocardiograms (AGES, CHS, RS), or prior to DNA 
collection (FHS). Incident AF was defined as AF that first occurred after the collection 
of DNA (FHS, ARIC), or after the baseline examination (other cohorts). There was no 
overlap in AF cases between prevalent and incident AF analyses.
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The AGES study ascertained AF based on AGES examination Minnesota coded 
electrocardiograms, and ICD-10 I48 recorded from hospitalizations from 1997 through 
March, 2008.
The ARIC study determined AF from three sources: electrocardiograms at study visits, 
hospital discharge records and death certificates[14] (first reviewed and confirmed by 
a cardiologist, latter two reviewed by trained abstractor, ICD-9 code 427.31 or 427.3; 
ICD-10 I48). Incidence of AF was identified through 2004 as the first occurrence of AF 
by any of the sources. ARIC excluded 37 atrial flutter without subsequent AF cases. In 
CHS, prevalent AF was identified by 12-lead ECG at baseline. Incident AF in up to 16 
years follow-up (median 13 years) was identified by the first occurrence of AF on annual 
CHS study electrocardiograms or the first occurrence of a hospital discharge ICD-9 code 
for AF. CHS participant hospital discharge diagnosis codes for AF were found to have a 
sensitivity of 71% for AF.[15]
In FHS, all cardiovascular hospital and outside records were routinely obtained and 
electrocardiograms were recorded at all FHS examinations; AF cases through 2007 were 
verified by 2 FHS cardiologists.[16]
For the RS the ascertainment of AF included review of hospital discharge informa-
tion, general practitioner diagnoses and RS electrocardiograms. AF was verified by 2 
physicians and verified by electrocardiogram review by a cardiologist in the case of a 
disagreement.[2] 
AF Replication sample
The replication German Competence Network for Atrial Fibrillation (AFNET) is a national 
registry of patients with prevalent AF onset before 60 years (n=2,145) without struc-
tural heart disease. Referent subjects without AF or structural heart disease (n=4,073) 
were drawn from the population-based KORA S4 study.[17] Association testing was 
performed using logistic regression with an additive genetic model adjusting for age at 
DNA draw, sex and hypertension status. 
Genotyping and Imputation
Briefly, the five studies utilized a variety of high-density Illumina (Human CNV370, AGES 
and CHS; Infinium 550, RS) and Affymetrix (6.0, ARIC; 500K +50K human gene focused, 
FHS) platforms. Approximately 2.5 million autosomal genotypes were imputed within 
each study using the Phase II CEU HapMap reference panel (http://hapmap.org) and 
BIMBAM (CHS; http://stephenslab.uchicago.edu/software.html) or MACH v1.0.15/16 
(all others; http://www.sph.umich.edu/csg/abecasis/MaCH/index.html) software. 
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Statistical methods
Primary GWAS were performed within each cohort separately for prevalent and 
incident AF using an additive genetic model adjusting for age, sex, and, if relevant, 
cohort (FHS Original versus Offspring) or site (ARIC, CHS). Prevalent AF was examined 
with logistic regression; controls for prevalent analyses included all eligible participants 
without prevalent AF at the time of DNA collection. Incident AF was examined with 
proportional-hazards regression, censoring at death, loss to follow-up or date of last 
contact. The incident AF analyses included eligible participants without prevalent AF 
at the time of DNA collection. To account for its pedigree structure data, FHS used 
generalized estimating equations for logistic analyses and robust variance estimates for 
proportional-hazards analyses. 
Results and discussion
Our community-based participants were middle-aged to elderly, with mean ages at DNA 
collection from 57 (ARIC) to 76 (AGES) years (table 1). The Manhattan plot of –log10 
P values for combined prevalent and incident AF analyses is displayed in figures 1. We 
prespecified genome-wide significance as P < 5 * 10-8, corresponding to significance at 
5% adjusting for approximately one million independent tests as estimated in HapMap 
samples of European ancestry. To prioritize follow-up genotyping, we required that SNPs 
have P < 4 * 10-7 (corresponding to one expected false positive per GWAS) and that at 
least six of nine analyses (out of four prevalent and five incident AF analyses) contribute 
results for the SNP, to reduce possible false-positives due to poor imputation. We repli-
cated the association with a previously reported chromosome 4 locus 7 (rs17042171, P 
= 6.0 * 10-27; table 2), which was approximately 150 kb telomeric to the transcription 
factor gene PITX2. 
SNP rs2106261 on chromosome 16q22, located in an intronic region of transcription 
factor ZFHX3 (previously known as ATBF1), showed suggestive evidence of association 
(table 2, combined prevalent-incident P = 2.3 * 10-7, Fig. 1). Results were consistent 
in the separate prevalent (P = 9.0 * 10-6) and incident (P = 7.9 * 10-4) AF analyses. 
Table 1 Characteristics of the study cohorts
Prevalent (n=16,664) Incident (n=23,854)
AGES CHS FHS Rotterdam AGES ARIC CHS FHS Rotterdam
Age, years ≥66 ≥65 ≥30 ≥55 ≥66 ≥44 ≥65 ≥30 ≥55
Participants 
before exclusion
3219 3372 5282 5974 3219 11459 3372 5282 5974
Participants 
after exclusion
2959 3267 4464 5974 2718 8086 3201 4184 5665
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We replicated the association between SNP rs2106261 and AF in a large independent 
cohort, the German AF Network (AFNET), consisting of 2,145 cases and 4,073 controls 
(odds ratio = 1.44, P = 1.6 * 10-11; table 2). In a meta-analysis of the results from the 
discovery (CHARGE community AF) and replication (German AFNET) studies, rs2106261 
was significantly associated with AF (RR 1.25, P = 1.8 * 10-15; table 1). ZFHX3 appears 
to regulate myogenic [18] and neuronal differentiation.[19] ZFHX3 has been reported 
to be a tumor suppressor gene in several cancers [20], and recently SNPs in ZFHX3 have 
been associated with susceptibility to Kawasaki disease.[21] Although the function of 
ZFHX3 in cardiac tissue is unknown, it is expressed in mouse hearts. 
Another significant association signal was on chromosome 1p36 within MTHFR 
(rs17375901, P = 4.6 * 10-8), which encodes 5,10-methylenetetrahydrofolate reduc-
tase. The association with the MTHFR locus was not confirmed in independent subjects 
from the AFNET cohort (table 2). The initial MTHFR finding may be a false positive 
result. However, the region may merit further investigation because MTHFR is in linkage 
disequilibrium with NPPA, the atrial natriuretic peptide gene; a NPPA frameshift muta-
tion has been described in a family with AF.[22] 
We acknowledge several study limitations. Although our findings were generally con-
sistent, we observed some between-analysis heterogeneity in effect sizes (P = 0.01), 
possibly arising from variation in cohort participant characteristics, duration and etiology 
of AF, low study-specific precision, subtle locus-specific population stratification and 
population differences in underlying haplotype structure. We note that for the previously 
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validated PITX2 locus we observed between-study heterogeneity. Thus, heterogeneity 
appears to be a general feature of even the strongest genome-wide findings for AF, 
and it remains to be addressed in follow-up studies. In addition, our findings may not 
be generalizable to other populations. It also was not possible to perform a pooled 
analysis using participant-specific data given the restrictions imposed by the Institutional 
Review Boards at some study sites. Furthermore, there is a potential for survival bias in 
the prevalent AF analysis if the variant is associated with both AF onset and lethality; 
in this situation, individuals who die shortly after AF onset might not survive until DNA 
collection. Nonetheless, a moderate association was present in prevalent, incident, and 
combined AF meta-analyses for both the validated chromosome 4q25 and the new 
chromosome 16q22 loci. Another limitation is that, beyond single SNPs, our study did 
not analyze patterns of haplotypes, and thus this it may not have captured complex 
haplotype associations. However, our use of imputation to the HapMap does take 
advantage of available linkage disequilibrium information. Finally, we recognize that 
we likely have identified variants in linkage disequilibrium with causal variants rather 
than the specific functional variants; the pathophysiology by which locus variation 
contributes to AF risk remains unknown. The strengths of our approach include the 
use of five large community-based cohorts, whose participants were not selected for 
phenotypic characteristics, thereby enhancing the generalizability of our findings. The 
robustness of the chromosome 16q22 result is strengthened by its documentation in 
samples ascertained with different study designs, including case-control and cohort 
studies. In summary, by examining GWAS data for AF in five community-based cohorts, 
we replicated the previously reported association with chromosome 4q25 variants and 
we identified a new locus on chromosome 16 in a gene encoding the transcription 
Table 2 CHARGE AF GWAS meta-analysis with P≤ 4 * 10-7 and German AFNET replication 
Locus
Combined 
analysis prevalent 
and incident AF
German AF net
Meta-analysis 
CHARGE and German 
AFNET
SNP/ nearby 
gene
Chr
Minor/ 
major 
allele
MAF 
CHARGE 
AFNET
Relative 
risk
Meta 
P-value
Odds 
Ratio
P-value
Relative 
risk
P-value
rs17042171 
PITX2
4 A/C
0.122 
0.156
1.45 6.0 * 10-27 2.46 6.9 * 10-51 1.65 3.9 * 10-63
rs2106261 
ZFHX3
16 T/C
0.174 
0.192
1.19 2.3 * 10-7 1.44 1.6 * 10-11 1.25 1.8 * 10-15
rs17375901 
MTHFR
1 T/C
0.053 
0.058
1.34 4.6 * 10-8 1.04 0.68 1.26 5.9 * 10-7
MAF Minor allele frequency
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factor ZFHX3. We provided confirmatory support for the ZFHX3 finding by replicating 
our findings in a large independent study of AF. Further studies are needed to elucidate 
functional variants and mechanisms by which the 16q22 locus predisposes to AF.
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Abstract
The electrocardiographic PR interval reflects atrial and atrioventricular nodal conduc-
tion, disturbances of which increase risk of atrial fibrillation (AF). To identify underlying 
common genetic variation, we meta-analyzed genome-wide association results for PR 
interval from seven community-based studies of European-ancestry individuals: AGES, 
ARIC, CHS, FHS, KORA, Rotterdam Study and SardiNIA (n=28,517). Associated loci 
were tested for association with AF (n=5,741 AF cases). Significant association with PR 
interval was identified at nine loci (P<5x10-8). We identified 9 independent signals. Five 
of the nine loci were also associated with AF (P<0.0056). Common genetic variation 
contributes significantly to atrial and atrioventricular conduction and to AF risk.
Introduction
In myocardial excitation, the delay between the excitation of the atria and ventricles 
is determined by the sum of atrial and atrioventricular nodal conduction. This delay, 
measured in milliseconds, is reflected on the standard 12-lead electrocardiogram (ECG) 
by the PR interval or PQ interval. The PR interval has a substantial heritable component, 
with heritability estimates ranging between 30 and 50%.[1-4] 
Atrial fibrillation (AF) is the most common sustained arrhythmia and is independently 
associated with increased risk of stroke, heart failure, dementia, and death.[5] AF preva-
lence increases markedly with age, to nearly 9% in those 80-89 years of age, and is 
estimated to triple by the year 2050.[6] Common genetic risk factors for AF [7] include 
variants on chromosome 4q25 near the PITX2 gene [8], in 16q22.3 near the ZFHX3 
(ATBF1) gene [9] and the K897T variant in the KCNH2 gene on 7q36.1.[10] 
The PR interval is an intermediate phenotype for AF, as alterations in atrial action 
potential duration and in atrioventricular conduction influence both PR interval and AF 
risk.[11] Longitudinal data from the Framingham Heart Study (FHS) and the Athero-
sclerosis Risk in Communities Study (ARIC) demonstrate that PR interval prolongation 
is a predictor of increased AF risk.[12,13] In addition, PR interval prolongation has been 
shown in FHS to be an independent predictor in a multifactorial risk score for atrial 
fibrillation predisposition.[14] 
We undertook a meta-analysis of GWAS to investigate the genetic determinants of 
the PR interval and their relationship to AF risk. Our goal was to identify genes that can 
provide insights into atrial disease and lead to novel opportunities for AF prevention and 
therapy.
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Methods
We studied individuals of European descent from seven community based studies: the 
Age, Gene/Environment Susceptibility-Reykjavik Study (AGES) [15], ARIC [16], the Car-
diovascular Health Study (CHS) [17], FHS [18], the Kooperative Gesundheitsforschung 
in der Region Augsburg Study (KORA) [19], the Rotterdam Study (RS) [20], and the Sar-
diNIA study [3]. Phenotypic data including resting 12-lead electrocardiography, height, 
weight, systolic blood pressure, and medication use were collected using standardized 
protocols in all studies. 
Study participants were genotyped using a variety of genome-wide SNP arrays. To 
facilitate comparison of results across studies, we imputed to the 2.5 million HapMap 
SNPs. A recent review supports the validity of combining results across statistical and 
genotyping platforms.[21] 
After exclusions, 28,517 individuals were available for study (table 1). The association 
of each SNP with the PR interval was adjusted for age, sex, RR interval, height, body mass 
index (BMI), systolic blood pressure, and study site in studies with multiple recruitment 
sites. Studies adjusted for or excluded individuals using drugs known to alter the PR 
interval including beta-blockers, diuretics and non-dihydropyridine calcium antagonists. 
Due to restrictions imposed by Institutional Review Boards at several of the study sites 
on the sharing of individual genetic data, it was not possible to perform analyses based 
on combined individual-level data. Therefore, we conducted a meta-analysis of the beta 
estimates from linear regression of PR interval. The coefficients, generated for each SNP, 
estimate the difference in PR interval per additional copy of the minor allele, adjusted 
for the covariates in the model. The genome-wide significance threshold was 5x10-8. 
To determine if there was an association between the PR-associated loci and AF 
risk, we meta-analyzed results from 4 studies of AF in subjects of European descent. 
The first was a meta-analytic study of 896 prevalent AF cases and 15,768 referents 
from the CHARGE cohorts. The second was a meta-analytic study of 2,517 incident 
AF cases and 21,337 referents from the CHARGE cohorts. The third and fourth were 
Table 1 Characteristics of the study cohorts
AGES ARIC CHS FHS KORA F3 KORA S4 Rotterdam SardiNIA
Participants 
before exclusion
3219 11478 2084 12174 1644 1100 5271 4305
Participants after 
exclusion
2471 6486 1769 7636 1427 927 3710 4091
Gender, men (%) 922 (37.3) 2977 (45.9) 773 (43.7) 3511 (46.0) 728 (51.0) 447 (48.2) 1541 (39.8) 1782 (43.5)
Mean age, years 
± SD
76.1±5.4 53.9±5.7 72.9±5.4 39.9±10.3 61.6±9.9 56.2±7.1 67.8±8.5 42.5±17.1
Mean PR interval, 
ms ± SD
171.4±27.7 162.7±23.7 167.9±28.5 152.1±21.9 163.3±23.3 164.6±21.2 165.9±24.1 154.2±26.7
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independent case-control studies of prevalent AF: the German Competence Network 
on Atrial Fibrillation (AFNET, 2,145 cases and 4,073 controls); and the Cleveland Clinic 
AF study (CCAF, 183 cases and 164 controls). We performed a meta-analysis of the 
logistic-regression results from the prevalent AF studies and the proportional hazards 
result from the incident AF study. The Bonferroni adjusted significance threshold was P 
= 0.05/9 = 0.0056. 
The study was performed in accordance with the Helsinki declarations and was 
approved by the local medical ethics and institutional review boards. All participants 
gave signed informed consent to use their DNA for genetic analyses.
Results and discussion
Overall, nine loci showed independent association signals with P<5x10-8 (table 2). In 
one region we detected two association signals, (P = 2.1x10-74) and (P = 6.0x10-26). 
These variants are in low LD (r2 = 0.031). In a meta-analysis of linear regression results 
from models including both SNPs, these SNPs remained independently associated with 
PR interval (P= 9.7x10-82; P = 1.1x10-33), suggesting they represent independent associa-
tion signals. In addition, six PR interval associations were identified in or near genes 
involved in human cardiac development. 
Of the nine identified PR loci, five were associated with AF risk (p<0.0056) (table 3). 
In all instances the minor alleles were associated with a decrease in AF risk, irrespective 
of the direction of their association with PR interval (table 3). Protective ratios against 
AF were between 0.93 and 0.88 for any minor allele. The observation that the sign of 
effect on PR interval was not predictive of the risk decreasing or increasing effect on 
AF may initially appear counterintuitive. The possibility that PR intervals at high and 
low extremes may both be associated with increase in AF risk may provide a possible 
Table 2 Genome-wide significant association findings for PR interval
SNP Minor/ major allele beta (ms) SE (ms) P value
1 C/T 1.3624 0.207 4.62 * 10-11
2 C/G 3.0403 0.2886 6.00 * 10-26
3 C/T 3.7687 0.2065 2.10 * 10-74
4 A/G -2.0146 0.2203 5.99 * 10-20
5 C/T -1.4924 0.2091 9.45 * 10-13
6 A/G 2.2959 0.2086 3.66 * 10-28
7 G/A -1.1916 0.2155 3.22 * 10-8
8 A/G -2.0907 0.2872 3.34 * 10-13
9 C/T 1.9505 0.2311 3.13 * 10-17
Genome-wide significant threshold P<5 * 10-8
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explanation. Existing data from humans and animal models suggest that the effects of 
genetic variants on atrial repolarization and action potential duration, and their rela-
tionship with atrial arrhythmias, are complex. As long and short QT intervals are both 
associated with increased VT risk, also for AF linear association models with PR interval 
and and with underlying genetic variants may not capture the entire complexity of these 
relationships. 
Our study was subject to a number of potential limitations. False positive associations 
from multiple testing is a limitation of any GWAS, so we used a well-accepted genome-
wide association significance threshold equivalent to a Bonferroni correction for 1 mil-
lion independent tests to reduce false positive findings.[22] Population stratification is 
also a concern, so we only included study subjects of European descent. Our study also 
did not examine patterns of haplotype association. Thus complex haplotype associations 
may not have been captured.However, fully genome-wide meta-analyses of haplotypes 
are not currently feasible, and, in common with other GWAS, our use of imputation to 
the HapMap leverages available linkage disequilibrium information.
The biological mechanisms by which the identified variants influence PR interval 
and AF remain speculative, and detailed functional investigation will be required to 
determine the potential contribution of each genomic region.
Table 3 Meta-analytic results for the association of the nine genome wide significant PR SNPs with atrial fibrillation
SNP
PR 
prolonging 
allele
Frequency 
of PR 
prolonging 
allele
OR  (95% CI) for AF PR 
prolonging allele 
P-value 
(unadjusted)
P-value 
(adjusted)
Effect of PR 
prolonging allele 
towards AF risk
1 C 0.39 1.01 (0.97 – 1.06) 0.65 - -
2 C 0.15 0.90 (0.84 – 0.96) 7.0 * 10-4 6.30 * 10-3 Decreased
3 C 0.40 0.92 (0.88 – 0.96) 1.5 * 10-3 1.35 * 10-3 Decreased
4 G 0.69 1.01 (0.97 – 1.06) 0.56 - -
5 T 0.61 1.07 (1.03 – 1.12) 2.3 * 10-3 2.07 * 10-2 Increased
6 A 0.40 0.91 (0.87 – 0.95) 2.2 * 10-5 1.98 * 10-4 Decreased
7 A 0.67 0.94 (0.90 – 0.99) 0.01 - -
8 G 0.85 1.13 (1.06 – 1.20) 2.1 * 10-4 1.89 * 10-3 Increased
9 C 0.30 0.99 (0.95 – 1.04) 0.72 - -
The Bonferroni adjusted significance threshold is P= 0.05/9= 5.6 * 10-3
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Summary
Sudden death is among the most common causes of death in developed countries. 
Sudden death from cardiac causes accounts for approximately 50% of all deaths from 
cardiovascular diseases and 20% of all deaths. The majority of sudden cardiac deaths 
are caused by acute ventricular arrhythmia. An important potential cause of ventricular 
arrhythmia is prolongation of ventricular repolarization. Prolongation of ventricular 
repolarization may result in early after depolarizations, which in turn may induce re-
entry and thereby provoke Torsade de Pointes and fatal ventricular arrhythmia. This 
thesis focused on the effect of certain drugs and endocrine factors on QTc prolongation 
and sudden cardiac death.
Chapter 1 gives an overview of QTc prolongation and sudden cardiac death and its 
main risk factors, etiology and possibilities for prevention.
In chapter 2.1 we studied whether listed putative QTc prolonging psychotropic drugs 
indeed prolong the QTc interval under everyday circumstances, and evaluated whether 
this is a class effect or an individual drug effect. We were able to confirm the importance 
of antidepressants (in particular amitriptyline, imipramine, maprotiline and nortripty-
line) and antipsychotics (in particular lithium, olanzapine and thioridazine) as potential 
contributors to QTc prolongation. Especially starting of tricyclic antidepressant drugs is 
associated with a significant intra-individual increase in the QTc interval (approximately 
10 milliseconds) in comparison to the change in non-users. The tricyclic antidepressants 
appear to prolong the QTc interval as a class effect. 
Since common variation in the NOS1AP gene has been associated with QTc interval 
variation and NOS1 is presumed to influence intracellular calcium, we aimed to study 
in chapter 2.2 whether NOS1AP single nucleotide polymorphisms modify the QTc 
prolonging effect of calcium channel blockers. We demonstrated that the minor alleles 
of both NOS1AP SNPs significantly potentiate the QTc prolonging effect of verapamil. 
Because QTc prolongation is associated with an increased risk of sudden cardiac death, 
this gene-drug interaction may be of clinical importance.
Virtually all QTc prolonging drugs act by blocking the hERG (human ether a go-go 
related gene) encoded potassium channels, whereas not all QTc prolonging drugs 
are associated with an increased risk of serious cardiac arrhythmias. To investigate 
whether binding capacity to hERG-encoded potassium channels can actually predict 
hard clinical endpoints, we studied in chapter 3.1 whether non-cardiovascular drugs, 
which are known to block the hERG-encoded potassium channels, are associated with 
an increased risk of sudden cardiac death and whether the ratio between therapeutic 
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plasma concentrations and the concentration which inhibits 50% of the potassium 
channels is an indicator of the risk of sudden cardiac death. We confirmed that cur-
rent use of non-cardiovascular hERG-encoded potassium channels inhibiting drugs in 
the general population is associated with an increased risk of sudden cardiac death. In 
addition, we demonstrated that drugs with a high hERG-encoded potassium channels 
inhibiting capacity had a higher risk of sudden cardiac death than patients using drugs 
with a low potassium channels inhibiting capacity. In chapter 3.2 we evaluated the 
association between use of domperidone, which is also known to block the hERG-
encoded potassium channels, and serious non-fatal ventricular arrhythmias and sudden 
cardiac death in the general population. We confirmed that current use of domperidone 
and mainly high doses are associated with an increased risk of sudden cardiac death. We 
could not demonstrate an effect of domperidone on non-fatal ventricular arrhythmias 
due to absence of exposed cases. 
Since sudden cardiac death is frequently reported in epilepsy and the indications 
of anticonvulsant drug prescriptions now include chronic pain syndromes, we studied 
whether use of anticonvulsants is associated with an increased risk of sudden cardiac 
death. In chapter 3.3 we found that use of anticonvulsive drugs is associated with an 
increased risk of sudden cardiac death in the general population, even in persons who 
use anticonvulsive drugs for other indications than epilepsy. The risk of sudden cardiac 
death seems to be higher among users of carbamazepine and other anticonvulsants 
with sodium channel blocking properties.
Since the literature on the effect of excess thyroid hormone on ventricular repolarization 
is controversial, we aimed to examine whether free T4 and TSH are associated with QTc 
prolongation. In chapter 4.1 we showed that high levels of free T4 are associated with 
QTc prolongation in men, which can be explained by an increased activity of cardiac 
Na+/ K+ ATPase in thyroid hormone excess, leading to increased intracellular K+ with 
subsequent membrane hyperpolarization and an increase in QTc duration. Although a 
QTc interval prolongation of 10 milliseconds in one individual usually remains without 
clinical consequences, an average shift of 10 milliseconds in a Gaussian distribution on 
a population level will inevitably push more individuals into the upper percentiles of 
the QTc interval with its increased risk of Torsade de Pointes and sudden cardiac death. 
In chapter 4.2 we investigated whether use of antithyroid drugs (as a direct cause or 
as an indicator of poorly controlled hyperthyroidism) is associated with an increased 
risk of sudden cardiac death. We demonstrated in two independent studies that use 
of antithyroid drugs seems to be associated with a threefold increased risk of sudden 
cardiac death. Although this might be due to antithyroid drug use itself, it could be 
more readily explained by underlying hyperthyroidism, since increased free T4 levels are 
associated with QTc prolongation and treated patients who developed sudden cardiac 
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death still had low TSH levels shortly before death. This suggests that hyperthyroidism 
may be a risk factor for sudden cardiac death. 
It is assumed that testosterone is an important regulator of gender-related differences 
in ventricular repolarization. Therefore, we studied in chapter 5.1 whether serum levels 
of testosterone are associated with QTc, QT and RR interval variation. We demonstrated 
in two population-based studies that serum testosterone is associated with a decreased 
QTc interval and increased RR interval, however, not with a difference in the QT interval. 
The decreased QTc interval in men with higher levels is probably due to the association 
of serum testosterone with prolongation of the RR interval. 
Diabetes mellitus is a common disease in the elderly which adversely affects cardiac 
repolarization. Since hyperglycemia itself is a risk factor for cardiovascular disease, we 
studied whether non-diabetic persons with impaired fasting serum glucose and hyper-
insulinemia have QTc/QT-interval prolongation and RR-interval shortening, and whether 
these were associated with an increased risk of sudden cardiac death. In chapter 5.2 
we showed that impaired fasting glucose and hyperinsulinemia are associated with a 
significantly increased QTc-interval and shortening of the RR interval. We demonstrated 
in the same population that both prolongation of the QTc/ QT as well as shortening of 
the RR interval are associated with an increased risk of sudden cardiac death.
In chapter 6 we discussed the main findings of the studies presented in this thesis and 
the methodological considerations of these studies. In addition, we presented potential 
clinical implications and suggestions for future research.
In addition, we presented recently discovered genes involved in atrial fibrillation and the 
PR interval during studies. In chapter 7.1 we have replicated variants on chromosome 
4 associated with atrial fibrillation. The SNPs rs2200733 and rs10033464 are strongly 
associated with AF in four independent cohorts of European descent. The primary aim 
of genome-wide association (GWA) studies is to identify novel genetic loci associated 
with interindividual variation in the levels of risk factors and the degree of clinical dis-
ease. In chapter 7.2 we conducted meta-analyses of genome-wide association studies 
for atrial fibrillation in collaboration with the CHARGE (Cohorts for Heart and Aging 
Research in Genomic Epidemiology) Consortium and identified the new locus ZFHX3 for 
atrial fibrillation. The electrocardiographic PR interval reflects atrial and atrioventricular 
nodal conduction, disturbances of which increase risk of atrial fibrillation. In chapter 
7.3 we conducted meta-analyses of GWA studies for the PR interval in 7 community-
based studies and identified 9 loci. Five of these 9 loci were also associated with atrial 
fibrillation.
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Acute hartdood is één van de meest voorkomende doodsoorzaken in de westerse 
wereld. Acute hartdood is verantwoordelijk voor ongeveer 50% van alle cardiovascu-
laire doden en 20% van alle doden. De meerderheid van alle acute hartdoden wordt 
veroorzaakt door acute ventriculaire aritmiën. Een belangrijke oorzaak van ventriculaire 
aritmiën is verlenging van de ventriculaire repolarisatie (zichtbaar als verlenging van het 
QTc-interval op het ECG) resulterend in “early after depolarizations”, die op hun beurt 
re-entry kunnen induceren en Torsade de Pointes kunnen uitlokken, mogelijk leidend 
tot fatale ventriculaire aritmiën. Dit proefschrift bevat een aantal onderzoeken naar 
het effect van bepaalde geneesmiddelen en endocriene factoren op QTc verlenging en 
acute hartdood. 
In hoofdstuk 1 wordt een overzicht gegeven van QTc verlenging en acute hartdood, 
waarbij de belangrijkste risicofactoren, de etiologie en de mogelijkheden voor preventie 
zijn beschreven.
In hoofdstuk 2.1 hebben we bestudeerd of psychotrope geneesmiddelen, waarvan 
wordt aangenomen dat ze het QTc interval verlengen, inderdaad het QTc interval ver-
lengen. Bovendien hebben we geëvalueerd of dit een klasse-effect is of een effect van 
het individuele geneesmiddel. We hebben het belang van antidepressiva (met name 
amitriptyline, imipramine, maprotiline en nortriptyline) en antipsychotica (met name 
lithium, olanzapine en thioridazine) als mogelijke bijdrage aan QTc verlenging kunnen 
bevestigen. Vooral het starten van tricyclische antidepressiva is geassocieerd met een 
significante toename van het QTc interval (ongeveer 10 milliseconden) duidend op een 
klasse-effect. 
Variatie binnen het NOS1AP gen is geassocieerd met variatie in de lengte van het 
QTc interval, waarbij NOS1 van invloed is op intracellulair calcium. In hoofdstuk 2.2 
hebben we bestudeerd of NOS1AP “single nucleotide polymorphisms” (SNPs) het QTc 
verlengende effect van calciumantagonisten veranderen. We hebben aangetoond dat 
de variant allelen van beide NOS1AP SNPs het QTc verlengende effect van verapamil 
significant potentiëren. Omdat QTc verlenging geassocieerd is met een verhoogd risico 
op acute hartdood, kan deze gen-geneesmiddel interactie van klinisch belang zijn. 
Vrijwel alle QTc verlengende geneesmiddelen verlengen het QTc interval door blokkade 
van kaliumkanalen, gecodeerd door hERG (human ether a go-go related gene). Niet 
alle QTc verlengende geneesmiddelen zijn echter geassocieerd met een verhoogd risico 
op cardiale aritmiën. Om te onderzoeken of de bindingscapaciteit aan door hERG 
gecodeerde kaliumkanalen harde klinische eindpunten kan voorspellen, hebben we in 
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hoofdstuk 3.1 bestudeerd of het gebruik van niet-cardiovasculaire geneesmiddelen, 
waarvan bekend is dat ze deze kaliumkanalen kunnen blokkeren, geassocieerd is met 
een verhoogd risico op acute hartdood. Daarnaast hebben we onderzocht of de ratio 
tussen de therapeutische plasmaconcentratie en de concentratie die nodig is om 50% 
van de kaliumkanalen te remmen, een indicator is voor het risico op acute hartdood. 
We hebben bevestigd dat gebruik van niet-cardiovasculaire geneesmiddelen die deze 
kaliumkanalen blokkeren, in de algemene populatie geassocieerd is met een verhoogd 
risico op acute hartdood. Bovendien hebben we aangetoond dat gebruik van genees-
middelen met een hoge capaciteit om deze kaliumkanalen te blokkeren, geassocieerd is 
met een hoger risico op acute hartdood dan het gebruik van geneesmiddelen met een 
lage capaciteit. Domperidon kan tevens door hERG gecodeerde kaliumkanalen blokke-
ren. In hoofdstuk 3.2 hebben we de associatie tussen het gebruik van domperidon en 
ernstige non-fatale ventriculaire aritmiën en acute hartdood in de algemene populatie 
geëvalueerd. We hebben aangetoond dat gebruik van domperidon, voornamelijk in 
hoge doseringen, geassocieerd is met een verhoogd risico op acute hartdood. Doordat 
geen enkele patiënt - die een non-fatale ventriculaire aritmie ontwikkelde - domperidon 
gebruikte, konden we geen effect van domperidon op ventriculaire aritmiën vaststellen.
Aangezien acute hartdood vaak gerapporteerd wordt bij epilepsie en de indicaties 
van anti-epileptica uitgebreid zijn met het chronische pijn syndroom, hebben we bestu-
deerd of het gebruik van anti-epileptica geassocieerd is met een verhoogd risico op 
acute hartdood. In hoofdstuk 3.3 hebben we gevonden dat gebruik van anti-epileptica 
geassocieerd is met een verhoogd risico op acute hartdood in de algemene populatie, 
zelfs bij patiënten die anti-epileptica gebruiken voor een andere indicatie dan epilepsie. 
Het risico op acute hartdood blijkt hoger bij gebruikers van carbamazepine en andere 
anti-epileptica met natriumkanaal blokkerende eigenschappen. 
Aangezien de literatuur controversieel is over het effect van schildklierhormoon op de 
ventriculaire repolarisatie, hebben we onderzocht of vrij T4 en TSH geassocieerd zijn met 
QTc verlenging. In hoofdstuk 4.1 hebben we aangetoond dat hoge vrij T4 waarden 
geassocieerd zijn met QTc verlenging bij mannen. Dit effect kan verklaard worden door 
een verhoogde cardiale Na+/ K+ ATPase activiteit bij verhoogde serumwaarden van het 
schildklierhormoon, mogelijk geassocieerd met een verhoogd intracellulair kalium en 
een toename van de lengte van het QTc interval. Alhoewel een verlenging van het QTc 
interval van 10 milliseconden in één persoon normaliter zonder klinische consequenties 
blijft, zal een gemiddelde toename van 10 milliseconden in een normale verdeling op 
populatie-niveau meer personen naar de hoogste percentielen van het QTc interval 
verschuiven, geassocieerd met een verhoogd risico op Torsade de Pointes en acute hart-
dood. In hoofdstuk 4.2 hebben we bestudeerd of gebruik van thyreostatica (als een 
directe oorzaak of als indicator van matig ingestelde hyperthyreoïdie) geassocieerd is 
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met een verhoogd risico op acute hartdood. We hebben in twee onafhankelijke studies 
aangetoond dat gebruik van thyreostatica geassocieerd is met een drievoudig verhoogd 
risico op acute hartdood. De thyreostatica zouden dit zelf kunnen veroorzaken maar 
het is waarschijnlijker dat de acute hartdood veroorzaakt wordt door de onderliggende 
hyperthyreoïdie. Ten eerste omdat patiënten die waren behandeld met thyreostatica 
en een acute hartdood ontwikkelden verlaagde TSH spiegels hadden kort voor het 
overlijden en ten tweede omdat hoge waarden van vrij T4 geassocieerd zijn met QTc 
verlenging. Dit maakt aannemelijk dat hyperthyreoïdie zelf een risicofactor voor acute 
hartdood is. Het risico lijkt vooral verhoogd te zijn in het begin van de behandeling met 
thyreostatica.
Het wordt verondersteld dat testosteron een belangrijke regulator is van geslachtsge-
relateerde verschillen in ventriculaire repolarisatie. Daarom hebben we in hoofdstuk 
5.1 bestudeerd of testosteronspiegels geassocieerd zijn met variatie in het QTc, QT 
en RR interval. We hebben in twee afzonderlijke studies aangetoond dat testosteron 
geassocieerd is met een verkort QTc interval en een verlengd RR interval, echter niet 
of in mindere mate met het QT interval. Het kortere QTc interval bij mannen met hoge 
testosteronspiegels kan waarschijnlijk worden verklaard door de associatie met het ver-
lengde RR interval bij mannen. In de formule van Bazett voor het QTc-interval, hangen 
RR-interval en QTc-interval rechtstreeks samen.
Diabetes mellitus heeft een negatief effect op de cardiale repolarisatie. Aangezien 
hyperglycemie reeds een risicofactor voor cardiovasculaire ziekte is, hebben we onder-
zocht of personen zonder diabetes mellitus met een verhoogde nuchtere glucose spiegel 
en hyperinsulinemie, ook QTc/ QT-verlenging en RR-verkorting ontwikkelen. Daarnaast 
hebben we onderzocht of een verlengd QTc/ QT interval en een verkort RR interval 
geassocieerd is met een verhoogd risico op acute hartdood. In hoofdstuk 5.2 hebben 
we aangetoond dat een verhoogde nuchtere glucose spiegel en hyperinsulinemie geas-
socieerd zijn met een significant verlengd QTc interval en een verkort RR interval. We 
hebben in dezelfde populatie aangetoond dat zowel verlenging van het QTc/ QT interval 
als een verkorting van het RR interval geassocieerd zijn met een verhoogd risico op acute 
hartdood. 
In hoofdstuk 6 hebben we de belangrijkste bevindingen van de studies in dit proefschrift 
en de methodologische overwegingen van deze studies besproken. Bovendien hebben 
we de klinische implicaties en suggesties voor toekomstig onderzoek besproken.
Daarnaast hebben we recent ontdekte genen besproken, die geassocieerd zijn met atri-
umfibrilleren en het PR interval. In hoofdstuk 7.1 hebben we 2 SNPs op chromosoom 4 
met betrekking tot atriumfibrilleren gerepliceerd. De SNPs rs2200733 and rs10033464 
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zijn sterk geassocieerd met atriumfibrilleren in 4 onafhankelijke cohorten van Europese 
afkomst. Het doel van genoom-brede associatie (GWA) onderzoeken is om nieuwe 
genetische loci te identificeren die geassocieerd zijn met interindividuele variatie van de 
ziekte. In hoofdstuk 7.2 hebben we een meta-analyse uitgevoerd van GWA onderzoe-
ken voor atriumfibrilleren in samenwerking met het CHARGE (Cohorts for Heart and 
Aging Research in Genomic Epidemiology) Consortium. We hebben een nieuw gen 
(ZFHX3) geïdentificeerd, dat geassocieerd is met een verhoogd risico op atriumfibrilleren. 
Het PR interval op het ECG is een maat voor de atriale en atrioventriculaire geleiding. In 
hoofdstuk 7.3 hebben we een meta-analyse uitgevoerd van GWA onderzoeken voor 
het PR interval in 7 studies. We hebben 9 onafhankelijke loci geïdentificeerd. Vijf van 
deze 9 loci waren tevens geassocieerd met atriumfibrilleren. 
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